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Le corps humain est composé d’environ 40 % de muscle. Le muscle est un tissu 
composé de cellules hautement spécialisées dans la génération de la force. En conséquence, 
le muscle est impliqué dans de nombreux processus fondamentaux comme par exemple le 
mouvement, la maintenance de la posture, la pression sanguine, le péristaltisme et la 
production de chaleur. Le muscle est divisé en 3 catégories, basées sur ses propriétés 
fonctionnelles et physiologiques : - le muscle lisse, n’est pas strié et est formé par de petites 
cellules, il est trouvé dans les parois des vaisseaux sanguins ; - le muscle cardiaque qui, 
comme son nom l’indique forme le cœur, est strié et composé de cellules pacemaker qui 
permettent à cet organe de se contracter de manière spontanée ; - et le muscle squelettique qui 
lui aussi est strié et qui est responsable des mouvements volontaires du corps. Le muscle 
squelettique est impliqué dans un grand nombre de maladies qui peuvent malheureusement 
être mortelles. C’est le cas par exemple de la Dystrophie Musculaire de Duchenne. 
 
Le muscle squelettique est formé par la fusion des myoblastes en myotubes. Les 
myoblastes sont des cellules mononucléées et légèrement étoilées et sont les précurseurs 
immatures du muscle. Après leur fusion, ils forment des myotubes qui peuvent contenir  
plusieurs centaines de noyaux et mesurer plusieurs µm. Ces cellules représentent encore un 
stade précoce de la myogénèse. Finalement, après innervation, le muscle atteint le stade 
ultime de maturation et est alors composé par de fibres musculaires qui sont globalement 
cylindriques, avec un diamètre de 10 à 100 µm et une longueur pouvant atteindre plusieurs 
centimètres. Entre les fibres se trouvent la lame basale et un grand nombre de cellules 
satellites. Ces dernières sont impliquées dans la croissance et la réparation du muscle. Ce sont 
des cellules quiescentes et elles se différencient en précurseur du muscle après un dommage 
(radiation, étirement, déchirure). Les fibres musculaires sont composées de myofibrilles. 
Chaque myofibrille est elle-même composée par les protéines qui sont responsables de la 
contraction du muscle, l’actine et la myosine. La myosine génère la force de contraction par 
le glissement de l’actine sur la myosine. Ce glissement est énergie-dépendant. L’énergie se 
trouve sous la forme d’adénosyl-triphosphate (ATP). Elle est nécessaire pour la contraction et 
est en partie contenue dans le muscle. Cependant, l’énergie stockée dans le muscle n’est pas 
suffisante pour assurer de multiples contractions. Le muscle doit donc avoir d’autres sources 
d’énergie comme le glucose et le glycogène qui proviennent de la nourriture. Le glycogène 
est la forme de stockage du glucose. De plus, le muscle tire son énergie de réactions 
aérobiques qui ont lieu dans la mitochondrie et de réactions anaérobiques. Ce dernier procédé 
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n’est pas très efficace et peut être toxique car il entraîne la formation d’acide lactique. Enfin, 
la créatine peut être utilisée pour fournir de l’énergie. 
Le muscle squelettique est formé de différents types de fibres : les fibres lentes ou 
fibre de type I, les fibres rapides ou fibre de type II (IIA et IIB) (Ruegg, 1992). La proportion 
de chaque fibre donne les propriétés contractiles du muscle. Ainsi un muscle composé 
principalement de fibres de type I sera peu fatigable et utilisé dans des contractions longues et 
répétées. 
 
Un autre élément essentiel à la contraction du muscle est le calcium (Ca2+). Cet ion est 
responsable du couplage excitation-contraction, c'est-à-dire que c’est lui qui permet de 
transformer un potentiel d’action généré dans le cerveau en contraction musculaire. En effet, 
après que le nerf a libéré son neurotransmetteur (l’acétylcholine, ACh) au niveau de la 
jonction neuromusculaire et ainsi provoqué une dépolarisation de la cellule musculaire, le 
Ca2+ est libéré en grande quantité par le réticulum sarcoplasmique (RS) dans le cytoplasme de 
la cellule. Ceci entraîne la contraction. Une fois le Ca2+ repompé dans le RS, la contraction 
est stoppée. Le Ca2+ joue donc un rôle primordial dans la contraction. Pour que le muscle 
puisse se contracter de façon répétitive, il faut que l’ion soit efficacement libéré, repompé et 
stocké dans le RS pour pouvoir être réutilisé plus tard. C’est le rôle d’un grand nombre de 
protéines comme les canaux voltage-dépendants, les protéines qui lient le Ca2+, des 
échangeurs membranaires ou des pompes ATP-dépendantes mais aussi d’organelles 
intracellulaires comme les mitochondries ou le RS. 
Le récepteur à l’ACh (nAChR) est responsable de la dépolarisation de la cellule 
musculaire. L’activation du récepteur permet en effet l’entrée de Na+ dans la cellule. 
Les canaux calciques voltage-dépendants sont sensibles à la dépolarisation provoquée 
par le nAChR et permettent l’entrée de Ca2+ dans la cellule. Le canal le plus connu est le 
canal sensible à la dihydropyridine (DHPR). Ce DHPR est couplé directement ou 
indirectement à un canal calcique situé sur la membrane du RS, le récepteur à la ryanodine 
(RyR). Ce canal est un des principaux canaux impliqués dans la libération massive de Ca2+ 
lors d’une contraction (Franzini-Armstrong & Protasi, 1997). 
L’autre canal Ca2+ responsable de la libération de l’ion pendant la contraction est le 
récepteur à l’inositol 1, 4, 5-trisphosphate (IP3R). Cependant, ce canal n’a pas été totalement 
étudié dans le muscle squelettique mais il a été montré qu’il peut provoquer une contraction 
musculaire. Il est composé de 3 parties, la partie N-terminale étant responsable de la fixation 
du ligand du récepteur (l’inositol 1, 4, 5-trisphosphate, IP3). En effet, l’activation de la 
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phospholipase C (PLC), qui est une protéine ancrée à la membrane plasmique, va entraîner la 
formation d’IP3 qui va activer le récepteur et libérer le Ca2+. La partie C-terminale est 
responsable de l’ancrage du récepteur à la membrane du RS et elle partage des homologies de 
séquence avec le RyR. Enfin, la partie centrale du récepteur est la patrie régulatrice. En effet, 
il a été montré que le IP3R est régulé par de nombreux composants tels que le Ca2+ lui-même 
(inhibition du récepteur quand la concentration de Ca2+ ([Ca2+]) est élevée), l’ATP et 
différentes protéines kinases qui régulent le degrés de phosphorylation du récepteur. Le IP3R 
interagit aussi avec des protéines du cytosquelette comme par exemple l’ankyrine (Patel et 
al., 1999). 
Comme exposé précédemment, la contraction musculaire entraîne une fuite de Ca2+ 
du RS. Pour arrêter la contraction, le Ca2+ doit être repompé dans des stocks comme le RS. 
C’est le rôle de la sarcoplasmique-endoplasmique reticulum ATP-ase (SERCA). Cette 
protéine est une pompe ATP-dépendante. Son expression est très forte dans les cellules 
musculaires. Depuis quelques années, de nombreux groupes ont montré que la mitochondrie 
pouvait aussi jouer un rôle très important dans le stockage de Ca2+. 
D’autres canaux calciques situés sur la membrane plasmique sont aussi importants. 
Ainsi, les canaux calciques activés par la vidange des stocks (store-operated Ca2+ channels, 
SOC) permettent l’entrée de Ca2+ extracellulaire lorsque les stocks se vident. Les canaux 
calciques d’étirement sont activés par la pression et permettent l’entrée de Ca2+ dans la 
cellule. Pour finir, il existe aussi sur la membrane plasmique des échangeurs d’ions (entrée 
Na+ et sortie Ca2+), une pompe ATP-dépendante qui permet l’exclusion du Ca2+ de la cellule 
(PMCA).  
 
 
La Dystrophie Musculaire de Duchenne (DMD) est une des maladies génétiques liées 
au chromosome X des plus graves et des plus fréquentes : elle frappe un garçon sur 3500 
(Emery, 2002). Elle a été décrite pour la 1ère fois en 1860 par le docteur G. Duchenne. Elle se 
déclare dès l’enfance et conduit à une dégénérescence progressive de la musculature, 
obligeant les jeunes patients à se déplacer très tôt en chaise roulante. Actuellement, il n’existe 
pas de traitement et la mort survient aux alentours de la 30ème année, lorsque les muscles 
cardiaque et respiratoires sont touchés. La maladie est due à l’absence d’une énorme protéine, 
la dystrophine (le gène qui la code est le plus grand gène existant chez l’Homme), qui 
normalement maintien l’intégrité de la cellule musculaire lors d’un exercice (Monaco et al., 
1986). Il existe une variante moins grave de la DMD, appelée Dystrophie Musculaire de 
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Becker (BMD). Dans ce cas, quelques cellules expriment la dystrophine et la maladie est 
moins grave. Certains patients atteints de BMD ont une espérance de vie normale. Bien que 
la cause de la maladie soit parfaitement connue, la pathologie exacte de la DMD est encore 
mal comprise. Il semblerait cependant que l’augmentation de la concentration de Ca2+ dans la 
cellule soit responsable de la dégradation du muscle (Ruegg & Gillis, 1999). En effet, 
l’absence de dystrophine est accompagnée par l’altération du complexe de glycoprotéines 
associées à la dystrophine (DGC). Il en résulte une fragilité membranaire qui entraîne une 
augmentation de Ca2+  mais aussi activation de protéines sensibles au Ca2+ comme les 
calpaïnes. Ces dernières sont responsables de la dégradation d’un grand nombre de protéines 
impliquées dans la maintenance de l’homéostasie calcique. De plus, l’invasion de cellules 
immunitaires entraîne une inflammation des tissus. Cela forme un cercle vicieux conduisant à 
la mort de la cellule. Le muscle est remplacé petit à petit par du tissu adipeux et du tissu 
fibrotique. 
Malheureusement, la DMD est aujourd’hui encore incurable. Certains traitements 
pharmacologiques comme les stéroïdes (la prédnisolone et son dérivé présentant moins 
d’effets secondaires le deflazacort) ou encore la créatine apportée en complément alimentaire, 
des anti-inflammatoires ont permis d’augmenter la durée de vie des patients ainsi que 
d’améliorer leur qualité de vie (Dubrovsky et al., 1998; Bonifati et al., 2000 ). Les espoirs de 
thérapie reposent principalement sur la thérapie génique. En effet, l’idée est de permettre aux 
cellules musculaires de réexprimer la dystrophine en apportant le gène de façon exogène. 
Pour cela, les chercheurs peuvent utiliser des virus modifiés (cette approche est rendue très 
difficile par la taille du gène), des cellules souches ou des transplantations de myoblastes 
sains. Toutes ces techniques sont prometteuses mais aucune n’a encore abouti à de réels 
progrès. Cependant, à la vue des moyens engagés, on peut légitimement penser que ces 
techniques permettront de guérir la maladie dans les décennies à venir. 
 
La DMD est caractérisée par une dégradation de la masse musculaire. Il n’a pas 
encore été clairement démontré quel type de mort cellulaire est impliqué dans cette perte. Il 
existe 2 types de mort cellulaire. La nécrose qui est due en général à un accident et qui est 
caractérisée par une inflammation des tissus. L’apoptose est la mort programmée des cellules 
(Zimmermann et al., 2001). C’est un processus physiologique très important car il permet par 
exemple la destruction des cellules malades (cancer). L’apoptose est hautement régulée par 
des protéines appartenant à la famille Bcl-2. Il existe 2 sous-types dans cette famille. Les 
protéines anti-apoptotiques comme Bcl-2 et bcl-XL. Ces protéines inhibent l’apoptose. 
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L’autre sous-type comprend les protéines pro-apoptotiques comme Bax, Bid.  Ces protéines 
activent l’apoptose (Tsujimoto & Shimizu, 2000). 
L’apoptose est caractérisée par le relâchement par la mitochondrie de facteurs comme 
le cytochrome c, l’apoptosis inducing factor (AIF)… Ces derniers vont activer des protéases 
(caspases) qui vont digérer des protéines cibles et ainsi entraîner la cellule vers la mort. 
Dans la DMD, le type de mort cellulaire impliqué est encore discuté. Certains auteurs 
ont montré une nécrose des tissus musculaires (Badalamente & Stracher, 2000), d’autres une 
apoptose (Podhorska-Okolow et al., 1998). D’autres ont montré que les 2 types de mort 
étaient impliqués (Tidball et al., 1995). 
 
 Une des conséquences de la DMD étant l’augmentation du Ca2+ intracellulaire, il a 
fallu développer des techniques permettant d’étudier l’homéostasie calcique de la cellule. 
Une des techniques disponible est l’utilisation d’une protéine issue de la méduse Aequorea 
victoria qui est sensible au Ca2+, l’aequorine. En effet, cette protéine émet de la lumière 
lorsqu’elle se lie au Ca2+. L’émission de lumière peut être enregistrée à l’aide d’appareils 
appropriés. Le principal avantage de cette sonde est qu’elle peut être ciblée dans n’importe 
quel compartiment de la cellule (Brini et al., 1994). L’aequorine spécifique est transfectée 
dans les cellules en prolifération avant chaque expérimentation et les myotubes sont utilisés 
entre 4 et 5 jours après la transfection. 
 
Le but de ce travail a été de mieux comprendre l’homéostasie calcique de la DMD par  
l’étude d’un des récepteurs libérant le Ca2+ à partir des stocks intracellulaires, l’IP3R. Pour 
cela, nous avons utilisé des cellules musculaires (myotubes) dérivées du modèle murin de la 
DMD, les cellules dystrophiques ou mdx. Nous les avons comparées avec leurs homologues 
sains, les cellules C57. Nous avons montré, en utilisant l’aequorine ciblée dans des endroits 
spécifiques de la cellule que, dans les myotubes dystrophiques uniquement, la réponse 
calcique mesurée sous la membrane plasmique et provoquée par la stimulation du nAChR est 
dépendante de l’IP3. Cette réponse est 4.5 fois plus grande dans les myotubes dystrophiques 
que dans les myotubes sains. Cette surcharge calcique est aussi retrouvée lorsque l’on 
mesure, dans les mêmes conditions, la concentration de Ca2+ dans les mitochondries. A 
l’opposé, la réponse calcique observée dans les myotubes contrôles est indépendante de l’IP3. 
De plus, nous avons aussi montré qu’en surexprimant dans nos cellules la protéine anti-
apoptotique Bcl-2, la surcharge calcique était diminuée, provoquant ainsi une amélioration de 
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la survie de myotubes dystrophiques uniquement. Cette amélioration pourrait être due à 
l’inhibition du récepteur à l’IP3 par Bcl-2. 
 
 
De nombreuses études ont montré que le RyR est le principal canal calcique impliqué 
dans la contraction musculaire. Cependant, il existe aussi l’IP3R et ce dernier n’a été que peu 
étudié dans les cellules musculaires squelettiques. Or, il a été suggéré récemment que l’IP3R 
et son messager l’IP3 sont très fortement augmentés dans les cellules dystrophiques (Liberona 
et al., 1998). Etonnemment, aucune expérience supplémentaire n’a été conduite. Nous avons 
donc étudié l’implication de l’IP3R dans la réponse calcique induite par l’activation 
physiologique du nAChR dans les cellules saines et dystrophiques. 
La stimulation du nAChR par un agoniste tel que le carbachol (CCh) entraîne une 
augmentation de la concentration de Ca2+ dans la zone située sous la membrane plasmique 
(pm[Ca2+]). Cette réponse est environ 5 fois plus élevée dans les myotubes dystrophiques que 
dans les myotubes sains (figure 1). De la même façon, la stimulation du nAChR par le CCh 
entraîne une augmentation de la concentration de Ca2+ dans la mitochondrie (m[Ca2+]). Cette 
augmentation est environ 1.5 fois plus grande dans les cellules dystrophiques. 
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Figure 1: la stimulation du nAChR entraîne une réponse calcique au niveau de la zone sous-
membranaire (gauche) ainsi qu’au niveau de la mitochondrie (droite). (n≥8, * et *** 
représentent une inhibition significativement différente (p<0.05 et p<0.001 respectivement) 
calculée grâce à un test-t) 
 
 
Ainsi, nous avons montré une nouvelle fois une dérégulation calcique dans les 
cellules dystrophiques et l’importance du Ca2+ dans la maladie. Nous avons ensuite déterminé 
quelles étaient les composantes de cette réponse induite par le CCh. Nous avons donc étudié 
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l’effet d’un inhibiteur de l’IP3R, le 2-aminoethoxydiphényle borate (2-APB) sur la réponse 
calcique induite par le CCh. L’incubation pendant 10 minutes avec 75 µM 2-APB diminue 
fortement la réponse calcique sous membranaire induite par 100 µM CCh dans les myotubes 
dystrophiques uniquement (figure 2). La réponse calcique dans les cellules saines reste 
inchangée. Ainsi, nous montrons que l’IP3R joue un rôle clef dans la réponse calcique induite 
par le CCh uniquement dans les myotubes dystrophiques. De plus, il semble que ce récepteur 
soit responsable de la surcharge calcique observée dans la zone sous-membranaire dans les 
myotubes dystrophiques. L’implication de ce récepteur représente une voie de signalisation 
surprenante et inattendue et qui pourrait avoir des conséquences thérapeutiques importantes. 
Il existe donc 2 voies de signalisation différentes si l’on compare les 2 types de cellules. En 
effet, la réponse calcique induite par le CCh ne passe pas par la voie de l’IP3 dans les cellules 
musculaires saines. 
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Figure 2 : effet d’un inhibiteur de l’IP3R sur la réponse calcique sous membranaire induite 
par le CCh (n≥4, ns représente une inhibition non significative, *** représente une inhibition 
significativement différente (p<0.001) calculée grâce à un test-t). 
 
 
Comme les mécanismes de dégradation cellulaire dans la DMD ne sont pas encore 
clairement identifiés, nous avons exploré les conséquences de la surcharge de Ca2+ sur la 
survie et la mort de la cellule. En effet, il a été montré que l’apoptose peut être déclenchée par 
une surcharge de Ca2+. Comme l’apoptose est hautement régulée par les membres de la 
famille Bcl-2, nous avons surexprimé dans nos cellules, de façon transitoire, la protéine anti- 
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apoptotique Bcl-2. Nous avons donc étudié l’effet de cette protéine sur la réponse calcique 
induite par le CCh dans la zone sous-membranaire et dans la mitochondrie. Nous avons aussi 
déterminé l’effet de la surexpression de Bcl-2 sur la survie et l’apoptose induites par 
différents stresses dans les cellules saines et dystrophiques. En effet, il a été montré que Bcl-2  
agissait en diminuant la surcharge calcique (Foyouzi-Youssefi et al., 2000) et notre hypothèse 
est que la surexpression de cette protéine pourrait diminuer la [Ca2+] dans les myotubes 
dystrophiques et ainsi diminuer la dégradation observée dans ces cellules. 
 Nous avons donc tout d’abord vérifié la surexpression de Bcl-2 dans nos cellules. 
Comme le montre la figure 3, Bcl-2 est surexprimée dans les cellules saines et dystrophiques. 
La protéine n’a pas été détectée dans les cellules non transfectées. 
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Figure 3 : western blot montrant la surexpression de la protéine Bcl-2 dans les myotubes 
sains et dystrophiques. 
 
 
Nous avons ensuite étudié l’effet de la surexpression de Bcl-2 sur la réponse calcique 
mesurée dans la zone sous-membranaire et dans la mitochondrie induite par le CCh. Comme 
le montre la figure 4, la surexpression de Bcl-2 diminue la réponse calcique dans la zone 
sous-membranaire uniquement dans les myotubes dystrophiques. Dans la mitochondrie, la 
surexpression de Bcl-2 diminue les réponses calciques induites par le CCh dans les 2 types 
cellulaires. Bcl-2 a donc un effet positif sur la surcharge calcique observée dans les cellules 
dystrophiques. Il a été publié récemment que Bcl-2 pourrait agir en inhibant l’IP3R (Chen et 
al., 2004). Le fait que la voie de signalisation de l’IP3 soit impliquée dans la réponse calcique 
induite par le CCh dans les myotubes dystrophiques permet de penser que l’action de Bcl-2 
se fait par l’inhibition de l’IP3R. Nous avons vérifié cette hypothèse en incubant les cellules 
 xi
avec des inhibiteurs de l’IP3. En effet, si Bcl-2 inhibe le récepteur, l’ajout de ces inhibiteurs 
n’aura pas ou très peu d’effet. Comme le montre la figure 5, l’incubation pendant 10 minutes 
du 2-APB et d’un autre inhibiteur de l’IP3R, la xestopongine D (0.1 µM) n’a pas d’effet 
additif sur la diminution de la réponse calcique observée. Bcl-2 pourrait donc agir en inhibant 
l’IP3R dans les myotubes dystrophiques. 
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Figure 4 : effet de la surexpression de Bcl-2 sur la réponse calcique induite par 100 µM CCh 
dans la zone sous-membranaire (gauche) et dans la mitochondrie (droite) (n≥5, ns représente 
une inhibition non significative, ** représente une inhibition significativement différente 
(0.01<p<0.001) calculée grâce à un test-t). 
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Figure 5 : effet de 2 inhibiteurs de l’IP3R sur la réponse calcique mesurée dans la zone sous-
membranaire induite par le CCh dans des myotubes dystrophiques surexprimant Bcl-2 (n≥8, 
*** représente une inhibition significativement différente (p<0.001) calculée grâce à un test 
ANOVA suivi du test de Dunnett ;  la barre contrôle est notée control)  
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 Nous avons ensuite étudié la survie cellulaire dans des myotubes qui surexpriment ou 
non la protéine Bcl-2. Ces cellules ont été stressées par la staurosporine (STS) qui entraîne 
une apoptose Ca2+ dépendante (Kruman et al., 1998) et par H2O2 qui entraîne une mort 
cellulaire par formation de radicaux oxygénés toxiques pour la cellule. La figure 6 montre 
que les myotubes dystrophiques sont plus sensibles aux stresses que les myotubes sains. De 
plus, la surexpression de Bcl-2 ne protège que les myotubes dystrophiques dans le cas de 
l’apoptose induite par la STS uniquement. Bcl-2 n’a aucun effet sur la mort cellulaire induite 
par H2O2. Bcl-2 ne protège donc que les cellules dystrophiques dans le cas d’une apoptose 
Ca2+-dépendante (STS). 
 On retrouve les mêmes résultats lorsque l’on effectue un test qui mesure 
spécifiquement le taux de cellules en apoptose. Là encore, la surexpression de Bcl-2 ne 
protège que les myotubes dystrophiques, dans le cas du stress induit par la STS (figure 7). 
Finalement, nous avons étudié l’effet de l’éponge IP3 qui va capturer tous les messagers IP3 et 
va ainsi inhiber les réponses déclenchées par la voie de l’IP3R (Uchiyama et al., 2002). 
L’éponge IP3 est très spécifique (Kd=92 nM). L’expression transitoire de cette éponge dans 
les myotubes dystrophiques a permis de diminuer le taux d’apoptose induite par la STS 
(figure 7). Bcl-2 pourrait donc bien agir en inhibant la voie IP3 dans les myotubes 
dystrophiques. 
 
c57/stauroc57/stauro/bcl-2c57/h2o2 c57/h2o2/bcl-2
0
25
50
75
100
STS
H2O2
bcl-2
-
-
-
-
-
-+
+
++
+
+
ns
ns
C57
ce
ll 
su
rv
iv
al
(%
 o
f c
on
tro
l)
md
x/s
tau
ro
md
x/s
tau
ro
/bc
l-2
md
x/h
2o
2
md
x/h
2o
2/b
cl2
0
25
50
75
100
-
-
-
-
-
-+
+
++
+
+
*
ns
mdx
STS
H2O2
bcl-2
ce
ll 
su
rv
iv
al
(%
 o
f c
on
tr
ol
)
 
 
Figure 6 : effet de la surexpression de Bcl-2 sur la mort cellulaire induite par la 
staurosporine  et l’H2O2  (ns représente une inhibition non significative, * représente une 
inhibition significativement différente (p<0.05) calculée grâce à un test-t). 
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Figure 7 : effet de la surexpression de Bcl-2 sur l’apoptose induite par la STS et l’H2O2 
(gauche) ; effet de l’éponge IP3 sur l’apoptose induite par la STS dans des myotubes 
dystrophiques (droite) (ns représente une inhibition non significative, ** et *** représentent 
une inhibition significativement différente (0.01<p<0.001 et p<0.001 respectivement) 
calculée grâce à un test-t ou un test ANOVA suivi d’un test de Dunnett). 
 
 
 
Ce travail met en évidence une nouvelle fois la surcharge calcique dans les myotubes 
dystrophiques et l’importance de cet ion dans la maladie. De plus, il a montré le rôle clef de 
l’IP3R dans les désordres calciques observés dans les myotubes dérivés de souris 
dystrophiques. L’étude de la voie d’activation de ce récepteur pourrait permettre de mieux 
comprendre la maladie et de trouver de nouveaux traitements. La surexpression de Bcl-2 a 
permis de monter que l’on pouvait améliorer la survie des cellules dystrophiques en 
diminuant la [Ca2+]. Finalement, nos résultats suggèrent que l’action de la protéine Bcl-2 se 
fait par une inhibition de la voie IP3. 
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2 SUMMARY 
 
Duchenne Muscular Dystrophy (DMD) is one of the most common and severe X-
linked myopathies. The disease affects 1 in 3500 males and results in progressive muscle 
degradation. As there is no treatment, patients are subject to premature death by respiratory or 
cardiac failure during the third decade. DMD is caused by the absence of dystrophin, a 
protein localized under the plasma membrane and that stabilizes it. The lack of dystrophin 
results in greater membrane fragility, greater sensitivity to mechanical stress and exercise and 
increased permeability to Ca2+. Ca2+ overload could then be responsible for the muscle 
degradation that occurs in the disease. 
We used the Ca2+-sensitive photoprotein aequorin targeted to different cellular 
compartment in order to investigate Ca2+ handling in myotubes derived from dystrophic and 
control mice. We show for the first time that the activation of the nicotinic acetylcholine 
receptor with carbachol triggers subsarcolemmal Ca2+ responses that are inositol 1, 4, 5-
trisphosphate (IP3) dependent in dystrophic myotubes only. Moreover, these Ca2+ responses 
are 4.5 times higher in dystrophic cells when compared to control cells. These exaggerated 
Ca2+ transients were also measured in mitochondria. On the opposite, carbachol-induced Ca2+ 
responses are not IP3-dependent in control cells. 
Using the same methodology, we investigated the effect of the anti-apoptotic protein 
Bcl-2, which is involved in the regulation of cell death and in Ca2+ homeostasis. Thus, we 
show that Bcl-2 overexpression decreases Ca2+ transients in mitochondria and 
subsarcolemmal area in our myotubes. We also demonstrate that Bcl-2 prevents 
staurosporine-induced apoptosis in dystrophic myotubes only. This protection could be due to 
a direct inhibition of the IP3 receptor by Bcl-2. Bcl-2 overexpression could therefore prevent 
muscle degradation that occurs in DMD. 
This work shows the key role of the IP3R in altered Ca2+ homeostasis in myotubes 
derived from dystrophic mice. The study of the activation pathway of this receptor improves 
our understanding of the disease, and may open new therapeutic approaches to the therapy of 
DMD. 
 xx
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1 CHAPTER 1-INTRODUCTION 
 
 
Human body weight is composed by about 40 % of muscle. Muscle tissue is composed 
of cells that are highly specialized for the generation of force. As a result, muscle tissue is 
involved in motion, maintenance of posture and blood pressure, gut peristalsis and heat 
production. Based on functional and physiological properties, muscles have been divided into 
3 types: smooth, cardiac and skeletal. 
Smooth muscle is located in the wall of internal structures such as blood vessels, 
stomach, intestines and is made of single, spindle-shaped, non-striated cells hence its 
designation. Smooth muscle is involved in involuntary movement such as maintenance of 
blood pressure.  
Cardiac muscle forms the contractile wall of the heart and is composed in part of 
pacemaker cells that trigger autonomous and involuntary contraction. Unlike skeletal muscle, 
cardiac fibers are branched altogether and gap junctions between cells permit the propagation 
of the action potential that triggers rhythmic contraction of the heart. Cardiac muscle is 
striated.  
Skeletal muscle is involved in voluntary movements of the body, and abnormalities of 
skeletal muscle tissue cause many muscle diseases such as Duchenne Muscular Dystrophy. 
An extended description of skeletal muscle is presented below.  
 
1.1 Skeletal muscle 
 
1.1.1 Skeletal muscle myogenesis 
Skeletal muscle myogenesis is a highly regulated process that involves hundreds of 
proteins. Briefly, during embryonic life, the intra-embryonic mesoderm differentiates into 
paraxial, intermediate and lateral plate portions. The paraxial mesodermal cells in the trunk 
become organized into somites and each somite differentiates in dermomyotome (dermatome 
and myotome) and sclerotome. The myotome will form the muscle cells through myogenic 
precursors. These cells express a protein, Pax 3 that triggers myogenic precursor proliferation 
and migration to specific locations (hindlimb, forelimb…). These myogenic precursors are 
also called satellite cells and are the cells that regenerate damaged muscles. These cells are 
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capable of dividing and fusing with existing fibers. Once localized, the expression of basic 
helix-loop-helix transcription factors (bHLH), Myf5 and MyoD, triggers the formation of 
myoblasts. Myoblasts represent the first step of myogenesis. They are small mono-nucleated 
cells, which eventually proliferate and fuse with each other when they are confluent. This 
process is regulated by Ca2+. The fusion of myoblasts forms multi-nucleated myotubes. 
Myotubes in culture can be very long (> 100 µm) and are capable of contraction. They 
express muscle-specific proteins such as myosin or actin. However, myotubes are non mature 
muscle cells. The last stage of muscle differentiation is fiber formation which occurs when 
muscle cells are innervated. A muscle fiber is a mature cell that is striated and contains all the 
proteins needed for contraction. 
 
 
 
Figure 1.1: Myogenesis. 
Multipotential precursors cells in the 
somatic mesoderm lead to myogenic 
lineages. Under control of growth 
factors like fibroblast growth factor 
and other factors such as erythro- 
poietin (Ogilvie et al., 2000), the 
resulting myoblasts proliferate and 
express muscle regulatory factors 
(MRFs) such as MyoD or Myf-5. 
After withdrawal from the cell cycle 
and under control of other MRFs like 
myogenin and MEF2, adjacent 
myoblasts align and fuse to give 
multinucleated myotubes that can have 
spontaneous contractions. This process 
is regulated by various factors such as 
Ca2+ ions or enzymes like calpains and 
accompanied by synthesis of muscle-
specific proteins such as actin or 
myosin. Elongated myotubes are then 
able to form highly organized myo- 
fibers. Nuclei, centrally placed at first, 
become distributed toward the 
periphery (red spots) while the 
contractile apparatus (observed as 
striations, green lines) is displaced 
toward the central part of the myotube 
during maturation. During late 
development through maturation of 
myotubes and innervation, muscle 
fibres are formed, showing specific 
striations and the ability to contract. 
(adapted from Constantin & Cronier, 
2000) 
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1.1.2 Structure and function 
A skeletal muscle is composed of a group of fibers that are roughly cylindrical, with 
diameters ranging between 10 and 100 µm and up to a few centimeters long (Figure 1.2). 
Skeletal fibers are formed by the fusion of myoblasts and can therefore have hundreds of 
nuclei that are localized near the plasma membrane (or sarcolemma). Between fibers and the 
extracellular matrix (or basal lamina) are large numbers of satellite cells that are important in 
the growth and repair of fibers. In adult muscle, these satellite cells are quiescent and 
differentiate only in case of muscle damage. 
Fibers are formed by a network of myofibrils that follow the muscle. Each myofibril is 
composed of proteins that are involved in force production. These proteins are actin which 
composes the thin filament and myosin, which composes the thick filament. Myosin is the 
protein which is responsible for force generation. It is composed of a globular head with both 
adenosine triphosphate (ATP) and actin binding sites. Actin, when polymerized into 
filaments, forms the "ladder" along which the myosin filaments attach to generate motion. 
The thick and thin filaments are regularly arranged and form the skeletal muscle typical 
pattern of light and dark bands visible with the light microscope. It is also because of these 
fibrils that skeletal muscle demonstrates its characteristic striated pattern. The functional unit 
of the muscle, called sarcomere, is composed by a light and a dark band. During contraction, 
actin and myosin slide one on each other.  
Other proteins are closely linked to actin and myosin and stabilize these proteins 
before and after contraction. Troponin, which is one of the major regulators of force 
production, blocks the myosin binding site of actin in the absence of Ca2+. Troponin itself is 
regulated by tropomyosin. Titin, an enormous protein involved in maintaining the striation 
pattern by close association with the myosin molecule, probably anchors the myosin network 
to the actin network. Nebulin, which is also associated with actin, acts by regulating the 
length of actin filaments. 
 
When muscle contracts, there is a close association between actin and myosin. During 
contraction the length of thin filaments and the length of thick filaments remain constant. 
Thus, during contraction the length of the sarcomere and band I decreases; the overlap 
between thick and thin filaments increases; and the length of the thick and thin filaments 
remains unchanged. Consequently, the 2 filaments slide on each other. This theory has been 
proposed in 1954 by A.F. Huxley and is called the sliding-filament theory (Huxley & Nieder- 
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Figure 1.2: Structure of skeletal muscle fiber. 
A muscle is composed of muscle fibers bundled in sheaths. Fibers are multinucleated cells and each is 
constituted by myofibrils. These are made of thick filaments (myosin) and thin filaments (actin). Thin 
and thick filaments form the contractile unit called sarcomere which appears as alternating light and 
dark bands when observed with a microscope. 
The thin filaments form the band I and the band between 2 thin filaments is called Z disc. Sarcomere is 
surrounded by Z discs. The region where thin and thick filaments overlap each other forms the band 
A. The central zone where there are only thick filaments is called H zone. 
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gerke, 1954).  
When ATP binds to the myosin head in the thick filaments, ATP is hydrolyzed by 
myosin and disconnects actin from myosin. The energy released by the splitting of ATP is 
stored in the myosin molecule and represents a high-energy state; this is the predominant state 
at rest. Upon muscle stimulation, the inhibition of actin-myosin interaction, imposed by the 
regulatory proteins, is lifted and consequently the myosin in high-energy state binds to actin. 
The actin-myosin interaction triggers the release of ADP from the myosin head, resulting in 
movement. The energy stored in the myosin molecule triggers a conformational change in the 
cross-bridge between actin and myosin modifying the angle from 90o to 45o. This tilting pulls 
the actin filament about 10 nm toward the center of the sarcomere, while the energy stored in 
myosin is utilized. Contraction occurs. With a new ATP a new cycle may begin and the 
cycling may continue until the regulatory mechanism stops the interaction of actin and 
myosin. 
 
The energy used by skeletal muscle is ATP. As normal metabolism cannot produce 
energy as quickly as a muscle cell can use it, an extra storage source is needed: the main 
energy suppliers are glucose and glycogen that can generate ATP through aerobic or 
anaerobic reactions. Glucose is brought by food and is taken up from the blood for a direct 
use. Glycogen is synthesized from glucose and stocked mainly in the liver but also in skeletal 
muscle. Thus, through glycogenolysis, glycogen is metabolized in glucose.  
The aerobic reaction takes place in mitochondria and is based on oxidative 
phosphorylation reactions: Nicotinamide Adenine Dinucleotide (NADH), which is generated 
during tricarboxylic acid (TCA) cycle from the degradation of glucose, plays a central role in 
oxidative metabolism. Through the mitochondrial electron transport chain, NADH can 
transfer two electrons and this is enough energy to synthesize approximately 7 ATPs from 
ADP. Flavin Adenine Dinucleotide (FADH2) is another important part of oxidative 
metabolism. Oxidation to FAD releases enough energy to generate nearly 6 ATPs. Muscle 
cells also use the creatine phosphate as energy supplier. The phosphate group of the creatine 
can be quickly transferred to ADP to regenerate the ATP necessary for muscle contraction. 
The reaction is catalyzed by creatine kinase which is found to be elevated in blood serum in 
DMD patients (see 1.2.3).  
Muscle can also use anaerobic metabolism to generate ATP. In this case, ATP is 
produced by degradation of glycogen into pyruvate and lactic acid. However, this process is 
not very efficient as only 3 ATP molecules are produced per cycle. It is also limited by the 
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accumulation of lactic acid which causes a pH decrease and extreme fatigue that leads to 
cramps. When combined, both anaerobic and aerobic pathway could produce 36 ATP 
molecules for 1 glucose molecule that is consumed. 
 
Skeletal muscles contain 2 different fiber types, the slow-twitch fibers (type I) and the 
fast-twitch fibers (type IIA and IIB). Their main characteristics are summarized in Table 1.1:   
 (from Ruegg, 1992) 
 Type I (red) 
SLOW-TWITCH 
Ex.: soleus 
Type II A (red) 
FAST-TWITCH 
Ex.: quadriceps 
Type II B (white) 
FAST-TWITCH 
Ex.: EDL 
Myoglobin content high high low 
Contraction speed low high high 
Myosin ATPase activity  low high high 
Myosin isoenzyme slow fast fast 
SR Ca2+ pumping capacity moderate high high 
Parvalbumin* content absence moderate high 
Resistance to fatigue high moderate low 
Number of mitochondria high high low 
Metabolism oxidative glycolytic and oxidative glycolytic 
Myofibre diameter moderate small large 
*Parvalbumin is a Ca2+-binding protein that transports Ca2+ from troponin to the SERCA during muscle 
relaxation. 
 
The relative proportion of type I and type II composing muscle fiber determines its 
characteristics.  Type II fibers are fatigable and are used for fast and strong contraction while 
type I fibers are less fatigable and are used for long and continuous contraction. In human, the 
soleus muscle is a slow muscle as it is composed by around 90 % of type I fibers, the 
quadriceps is considered as an intermediate muscle as it is made of equal amount of type I and 
type II fibers. Extensor Digitorum Longus muscle is considered as a fast muscle as it is 
composed by around 70 % of type II fibers.  
 
1.1.3 Excitation-contraction coupling 
Like most excitable cells, muscle fibers respond to the excitation signal with a rapid 
depolarization followed by its physiological response: contraction. As a result of the action 
potential generated in the central nervous system, the motor-neuron releases acetylcholine 
(ACh) at the neuromuscular junction (NMJ). ACh activates nicotinic receptors localized on 
the sarcolemma  resulting in Na+ entry that depolarizes the cell. The depolarization  wave fol- 
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to the adjacent T-tubule membrane. 
(C) Schematic diagram showing how a Ca2+ release
thought to be opened by a voltage-sensitive tr
membrane (from Molecular Biology of the Cell, 3rd
 
Figure 1.4: T-tubules and the
sarcoplasmic reticulum. 
(A) Drawing of the 2 systems of 
membranes that relay the signal to 
contract from the muscle cell 
plasma membrane to all of the 
myofibrils in the cell. 
(B) Electron micrograph showing 
two T-tubules. Note the position 
of the large Ca2+ release channels 
(RyR) in the sarcoplasmic reti- 
culum membrane; they look like 
square-shaped "feet" that connect 
 Figure 1.3: Excitation-Contraction coupling. 
(A) An action potential is generated in the brain 
and propagated across the motor neuron and arrives 
at the neuromuscular junction.   
(B) 1- The action potential triggers neuro- 
transmitter release (ACh); 
 2- Released neurotransmitter diffuses across the 
synaptic cleft and binds to his receptors on the 
plasma membrane. Then the action potential is 
propagated along the T tubules; 
3- The action potential induces Ca2+ release from 
the sarcoplasmic reticulum; 
4, 5- Ca2+ ions bind to troponin. The conformal 
change in troponin removes the blocking action of 
tropomyosin and the contraction occurs; 
6- Ca2+ is actively pumped in the sarcoplasmic 
reticulum when the action potential ends; 
7- Tropomyosin blockade is restored and the 
muscle relaxes.   channel (RyR) in the sarcoplasmic reticulum membrane is 
ansmembrane protein (DHPR) in the adjacent T-tubule 
 edition) 
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lows the plasma membrane and in a few milliseconds reaches a series of infoldings of the 
membrane called transverse tubular system or T-tubules. These last are in contact with the 
sarcoplasmic reticulum (SR) which closely surrounds myofibrils and that efficiently 
sequesters and releases Ca2+ needed for contraction. Another extremely important component 
localized in the T-tubule that is sensing depolarization is the dihydropyridine receptor 
(DHPR). DHPR is an L-type Ca2+ channel, localized in specific areas that face the main 
effector of the excitation-contraction coupling, ryanodine receptor (RyR) (see 1.1.4). The 
DHPR triggers RyR opening which results in massive SR Ca2+ release in the cytosol (Rios & 
Brum, 1987). Released Ca2+ binds to troponin. The conformal change in troponin removes the 
blocking action of tropomyosin and contraction occurs (see 1.1.2). Muscle contraction stops 
when Ca2+ is pumped back into the SR by SR Ca2+-ATPases (SERCA). Then the 
troponin-tropomysin complex blocks the myosin binding site on the actin molecule (Figure 
1.3 and 1.4). 
 
1.1.4 Calcium handling in skeletal muscle cell 
Ca2+ is a ubiquitous intracellular messenger that is involved in many cellular processes 
such as fertilization, gene transcription and, in our purpose, muscle contraction. Since 
numerous Ca2+ tools are available, this ion has been widely studied in a wide range of cell 
types. In skeletal muscle cells, depolarization of the T-tubule system triggers the release of 
Ca2+ from the SR and produces contraction through actin and myosin, as exposed previously. 
Then, in order to promote repetitive and effective contractions, skeletal muscle cells must 
have the capability to handle, release and recapture Ca2+ in a highly reproducible manner. 
Thus, Ca2+ fluxes within skeletal muscle cell are regulated by hundreds of molecules such as 
voltage-gated channels, Ca2+-binding proteins, exchanger, pumps… or intracellular organelles 
such as SR and mitochondria. All these proteins are involved in the maintenance of a 
cytosolic [Ca2+] close to 100 nM while the extracellular [Ca2+] is around 1.3 mM. A 
summarized view of these Ca2+ regulators is given below (figure 1.5). 
 
Nicotinic acetylcholine receptor (nAChR) belongs to the class of the receptor-
operated channel (ROC). nAChR is a 290 kDa, hetero-pentameric glycoprotein (subunits: α, 
γ, α, β, δ; the γ subunit is replaced by a ε subunit in adult form). The receptor is localized on 
the plasma membrane, more precisely at the post-synaptic part of the NMJ. It is responsible 
for the depolarization that triggers the excitation-contraction coupling. Indeed, ACh is 
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released in the NMJ in response to an action potential. ACh then binds to nAChR and triggers 
Na+ entry and to a lesser extent Ca2+ entry with a ratio permeability PCa2+/PNa+ of ~0.2 (Karlin, 
2002).  
Voltage-operated Ca2+ channels (VOC) are localized at the plasma membrane. 
Voltage-operated Ca2+ channels are hetero-multimers composed of an α1 subunit and 3 
auxiliary subunits, α2-δ, β and γ. The α1 subunit is pore-forming, provides extracellular 
binding for the agonists and antagonists and has 4 homologous domains that form 6 
transmembrane domains. Today 6 subfamilies have been found (L-, P-, Q-, N-, R-, T-type) 
and each has different properties. The L-type is localized in muscle cells (skeletal, heart, 
smooth) and is inhibited by dihydropyridines (DHP, see below). T-type Ca2+ channel is 
involved in pacemaking in neurons and cardiac myocytes and contributes to a standing Ca2+ 
current near the resting membrane potential in various cell types. P-, Q-, N- and R-type Ca2+ 
channel are mainly localized in neurons and differ in their voltage activation and speed of 
inactivation. 
Dihydropyridine receptor (DHPR) and ryanodine receptor (RyR): DHPR is 
localized at the plasma membrane, more precisely in the T-tubule. It is an L-type 
voltage-operated Ca2+ channel that interacts directly (through conformational changes) or 
indirectly (through Ca2+ influx) with the RyR. Indeed, it has been shown in skeletal muscle 
that DHPR are connected with RyR (Kugler et al., 2004). Then, DHPR conformational 
changes triggered by plasma membrane depolarization are translated into signal by a direct 
mechanical interaction with the RyR while in cardiac muscle cells depolarization triggers a 
Ca2+ influx through DHPR that activates RyR. RyRs are localized on the SR membrane and 
release Ca2+ in the cytosol (Franzini-Armstrong & Protasi, 1997). RyR have general structure 
similarities with another intracellular Ca2+ release channel, the inositol 1,4,5-trisphosphate  
receptors (IP3R, see below), with which they share the task of releasing Ca2+ from the SR (see 
below). However, RyR have higher conductivity than IP3R for Ca2+. RyR is composed by 4 
equal subunits that are closely associated to form a pore (Inui et al., 1987). Moreover, a large 
cytosolic part of the receptor, called foot, allows a direct connection between the channel and 
the plasma membrane. Three isoforms of RyR exist: RyR1 is predominantly found in skeletal 
muscle, RyR2 is found in heart and in some type of smooth muscle and RyR3 is widely 
distributed (Protasi et al., 2000; Brini, 2004). 
Inositol 1, 4, 5-trisphosphate receptor  is also localized at the SR membrane (Patel et 
al., 1999; Patterson et al., 2004) but can also been found in the nuclear envelope (Nicotera et 
al., 1990), plasma membrane (Khan et al., 1992) and Golgi apparatus (Pinton et al., 1998). As 
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RyR, IP3R releases Ca2+ from the SR. To date, full length sequences for 3 distinct IP3R genes 
have been described (IP3R1, IP3R2 and IP3R3). IP3R1 is mainly found in cerebellum, lung and 
heart, and in general have the widest distribution amongst tissue and cell types (Taylor, 1998). 
Type 2 receptors, while also found in brain and lung, are additionally present in placenta and 
thymocytes and type 3 receptors are predominantly expressed in the gastrointestinal tract 
(Pattni & Banting, 2004). IP3R is thought to traverse the plasma membrane 6 times and is a 
large tetrameric protein which forms a Ca2+ channel. Each subunit contains 3 functional 
domains:  
- a large ligand-binding site at the N-terminal region. Activation of the plasma 
membrane associated phospholipase C (PLC) by increases in cytosolic Ca2+ concentration 
(Berridge et al., 2003), G protein activation (Araya et al., 2002) or membrane depolarization 
(Vergara et al., 1985) stimulates the hydrolysis of phosphatidylinositol 4, 5-biphosphate and 
generates inositol 1, 4, 5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 is the ligand of the 
IP3R and binds to this N-terminal region. It triggers Ca2+ release from the SR. 
- a C-terminal domain. This region is located in the cytosol and shares homology with 
the corresponding region of the RyR. It is responsible for the anchoring of the receptor in the 
SR membrane, the tetramer formation and is likely to form the Ca2+ channel of the protein. 
- a regulatory site between N- and C-terminal regions. IP3R can be regulated by 
different components. Cytosolic Ca2+ have been shown to play a key role as there is Ca2+ 
binding sites located on the receptor (Sienaert et al., 1996). Indeed, 7 Ca2+ sites have been 
described with a part of them located directly in the IP3 binding site. Then, IP3R is inhibited 
by high Ca2+ concentration (µM) while lower concentration (< 0.8 µM) potentiates the effect 
of IP3 (Iino, 1990; Bezprozvanny et al., 1991). ATP, which is thought to be a competitive 
antagonist for IP3, can also regulate IP3R activity. It has been shown that the activity of the 
receptor is increased by micromolar ATP concentration while millimolar concentrations 
inhibit the receptor. There are 2 different binding sites for ATP (Bezprozvanny & Ehrlich, 
1993). In addition to its own autophosphorylation (Ferris et al., 1992), IP3R can be 
phosphorylated and regulated by several protein kinases. Then, cyclic AMP-dependent 
protein kinase (PKA) has been shown to enhance IP3-dependent Ca2+ release in hepatocytes 
(Hajnoczky et al., 1993) but to decrease it in cerebellar cells (Volpe & Alderson-Lang, 1990). 
Cyclic GMP-dependent protein kinase (PKG) enhances IP3-dependent Ca2+ release in 
different types of cells such as smooth muscle and hepatocytes presumably by increasing the 
sensitivity of the IP3R to its agonist (Komalavilas & Lincoln, 1994). Protein kinase C (PKC) 
and Ca2+-calmodulin dependent protein kinase II (CamKII) have the same effect as PKG 
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(Ferris et al., 1991). Ca2+-binding proteins have also been described to modulate IP3R activity. 
For example, calmodulin binds directly to IP3R and decreases the affinity of the receptor for 
IP3 in a Ca2+-independent manner (Patel et al., 1997). Moreover, as calmodulin is also a target 
for many kinases, this Ca2+-binding protein could be very important for IP3R phosphorylation. 
Finally, IP3R have been shown to interact with cytoskelal protein such as ankyrin, which can 
inhibit the receptor in lymphocytes cells (Bourguignon & Jin, 1995).  Ankyrin-like motifs 
have also been found in plasma membrane Ca2+ channels called store-operated channel (SOC) 
(Bennett et al., 1995). Then, by a direct link between IP3R and the cytoskeletal protein, IP3R 
could control SOC opening and Ca2+ entry within the cells in addition to its primary function, 
Ca2+ release from the internal store (see below). 
IP3R has not been yet fully studied in skeletal muscle cells as it is thought that the 
main receptor involved in the excitation-contraction coupling is the RyR. However, it has 
been shown that IP3 can potentiate depolarization-induced Ca2+ release or produce the 
contraction of intact or skinned skeletal muscle fibers (Talon et al., 1999); (Lopez & Parra, 
1991) and that T-tubules contain PLC which generates IP3 (Varsanyi et al., 1986). 
Furthermore, IP3 levels may be increased by repetitive depolarizations (Vergara et al., 1985; 
Hidalgo et al., 1993) suggesting that this second messenger may play a role in excitation-
contraction coupling in skeletal muscle. 
IP3 may also be involved in apoptosis. Indeed, it has been shown recently that caspase 
3, once apoptosis is induced by staurosporine in COS-7 and HeLa cells, can remove the IP3 
binding site and the most part of the regulatory domain of the IP3R1 then leading to the 
formation of a “channel only” domain that remains constitutively open and triggers Ca2+ leak 
(Assefa et al., 2004; Nakayama et al., 2004). 
Opening of both RyR and IP3R deplete internal Ca2+ stores that have to be refilled 
after each Ca2+ release. This can be mainly achieved by Ca2+ pump (SERCA, see below) and 
by Ca2+ entry through SOC (see below). 
SR and sarcoplasmic-endoplasmic reticulum Ca2+-ATPase (SERCA): the SR is the 
main organelle involved in the intracellular Ca2+ handling and Ca2+ release during contraction. 
Indeed, [Ca2+] in this compartment can be as high as 1 mM and sometimes more. Moreover 
and as described before, all important Ca2+ release channels (IP3R and RyR) are located on 
the surface of this organelle. After Ca2+ release, Ca2+ has to be taken up into the SR for further 
Ca2+ release. This Ca2+ refilling occurs through the SERCA which is a pump that uses ATP 
generated by the cytosolic creatine kinase. This last is bound to SERCA (Korge & Campbell, 
1994). SERCA expression is very high in muscle cell as compared with non-muscle cells. 
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Different isoforms of the pump have been found in muscle cells: SERCA1 is preferably 
located in fast muscle while SERCA2 is mainly localized in slow muscle (Zhang et al., 1997). 
Recently it has been shown that SR and mitochondria could exchange Ca2+ in microdomains 
of elevated [Ca2+] that exist between the 2 organelles (Rizzuto et al., 2004). Indeed, Ca2+ 
release from the SR is associated with an increased mitochondrial [Ca2+]. Blocking the 
SERCA with specific compounds such as thapsigargin induces Ca2+ store depletion. 
Mitochondria, uniporter, mitochondrial Na+-Ca2+ exchanger (mNCX) and mPTP: 
mitochondria are responsible both for maintaining cellular energy (ATP) through oxidative 
phosphorylation and fro initiation of apoptosis for example (see 1.4.2). Moreover, 
mitochondria are implicated in Ca2+ handling (Pozzan & Rizzuto, 2000). Ca2+ uptake by 
mitochondria is mediated by the uniporter (Gunter et al., 2000). Uniporter is a gated channel 
driven by the electrochemical gradient across the inner mitochondrial membrane (~180 mV) 
which is generated by the respiratory chain and ATP hydrolysis. The affinity for the Ca2+ ion 
is low (Kd > 20 µM) (Pozzan et al., 2000). In spite of this low affinity mitochondria can 
rapidly accumulate Ca2+ under physiological conditions (Rizzuto et al., 1992). Ca2+ efflux is 
catalyzed by antiporters that drive Ca2+ out of the mitochondrial matrix in exchange with 
either Na+ (3 Na+ for 1 Ca2+) or H+ (the stoichiometry is not well known yet but could be 2 H+ 
for 1 Ca2+) (Carafoli, 2003). mPTP is a non-specific pore, permeant to any molecule up to 1.5 
kDa, that opens in the mitochondrial inner membrane under conditions of elevated matrix 
[Ca2+], especially when this is accompanied by oxidative stress and depletion of adenine 
nucleotides. Opening of the mPTP causes massive swelling of mitochondria, rupture of the 
outer membrane and release of intermembrane components that induce apoptosis (see 1.4.2) 
(Bernardi, 1999; Halestrap, 2002). 
Store-operated channels (SOCs) are channels that are activated by the depletion of 
the internal Ca2+ stores. Indeed, SR depletion triggers Ca2+ entry through these channels 
which is called capacitative Ca2+ entry (CCE). Two mechanisms are hypothesized for channel 
activation: the first is a direct interaction between IP3R or RyR (Irvine, 1990; Kiselyov et al., 
2000; Ma et al., 2000; Pan et al., 2002; Launikonis et al., 2003) that activates SOCs once 
store has been depleted. The interaction between IP3R, RyR and the Ca2+ entry channel is 
thought to occur in junctional zones where portions of the SR containing the coupled 
receptors are close to the plasma membrane (Berridge, 2004). The other hypothesis, which 
has been forgotten for a while is the involvement of an unknown messenger called CIF (Ca2+ 
influx factor) that is released when stores are depleted and that activate SOCs 
(Randriamampita & Tsien, 1993). CIF could activate phospholipase A2 (through inhibition of 
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calmodulin) that triggers lysophospholipid formation. These last activates SOCs. Very 
recently this pathway has been shown in different type of cells (Smani et al., 2004; Vanden 
Abeele et al., 2004). The exact molecular nature of these SOCs is still unknown but it could 
belong to the Transient Receptor Potential Channels (TRPC) family. TRPCs are composed by 
6 transmembrane subunits that assemble as tetramers to form cation-permeable pore 
(Clapham, 2003) and some of them have been found to be involved in abnormal Ca2+ influx in 
mdx mouse (Vandebrouck et al., 2002). 
Stretch-activated Ca2+ channels are activated by stretch or pressure on the plasma 
membrane. They belong to the class of mechanosensitive ion channels. They have been 
shown to be involved in the Ca2+ entry in mdx mice, the murine model of DMD (see 1.2.4) 
and in the Ca2+ overload that could trigger fiber degradation in DMD (see 1.2.3) (Yeung et 
al., 2003; Yeung et al., 2004). Today, the interest of these channels and their involvement in 
DMD has risen because of the availability of specific inhibitors such as the spider venom 
gramotoxin (Yeung et al., 2004).   
Plasma membrane Ca2+-ATPase (PMCA) and Na+-Ca2+ exchanger (NCX): PMCA 
uses ATP to extrude Ca2+ from the cytosol (Strehler & Treiman, 2004). In skeletal muscle 
cells this pump has a minor activity when compared to SERCA. NCX catalyses an exchange 
of 2 Na+ ions (entry) and 1 Ca2+ ion (exit). The primary function of NCX is extrusion of Ca2+ 
from myocytes during relaxation. The particularity of this exchanger is that it can function in 
reverse-mode depending on the electrochemical gradient and by this way triggers Ca2+ entry 
into the cells. Ca2+ influx through the NCX reverse-mode could refill the Ca2+ store 
(Shigekawa & Iwamoto, 2001). Three different isoforms have been found and NCX2 and 
NCX3 are expressed in skeletal muscle cells. 
Ca2+-binding proteins such as calmodulin and parvalbumin in the cytosol or 
calsequestrin and calreticulin in the SR participate to the Ca2+ handling. Calmodulin is a 15 
kDa protein which belongs to the EF-hand family protein. It is the most important protein for 
cytosolic Ca2+ handling. One molecule of calmodulin binds 4 Ca2+ ions (Vetter & Leclerc, 
2003). Parvalbumin has 2 high affinity binding sites for Ca2+. An increase in mRNA levels of 
parvalbumin has been found in fast muscle from dystrophic mice but not in DMD patients 
even if the protein level is normal or decreased in these cells (see 1.2.3) (Gailly et al., 1993). 
Calsequestrin is a ~60 kDa acidic protein which is contained in the lumen of the SR of 
skeletal, cardiac and smooth muscle and is anchored to the SR membrane. The anchorage is 
responsible for maintaining calsequestrin in the region of the SR close to the calcium-release 
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channels (IP3R and RyR). Calsequestrin has a low affinity (Kd ~1 mM) but high capacity for 
Ca2+ (~50 Ca2+ ions per molecule) (Franzini-Armstrong et al., 1987). 
 
 
 
Figure 1.5: Summarizing scheme of the Ca2+ regulation (adapted from Orrenius S. et al., 
2003) 
 
1.1.5 A specific area just under the plasma membrane 
The amount of ions entering through voltage-gated channels is thought to be too small 
to produce a significant change in the bulk cytosol ion concentration unless it enters a 
subplasmalemmal space of restricted diffusion. This restricted area which has been called 
fuzzy space (Lederer et al., 1990) is a ~10 nm microdomain localized at the junction of the T-
tubules and the SR (figure 1.6) and is involved in excitation–contraction coupling. Indeed, it 
is postulated that voltage-operated Ca2+ channels, ryanodine receptors are located in the fuzzy 
space, where Ca2+ ion concentrations could be significantly higher than in the cytosol 
(Adachi-Akahane et al., 1996). There is also a Na+ microdomain which contains NCX, Na+ 
channels and Na+/K+-ATPase (Verdonck et al., 2004). Moreover, it has been shown that 
mitochondria that are localized in this space have different properties when compared to the 
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mitochondria that are localized in the cytosol (Szado et al., 2003). Indeed, such “peripheral” 
mitochondria have close and functional contacts with the superficial SR and the plasma 
membrane. They are able to handle Ca2+ that is released from the SR and that enters the cell 
through plasma membrane Ca2+ channels (Rizzuto et al., 2004). By this way, mitochondria 
affect both Ca2+ release from the SR and CCE across the plasma membrane, thereby shaping 
the size and duration of the intracellular Ca2+ signal. 
As [Ca2+] is increased in DMD (see 1.2.3) this area localized just under the plasma 
membrane could be very important for the maintenance of Ca2+ homeostasis in this specific 
disease. Thus, studying Ca2+ fluxes in this area could lead to interesting findings in DMD. 
The use of plasma membrane targeted Ca2+ probes such as aequorin (see 1.3) allows Ca2+ 
measurements in this area (see Results). 
 
      
 
 
Figure 1.6: Scheme of the fuzzy space in a cardiac myocyte (from Verdonck et al., 2004) 
The green shaded area indicates the Ca2+ microdomain between the Ca2+ release channel (RyR) of the 
SR and the L-type Ca2+ channel (DHPR) in the T-tubule membrane. The Na+ microdomain contains 
the NCX, the Na+ channels and the Na+/K+-ATPase, and extends beyond the Ca2+ microdomain, as 
indicated by the more lightly shaded zone. 
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1.2 Duchenne Muscular Dystrophy 
 
1.2.1 Genetic and clinical features of Duchenne Muscular Dystrophy 
Duchenne muscular dystrophy (DMD) is an X-linked neuromuscular disease that 
affects about 1 in 3500 males and which results in progressive muscle degeneration (Emery, 
2002). It was first described in 1860 by the French doctor Guillaume Duchenne who gave his 
name to the disease. All muscle types (skeletal, smooth and cardiac) can be affected. An 
intriguing point exists in that extraocular muscles remain clinically and pathologically 
unaffected during all the disease, even at late stage (Khurana et al., 1995). The young DMD 
patients do not present any symptoms during the first three to five year of life. Parents only 
note a delayed ability to walk, frequent falls and difficulties to stand up. Year after year the 
young boys loose their muscle mass and they have difficulties to climb stairs. A 
pseudohypertrophy of the calf muscle is sometimes visible. A global muscle weakness 
appears and the walk is impossible at the age of 12-13. Affected boys are then moving only 
with a wheel chair. At the same time of the muscle loss, fatty tissues are appearing. DMD 
patients often have nutritional problems (obesity or severe thinness) and sometimes a big toe. 
Due to a heavy scoliosis young boys often carry corset in order to maintain the straight 
posture. Thirty percent of the DMD patients display a variety of forms of mental retardation 
that involves verbal skill and low IQ suggesting that brain functions could be affected in the 
disease. Because cardiac muscle and diaphragm are affected by the disease, DMD patients 
generally die before the age of 30 because of cardiac or respiratory failure (AFM, 2001). 
The disease is due to the lack of a protein, dystrophin. This protein is localized just 
under the plasma membrane of muscle cells and links the extracellular matrix with the 
cytoskeleton (see 1.2.2). The defective gene responsible for the disease was localized in 1986 
on the X-chromosome at the Xp21 region (Monaco et al., 1986). The affected boys inherit the 
gene from their carrier mother. There are deletions/duplications or point mutations in the 
DMD-gene that span at least one exon. For example, a mutation of the gene results in a stop 
codon that triggers the formation of a truncated dystrophin which is quickly degraded. 
However, mutations that do not disrupt the reading frame lead to a milder variant of the 
disease called Becker Muscular Dystrophy (BMD) where dystrophin is functional but smaller 
than the wild type protein or not expressed in sufficient quantity. The frequency of BMD is 1 
in every 20,000 newborn boys. The amount of dystrophin in BMD is inversely proportional to 
the severity of the disease.  
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Diagnosis of DMD is performed by analysis of serum creatine kinase levels (creatine 
kinase has been found to be drastically increased in DMD patients) and muscle biopsy. This 
last confirms the results of the blood analysis. With the muscle biopsy, the lack of dystrophin 
is confirmed by immunohistochemistry and the typical characteristics of the disease are 
observed: necrotic fibres, regenerative fibres with central nucleus, fatty and connective 
tissues. Today, prenatal diagnosis is usually performed for the families at risk. 
 
1.2.2 Dystrophin and dystrophin-associated proteins 
The dystrophin gene is the largest gene in the human genome (2.3x106 base pairs (bp)) 
localized on the X chromosome. This large size contributes to the high spontaneous mutation 
rate. It corresponds to about 0.1 % of the total human genome or about 1.5 % of the entire X 
chromosome. 99 % of the gene for dystrophin is made of introns and the coding sequence 
consists of 79 exons. The full length (14,000 bp) mRNA transcribed from the dystrophin gene 
is predominantly expressed in skeletal and cardiac muscle with small amounts expressed in 
the brain (Purkinje cells, Schwann cells) but this protein has also well characterized isoforms 
in smooth muscle and retina (Hoffman et al., 1987). The different isoforms (full length or 
truncated) are generated by 7 tissue-specific promoters (Feener et al., 1989). The gene codes 
for a 427 kDa protein which represents approximately 0.002% of total striated muscle protein. 
The protein belongs to the spectrin superfamily and measures 100 to 150 nm. Dystrophin can 
be divided into 3 domains: the amino-terminal actin binding site, a central rod-domain 
composed by 24 spectrin repeats that give the elasticity to the protein and the 
carboxy-terminal part rich in cysteine. This last interacts with the Dystrophin Glycoprotein 
Complex (DGC). In cell culture, transcription of dystrophin is initiated when myoblasts fuse 
to differentiate into myotubes.  
 
Dystrophin is localized under the plasma membrane (Bonilla et al., 1988) where the 
protein is associated with the DGC. This last forms a linkage between the F-actin of the 
cytoskeleton and the extracellular matrix or basal lamina. The proteins that form the DGC can 
be divided in 3 different groups. Firstly, the cytoskeletal proteins represented by dystrophin 
itself and the associated α and β syntrophins. Secondly, the plasma membrane localized 
dystroglycan complex (α and β subunits) and finally the sarcoglycans (α, β, γ, δ, ε, ζ) and 
sarcospan. Moreover, a number of extra- and intracellular proteins such as the neuronal nitric 
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oxide synthase (NOS), dystrobrevin, syncoilin and laminin-2, are also associated with the 
DGC (Figure 1.7). 
One of the main roles of dystrophin is to stabilize the plasma membrane, to provide a 
strong mechanical link between intracellular cytoskeleton and extracellular matrix and to 
protect muscle fibers from long-term contraction-induced damage (Kumar & Boriek, 2003; 
Lapidos et al., 2004). Moreover, dystrophin seems to play a role in the correct localization of 
the DGC proteins. Indeed, the lack of dystrophin is associated with nNOS mislocalization 
(Brenman et al., 1995) but also a reduction in the dystroglycans, sarcoglycans and sarcopsan 
which are quickly degraded due to their dispersion in the cytosol (Ohlendieck & Campbell, 
1991). Thus, the lack of dystrophin leads to a deficiency of the DGC, indicating the close 
dependence between the proteins and the potential role of DGC in DMD. Indeed, DGC 
complex defect is associated with severe disease such as Limb-Girdle Muscular Dystrophy. 
 
 
Figure 1.7: Dystrophin-glycoprotein complex. 
Box: dystrophin localization at the plasma membrane (red fluorescence) assessed by immunochemistry 
in control skeletal muscle myotube (from Khurana TS. et al.). 
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1.2.3 Pathogenesis of Duchenne Muscular Dystrophy and Ca2+ involvement 
The lack of dystrophin has dramatic consequences on skeletal muscle cells (figure 
1.8). Indeed,  although  the primary  pathogenetic  processes are apoptotic  or necrotic muscle  
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Figure 1.8: Pathogenesis of DMD. 
In DMD muscle, the lack of dystrophin is accompanied by alteration in the dystrophin-glycoproteins 
complex (DGC). This results either in membrane fragility or activation of Ca2+-channels (stretch-
activated Ca2+ channels, altered AChRs), leading to increase in cyotosolic or subsarcolemmal [Ca2+], 
particularly under mechanical stress conditions such as muscle contraction. Other cellular signalling 
pathways such as NO might be also affected.  
On the one hand, the increase in [Ca2+]i likely activates the Ca2+-activated proteases calpains, which 
hydrolyse various cellular targets including stretch-activated Ca2+ channels and perhaps also other 
proteins involved in the maintenance of Ca2+ homeostasis, thus creating a vicious cycle. Cytoskeletal 
proteins might also be degraded after prolonged activation. Cellular mechanisms such as Ca2+ uptake 
into organelles are stimulated to compensate for the increased [Ca2+]i, but finally fail as a result of 
metabolic alteration such as a drop in phosphocreatine, resulting in a further increase in [Ca2+]i. 
Altogether, these mechanisms lead to muscle damage by necrosis and/or apoptosis, associated with 
release of cytokines and potential damage to surrounding non necrotic fibers. Fiber regeneration 
occurs, but is rapidly replaced by adipose tissue and fibrosis. 
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cell death, the molecular mechanism(s) that causes muscle degradation in the absence of the 
dystrophin is still unknown. Moreover and even it is still controversial, the disease seems to 
be related to an alteration of the Ca2+ homeostasis: Ca2+ influx and total [Ca2+] are increased 
in mdx mice (Turner et al., 1988; Ruegg & Gillis, 1999). The controversy remains on the fact 
that some groups reported this elevated [Ca2+] in resting cells (Dunn & Radda, 1991; Hopf et 
al., 1996) while others did not (Pressmar et al., 1994; Gillis, 1996). However, [Ca2+] has been 
found to be elevated during stimulation (Imbert et al., 1995; Leijendekker et al., 1996; 
Mallouk et al., 2000; Robert et al., 2001). Different hypotheses have been proposed to explain 
the altered mechanical properties that underlie biochemical mechanism(s) leading to the 
activation of cell death possibly by the activation of Ca2+-dependent proteases such as calpain 
(Alderton & Steinhardt, 2000). 
The first hypothesis could be a direct link between the lack of dystrophin, the rupture 
of the DGC complex that leads to plasma membrane fragility and muscle degradation. It has 
been shown recently that the loss of dystrophin triggers aberrant mechanotransduction (the 
process by which cells transduce physical force-induced signals into biochemical responses) 
in mdx mice (Kumar et al., 2004). This could trigger inflammation and further muscle 
degradation. Inflammation is proposed to have an important role in muscle degradation that 
occurs in DMD (Spencer & Tidball, 2001; Grounds & Torrisi, 2004). Mechanical force can 
activate the mitogen-activated protein (MAP) kinase that acts by stimulation of the activity of 
many transcription factors such as c-myc and activator protein-1 (AP-1). Lack of dystrophin 
increases activation of MAP kinase and downstream transcription factor AP-1 in response to 
mechanical stretch in the muscle fibers of mdx mice. Furthermore, it has been shown that an 
increased Ca2+ influx and a greater activity of stretch-activated Ca2+ channels are responsible 
for the activation of MAP kinase. As  many inflammatory genes such as interleukin-1 (IL-1) 
or tumor necrosis factor-α (TNF-α) contain AP-1 consensus binding sites in their promoter 
region (Ramji & Foka, 2002), the activation of AP-1 in mdx muscle fibers could trigger the 
initiation of muscular dystrophy. Thus, it has been shown that levels of TNFα and IL-1 were 
higher in mdx mice through activation of nuclear factor κB (NF-κB) (Kumar & Boriek, 2003). 
Moreover, it has been shown that the lack of dystrophin increases susceptibility to oxidative 
stress (Rando et al., 1998). Indeed, the fact that DGC complex is altered in DMD, results in a 
mislocalization of specific proteins such as the neuronal isoforms of the nitric oxide synthase 
(nNOS) (Brenman et al., 1995). NOS is implicated in antioxidant processes (Wink et al., 
2001). 
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Many groups have shown that Ca2+ homeostasis is altered in DMD. It is still unknown 
if Ca2+ overload is a consequence or a cause of the disease. However, the fact that stimulation 
of muscle cell triggers [Ca2+] increases in DMD is now well established and largely 
documented (Takagi et al., 1992; Mallouk et al., 2000; Robert et al., 2001). As it is very 
difficult to summarize all the dysfunctions that lead to increased [Ca2+], only a few examples 
are proposed here. Indeed, an important part of the proteins that are involved in Ca2+ 
homeostasis have been found to be overexpressed, deregulated or non-functional in DMD. 
For example, it has been shown that the SERCA-2 is functionally altered and has a decreased 
gene expression in mdx mice (Kargacin & Kargacin, 1996; Rohman et al., 2003). Moreover, 
the calsequestrin-like proteins or parvalbumin, which are Ca2+-binding proteins, are reduced 
in dystrophic muscle (Gailly et al., 1993; Culligan et al., 2002). RyR expression is also 
decreased in mdx mice cardiac myocytes. On the opposite, the second messenger IP3 and its 
receptor, IP3R, have been found to be more expressed in mdx mice (Liberona et al., 1998). 
Increased [Ca2+] is also thought to be triggered by plasma membrane Ca2+ channels. 
SOCs/TRPCs have been found to be implicated in the increased Ca2+ entry within the cells 
because of an enhanced activity (Vandebrouck et al., 2002).  Stretch-activated Ca2+ channels 
could also be implicated in the increased Ca2+ entry as they have been found to have an 
elevated open probability in mdx mice when compared to control cells (Franco-Obregon & 
Lansman, 2002; Yeung et al., 2004).
Altogether, these defects associated with Ca2+ homeostasis lead to Ca2+ overload and 
necrosis and/or apoptosis in DMD. 
 
1.2.4 Animal models of Duchenne Muscular Dystrophy 
There are 3 other mammals where mutations in the dystrophin gene have been 
identified: dogs, cats and mice (Allamand & Campbell, 2000). Because these animal models 
have common protein and genetic defects similar to those seen in DMD patients, they have 
been widely used to examine the effectiveness of gene therapy and the administration of 
drugs. However, the consequences of the lack of dystrophin vary in terms of pathology and 
physiology for each animal (Gorospe et al., 1994). 
- the Golden Retriever Muscular Dystrophy and German Shorthaired Pointer. The 
disease is due to a splice site mutation in the dystrophin gene that leads to the lack of the 
protein. The dog models are probably the best model for the human disease as the clinical 
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phenotype, histopathology and progression are close to the human disease. However, due to 
the infrastructures needed for dog breeding this model is rarely used. 
- the Hypertrophic Feline Muscular dystrophy. The disease is due to a mutation in the 
promoter of the dystrophin gene that leads to the lack of the protein. The cats have elevated 
serum creatine kinase but the symptoms are far less severe than in the human disease. 
- the mdx mouse. This model is currently the most used for DMD research because of 
the relative low cost of the animal, short gestation and good reproduction. The disease is due 
to a point mutation of a cysteine to a thymidine nucleotide that induces a stop codon. The 
expressed truncated dystrophin is quickly degraded because truncated protein cannot be 
correctly localized at the sarcolemma of the muscle fibers. The mice have elevated creatine 
kinase level but the phenotype of the disease is milder than that of the human disease. An 
acute muscle necrosis occurs during the fourth week after birth and continues for about 1 
month. At this time the mice muscle is very similar to the human DMD one. After this stage 
the muscle regenerates efficiently and the muscle wasting typical of the initial phase is no 
longer seen, assuming a normal life span to the animals. However, even after regeneration the 
diaphragm muscle is the only muscle that resembles muscle from DMD patients (Stedman et 
al., 1991). Moreover, mdx mice present some reverting muscle fibers that express dystrophin. 
To resolve this problem another model has been generated, the mdx2-5cv mouse, where no 
reverting fibers are found. 
Some laboratories also use invertebrates like Cænorhabditis elegans (Segalat, 2002) or 
more recently drosophila (Bermudez de Leon et al., 2004). 
 
1.2.5 Current therapeutic interventions in Duchenne Muscular Dystrophy 
As there is no treatment for DMD the goal of current therapeutic interventions is to 
improve life quality of the patients. For that, non-pharmacological procedures have been 
developed. Psychological help is dispensed to the patient and the family. Physiotherapy is 
used to relax muscle and helps prevent limb and joint stiffness. Moreover, equipment such as 
corset prevents bone and spinal cord deformations. If the equipment is not sufficient, surgery 
is used to correct the scoliosis. Usually, surgery occurs before the age of 13. When the 
respiratory defect appears, mechanical respiration enhances blood oxygenation. All these 
interventions enhance security and wellbeing of the young boys (AFM, 2001). 
Like non-pharmacological interventions, the goal of pharmacology is to improve life 
quality. Many clinical trials have been conducted with numerous types of drugs such as Ca2+ 
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channel blockers, growth hormone, steroids, vitamins. Much of them have been found to be 
totally inefficient on DMD. However, a few compounds have been used or are still used in 
DMD. 
So far, the only compounds that really slow down the course of the disease are steroids 
(Khan, 1993) which today, represent the choice treatment for DMD. Long-term use of 
prednisone or its derivative prednisolone has been shown to improve muscle strength and 
muscle mass for at least 3 years (Fenichel et al., 1994). However, this steroid has side effects 
such as weight gain, bone weakness, delayed puberty. More recently, deflazacort has been 
introduced in treatment of DMD (Biggar et al., 2001). This steroid is 70 % less toxic and as 
effective as prednisone (Bonifati et al., 2000), which today make it the preferred steroid for 
DMD treatment. Another steroid, Clenbutarol, has been tested on mdx mice and shows 
improvement in strength, protein production and satellite cell proliferation (Zeman et al., 
2000). The exact mechanism by which steroids help remains unclear. 
Creatine, a precursor of phosphocreatine which is widely used by athletes as a 
performance-enhancing substance has been used to improve the energy of the muscle. 
Creatine also enhances dystrophic myotubes survival (Pulido et al., 1998; Passaquin et al., 
2002) and muscle strength in DMD patients (Walter et al., 2000).  
Dantrolene, a drug that inhibits Ca2+ release from the SR has been tested on DMD 
patients and shows some benefits such as a decrease in creatine kinase serum levels and in 
exercise-induced muscle degradation (Bertorini et al., 1991). 
Dexamethasone and mastocytes stabilizers such as cromoglycate have been used to 
decrease the inflammation in DMD. Indeed, inflammation plays a crucial role in DMD as 
dystrophin-deficient tissues are invaded by cytotoxic T-cells and macrophages (Spencer & 
Tidball, 2001). These compounds are never used alone but in association with steroids. Very 
recently, Infliximab, an anti TNF-α antibody, has been shown to delay and greatly reduce the 
degradation of dystrophic muscle in mdx mice. Moreover, the use of this specific antibody 
caused no adverse effects on new muscle formation. Highly specific anti-inflammatory 
intervention could lead to clinical application for muscular dystrophies by the protective 
effect against skeletal muscle breakdown (Grounds & Torrisi, 2004).   
The use of aminoglycoside antibiotic such as gentamicin, which triggers ribosomal 
read-through of stop codon in mRNA, has been shown to be efficient in mdx mice (Barton-
Davis et al., 1999). Indeed, the expression of dystrophin was increased from 0 to 15 % in 
treated mice. However, this effect has never been described in humans and the use of such 
antibiotic remains dangerous due to side effects such as renal dysfunction (Kohlhepp et al., 
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1984) and non-specific misreading. Due to these side effects, a phase II study with gentamicin 
has been delayed in France. Recently, a Japanese study has shown that the dipeptide antibiotic 
negamycin increases the expression of dystrophin in the skeletal and cardiac muscles of the 
mdx mouse and in cultured myotubes (Arakawa et al., 2003). Negamycin is much less toxic 
than gentamicin. By preventing the presence of a stop codon in the dystrophin gene (it is the 
case in 10 to 15 % of the boys affected by muscular dystrophy), the protein is synthesized but 
never as the full-length. Negamycin could represent a new therapeutic candidate for DMD.  
Altogether these treatments have extended DMD patients life by around 10 years. 
 
1.2.6 Future therapeutic interventions, a new hope? 
Much of the research effort for DMD therapy has been pointed in the direction of gene 
therapy (Nowak & Davies, 2004), and different strategies for DMD-gene therapy have been 
tested and improved over the years. Some of these strategies are the most likely to lead to an 
effective DMD treatment in the ten to fifteen years to come. The most challenging part of 
gene therapy is the size of the dystrophin gene that does not allow easy transfection or 
infection.  
To deliver the 14 kbp dystrophin DNA vectors with large capacity are needed. Thus, 
common adenoviruses do not allow the delivery of genes bigger than 8 kbp. In order to have 
high capacity transporters (up to 28 kbp) mutated or gutted vectors have been synthesized 
(Kochanek et al., 1996). These adenoviruses do not trigger immune response as their 
immunogenic parts have been removed. Unfortunately these vectors are so big that they do 
not easily cross the extracellular matrix. However, some experiments on mice have shown 
that the adenovirus can be efficient when injected intra-muscularly (DelloRusso et al., 2002). 
In contrast, Herpes virus that can naturally carry large genes show a high transduction level 
but only in regenerating or newborn muscle (Akkaraju et al., 1999).  Unfortunately, these 
vectors do not allow a long term expression of the dystrophin gene and trigger immune 
response that is unconceivable for therapeutic approach. Due to the important size of the 
dystrophin gene, the delivery of fully functional but truncated dystrophin (mini or 
micro-dystrophin) also represents an important alternative that already gave interesting results 
(Fabb et al., 2002). 
Non-viral plasmids are fully synthetic vectors that trigger no immune response and 
carry large inserts. They are very efficient and a phase I clinical test is currently in progress 
(Romero et al., 2002). However these plasmids are very difficult to deliver and separate and 
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invasive techniques such as electroporation must be used to ensure good infection (Gollins et 
al., 2003). A phase I study directed by the French society Transgene was carried out in 2003 
on 9 DMD patients. After intramuscular administration of a pCMV-dystrophin plasmid, the 
study showed the safety of the injection and the expression of dystrophin in maximum 10 % 
of the fibers (Romero et al., 2004).  A phase I/II is now in preparation with the improved 
version of the plasmid, MyoDys®. The plasmid will be injected intravascularly in the fore-
arm. Thus, the use of non-viral plasmids is promising but still needs to be improved. 
Recently, stem cells that stably express dystrophin were injected in muscle of mdx 
mice (Peng & Huard, 2004). Some dystrophin-expressing fibers were found even 24 weeks 
after injection. However, the differential regenerating capacity observed among different stem 
cells clones, the relative low efficiency and the post-injection immune response are forcing 
the discontinuation of the clinical trails (Gussoni et al., 2002). 
As discussed before, in a part of DMD patients a mutation disrupts the open reading 
frame of the dystrophin gene. This mutation results in a stop codon in exon 23, which leads to 
the expression of a shortened, unstable dystrophin protein. The idea of inducing exon skipping 
during pre-mRNA splicing and by this way “jump” over the stop codon became obvious as 
soon as the molecular biology techniques allow it. Then, gene therapy studies based on this 
strategy progress rapidly. For example, antisense oligonucleotide directed against exon 23 
binds to its specific sequence in the pre-mRNA so that the exon becomes inaccessible for 
splicing factors. Consequently, the exon is spliced out along with its flanking introns. This 
exon skipping restores the open reading frame and accordingly allows the synthesis of “BMD-
like dystrophin” that may slow down the progression of the disease (van Deutekom et al., 
2001; Lu et al., 2003; Aartsma-Rus et al., 2004).  
The last strategy for gene delivery is myoblast transplantation. The idea is to bring 
dystrophin-expressing myoblasts in the DMD patient’s muscle. Thus, new myoblasts 
incorporate into the fibers so that the proportion of the nuclei that expressed dystrophin is 
sufficient to allow formation of the protein. The biggest problem triggered by this method is 
the immune response observed shortly after transplantation and the necessity to use 
immunosuppressive treatment such as cyclosporine. Moreover, myoblasts have a poor 
survival (Hodgetts et al., 2003; Skuk et al., 2004) and, more important, no benefit has been 
shown on injected patients (Miller et al., 1997). 
Nowadays, all these methods must be often repeated. However, in the future, new 
delivery systems and amelioration of the current methods should provide promising results. 
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In 1989, a homologue of dystrophin was identified on human chromosome 6 (Love et 
al., 1989). This dystrophin-related protein (DRP) was called utrophin and is ubiquitously and 
intensively transcribed. Utrophin is smaller (13 kbp) but otherwise very similar to dystrophin, 
particularly in the N- and C- terminal ends. Utrophin has the same functional properties of 
dystrophin for actin binding, although the binding process is differently regulated by the 
Ca2+-calmodulin complex (Winder & Kendrick-Jones, 1995). Utrophin can also bind other 
proteins such as syntrophin or dystrobrevin which belong to the DGC (Peters et al., 1998). 
Moreover, utrophin has been found to be expressed at high level during fetal development, 
during the first wave of muscle necrosis in mdx mice, at the NMJ of adult myofibers (Khurana 
et al., 1991) and in the brain. As it seems that ubiquitous overexpression of utrophin is not 
toxic (Fisher et al., 2001) and that the protein can functionally substitute for the missing 
dystrophin, a promising approach is the upregulation of the endogenous gene by activating 
specific promoters. Thus, specific promoters are known, A and B. In addition, an enhancer 
that acts on the A promoter has been described. As promoter A generates utrophin that is 
localized at the NMJ and promoter B generate utrophin localized mainly in blood vessels, the 
first promoter seems to be more relevant in DMD therapy and numerous groups try to activate 
it using peptides or signaling molecules. For example, it has been shown that heregulin, a 
nerve-derived trophic factor, could activate promoter A and thus upregulate utrophin through 
the Erk pathway (Gramolini et al., 1999). 
 
As one of the most important symptom of DMD is muscle loss, myostatin, a member 
of the transforming growth factor-β (TGF-β) family that acts as a negative regulator of 
skeletal muscle mass or insulin-like growth factor-1 (IGF-1) which activates satellite cells 
have been used to increase muscle mass (De Luca et al., 2003). Indeed, greater force of the 
musculature and less muscular degeneration have been observed in mdx mice injected for 3 
months with an antibody directed against myostatin (Bogdanovich et al., 2002) (Figure 1.9). 
A biotechnology company prepares mouse anti-myostatin antibodies and projects to 
manufacture antibodies suitable for the human use for various muscular dystrophies. 
Increasing muscle mass is one other emergent therapeutic strategy. 
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Figure 1.9: Effect of myostatin blockade on muscle formation (from Bogdanovich et al., 
2002). 
 
1.3 Aequorin 
 
1.3.1 History 
Aequorea victoria is a luminescent jellyfish from which aequorin is extracted and 
purified (Figure 1.10). Aequorin (AEQ), which emits light from the energy transfer between 
aequorin and the green fluorescent protein (GFP), is used by the jellyfish to protect itself 
against predators. Aequorin is a 22 kDa Ca2+-dependent photoprotein. Indeed, light is emitted 
when Ca2+ ions bind to the protein. This property permits to use aequorin as a Ca2+ indicator. 
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Figure 1.10: Aequorea Victoria 
 
 The principle of the reaction is the following (De Giorgi et al., 1996; 
Prendergast, 2000):  
 
 
 
Figure 1.11: Reaction of aequorin which allows light emission (from Molecular Probes) 
 
Apoaequorin is slowly converted to functional aequorin in the presence of molecular 
oxygen and the luminophore coelenterazine. When three Ca2+ ions bind to the aequorin, 
coelenterazine is oxidized to coelenteramide, with a concomitant release of carbon dioxide 
and blue light. This blue light can be measured at 466 nm with sensitive photomultiplier and 
allows the measurement of Ca2+ concentrations from ~0.1 µM to >100 µM (Alvarez & 
Montero, 2002). Unlike fluorescent Ca2+ indicators, Ca2+-bound aequorin can be detected 
without illuminating the sample, thereby eliminating interference from autofluorescence and 
allowing simultaneous labeling with caged probes. Because 2 tons of jellyfish typically yield 
only ≈125 mg of the purified photoprotein, a more convenient source is heterologous 
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expression of the cloned gene. Today the gene has been cloned (Inouye et al., 1985) and 
recombinant aequorins are available at high quantity. 
 
1.3.2 Recombinant aequorin and coelenterazine 
Since aequorin has been cloned, the principal interest of this Ca2+ probe has been the 
targeting of specific subcellular compartments such as cytosol (cytAEQ), mitochondria 
(mtAEQ), plasma membrane (pmAEQ), SR (srAEQ)… (Figure 1.12) (Brini et al., 1999). The 
targeting sequence is fused to the N-terminal part of aequorin, together with a hemaglutinin 
tag (HA1) that allows an easy immunolocalization of the probe to check proper targeting. All 
the recombinant aequorins are cloned in a pcDNAI vector that allows classical transfection 
such as electroporation or charged liposomes. Moreover, mutated aequorin has been cloned in 
order to measure Ca2+ in organelles where the Ca2+ concentration is high (> 100 µM).  
Figure 1.12: Example of targeted aequorins; COX: cytochrom
synaptosome-associated protein of 25 kDa, CSQ: calsequestrin. 
 
Synthetic coelenterazines (n-, f-, h-) are also available and all
sensitivity. For example, wild-type aequorin associated with wild-type
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method and the fact that there is no leakage of the probe out of the cells make this technique 
very strong. On the other hand, this technique has also some disadvantages. Indeed, the 
relatively low amount of emitted light makes difficult performing single-cell imaging studies 
and the reconstitution of aequorin with coelenterazine requires previous complete depletion of 
Ca2+ of the SR for a few hours. This depletion could have deleterious effects in some cells. 
Finally, the link between Ca2+ and aequorin results in an irreversible consumption of the 
probe that leads to a limitation of the experiment time. Indeed, once the aequorin is consumed 
no light will be emitted. 
 
1.4 Cell death 
 
1.4.1 Necrosis 
Necrosis is due to accidental cell destruction and is characterized by plasma membrane 
rupture followed by cytoplasm swelling and release of toxic compounds. This release is 
always linked with tissue inflammation. Necrosis could be responsible of the muscle 
degeneration that occurs in DMD (Badalamente & Stracher, 2000). However, this point is still 
debated as it has been shown that apoptosis, another type of cell death could also trigger 
muscle loss in the disease (Podhorska-Okolow et al., 1998). 
 
1.4.2 Apoptosis 
Opposite of necrosis, apoptosis is a form of programmed cell death. It has been first 
described in 1972 (Kerr et al., 1972). It is an essential physiological process required for 
normal development and maintenance of tissues. Apoptosis is characterized by cell shrinkage, 
plasma membrane disruption, nuclear fragmentation and apoptotic body formation 
(Hengartner, 2000). Moreover, the expression of specific proteins localized at the plasma 
membrane triggers macrophage activation. Macrophages will then integrate, digest the 
apoptotic cells and this process will avoid tissue inflammation. 
Programmed cell death is a highly regulated function and involves an important 
number of proteins such as anti-apoptotic proteins (Bcl-2, bcl-XL…), pro-apoptotic proteins 
(bax, bid…) (see 1.4.3) and effectors such as caspases (see below). Caspases are one of the 
main apoptosis effectors. These proteins are aspartate-specific cysteine proteases which are 
expressed as proenzymes. Once activated, they can cause degradation of several important 
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substrates (Martin et al., 1995; Brown et al., 1999). Today, 14 different caspases are known in 
mammalian species (Zimmermann et al., 2001). 
Upon stresses such as ATP depletion (Vander Heiden et al., 1999), DNA alterations, 
reactive oxygen species formation (Kim et al., 2001), etc. , 2 main pathways might lead to 
apoptosis (figure 1.13): 
- The intrinsic pathway is mostly mitochondria-mediated. Mitochondria play an essential role 
in apoptosis by releasing apoptogenic factors such as cytochrome c, Apoptosis Inducing 
Factor (AIF) and Apoptotic Proteinase Activating Factor-1 (apaf-1), a cytosolic protein 
containing a caspase recruitment domain in the cytosol. These factors can activate caspase 9 
through apoptosome formation (Cain et al., 2002). However, some mitochondrial factors 
could trigger caspase-independent apoptosis. Two models are described for apoptogenic 
factors release (Martinou & Green, 2001). The first one is the ability of the members of the 
Bcl-2 family to form autonomous channels (see 1.4.3). The second one is the permeabilization 
of the outer mitochondrial membrane (OMM) through mitochondrial permeability transition 
pore (mPTP) opening. The mPTP is formed by 3 subunits which are the voltage-dependant 
anion channel (VDAC), the adenine nucleotide translocator (ANT) and cyclophilin D 
(Crompton, 1999). Under stress conditions, opening of the mPTP, also called mega-channel, 
allows proteins up to 1.5 kDa to diffuse across the inner mitochondrial membrane (IMM) 
(Halestrap, 2002). The mPTP opening is highly regulated by the proteins of the Bcl-2 family 
(Shimizu et al., 1999; Belzacq et al., 2003) (see 1.4.3). Moreover, it has been shown that the 
pro-apoptotic members of the Bcl-2 family could interact with the mPTP. This interaction 
leads to the formation of a pore which allows big proteins such as cytochrome c (13 kDa) to 
be released from the intermembrane space across the outer mitochondrial membrane (OMM). 
To date, this association is not clearly demonstrated and the exact composition of the so-
called mega-channel is still debated. 
- The extrinsic pathway is receptor-mediated and linked to the so-called “death receptors” 
(Sartorius et al., 2001). These receptors belong to the tumor necrosis factor receptor (TNFR) 
family which is composed by 5 members (Zimmermann et al., 2001). This pathway is 
activated by cells which are in close contact with . Ligands of such receptors are Fas ligand 
(FasL) (Gamen et al., 1998), TNF (Alikhani et al., 2004) and the TNF-related apoptosis-
inducing ligand (TRAIL) (Seol et al., 2001). After binding to the receptor, caspase 8 is 
activated (this caspase is the initiator protease). Activated caspase 8 will further activate 
another caspase such as caspase 3 or bid, a member of the Bcl-2 family. Bid then triggers the 
translocation of other pro-apoptotic proteins such as Bax to the mitochondria (Eskes et al., 
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2000). Finally, cytochrome c and other apoptotic agent will activate caspases and the cell 
enters in apoptosis (Pan et al., 1998; Desagher et al., 1999). 
 
 
Figure 1.13: Schematic view of the apoptosis cascade (adapted from Orrenius S. et al., 2003) 
 
Ca2+ is linked to apoptosis (Demaurex & Distelhorst, 2003). Indeed, it is well 
established now that the increase of the cytosolic Ca2+ concentration (c[Ca2+]) can be 
responsible for the apoptotic pathway (Orrenius et al., 1992; Trump & Berezesky, 1992; 
Trump & Berezesky, 1995; Hajnoczky et al., 2003). Moreover, important changes in the 
ER/SR Ca2+ concentration (er[Ca2+] or sr[Ca2+]) that cause ER/SR stress but also in the 
mitochondria can be sufficient to trigger apoptosis (Szabadkai & Rizzuto, 2004). Thus, Ca2+ 
overload or depletion can activate caspase 12 (Breckenridge et al., 2003). Apoptotic stimuli 
that act by releasing the er[Ca2+] through RyR or IP3R trigger long term elevation of 
mitochondrial [Ca2+] (m[Ca2+]) which will, in term, cause apoptosis. It has been shown that 
the amount of released er[Ca2+] that will be taken up by mitochondria is important and not the 
global er[Ca2+] itself (Nakamura et al., 2000). During cell death, mitochondrial Ca2+ overload 
 32
may activate the mPTP. This results in transient mitochondrial depolarization and decreased 
ATP production. Moreover, the opening of the mPTP may also cause the release of 
cytochrome c (Strasser et al., 2000). The apoptosome is created and caspases are activated, 
resulting in cell death. 
 
Thus, apoptosis is also involved in a wide range of pathologic conditions, including 
acute neurological injuries, neurodegenerative diseases, cardiovascular diseases, 
immunological diseases, AIDS, and cancer. 
 
1.4.3 Bcl-2 family 
The proteins of the Bcl-2 family are proteins which are very important in the 
regulation of apoptosis (Antonsson & Martinou, 2000). All members have a sequence 
homology that consists in specific regions called BH (Bcl-2 homology) domains. Today, 4 
BH sequences are known. These sequences give functional properties to the protein. For 
example, BH3 domain is required for the pro-apoptotic activity (Chittenden et al., 1995). 
The family is composed of 3 groups, the pro-apoptotic proteins which have 3 BH 
domains (BH1, 2 and 3), the anti-apoptotic proteins which have 4 BH domains (BH1 to 4) and 
the BH3-only proteins (Tsujimoto & Shimizu, 2000) (see Figure 1.14 and Table 1.2). 
 
  
  
Figure 1.14: Structure of the Bcl-2 family proteins (adapted from Tsujimoto et al., 
2000)
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 Anti-apoptotic Pro-apoptotic BH3-only 
Bcl-2 Bax Bid 
Bcl-XL Diva Bim 
Bcl-w Bak Bik 
Mcl-1 Bok Blk 
Bfl-1  Bad 
Boo  Bnip3 
  Bnip3L 
Table 1.2: Proteins of the Bcl-2 family (non exhaustive list) 
 
The Bcl-2 family proteins have been shown to be localized on intracellular 
membranes: mitochondria, endoplasmic/sarcoplasmic reticulum and perinuclear area 
(Krajewski et al., 1993; Garcia-Saez et al., 2004) and in the cytosol. However, every member 
has his own localization (Nguyen et al., 1993; Kaufmann et al., 2003) and it has also been 
shown that the localization changes during apoptosis: cytosolic proteins move to internal 
membranes when apoptosis is induced (Wolter et al., 1997; Gross et al., 1998). 
All the members can interact with each other through the BH3 domain (Zha et al., 
1996) or act alone (Knudson & Korsmeyer, 1997). The interaction between members leads to 
inhibition when members are part of a different group (Yang et al., 1995; Ke et al., 2001; 
Ruffolo & Shore, 2003) or activation when members are part of the same group (Kuwana et 
al., 2002). The action of one or the other member is the result of equilibrium (where they are 
mutually neutralized) between the proteins. If the equilibrium goes to the pro-apoptotic 
protein advantage, apoptosis is induced.  
The action mode of the Bcl-2 family proteins is still debated and several hypotheses 
have been proposed. It has been shown that Bcl-2 proteins could form ions channels in 
synthetic lipid bilayers (Minn et al., 1997). Indeed, the structure of the proteins reveals 
similarity with the pore-forming domain of bacterial toxins (Muchmore et al., 1996). To allow 
pore formation, pro-apoptotic proteins could form oligomers and then trigger release of 
apoptotic factors such as cytochrome c (Antonsson et al., 2000; Degterev et al., 2001). 
These proteins could also regulate the mPTP by direct association. Indeed, it has been 
shown that anti-apoptotic proteins coimmunoprecipitate with VDAC (Narita et al., 1998). 
This fact strongly suggests that these proteins are associated with VDAC and induce a 
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conformational change to open the mPTP. Moreover, pro-apoptotic proteins such as Bax and 
Bak accelerate the opening of VDAC, whereas the anti-apoptotic protein closes VDAC by 
binding to it directly. Bax and Bak allow cytochrome c to pass through VDAC but passage is 
prevented by anti-apoptotic protein. 
Finally, apoptosis regulation of the Bcl-2 family proteins can be Ca2+-dependent 
(Williams et al., 2000; Nutt et al., 2002; Scorrano et al., 2003). Apoptosis is often linked with 
the dysregulation of the Ca2+ homeostasis (see before, paragraph 1.4.2). Recent studies have 
shown that Bcl-2 interacts directly with different proteins involved in the Ca2+ regulation. 
Indeed, in addition to Bcl-2-induced gene overexpression of important genes such as 
SERCA2, NCX, PMCA (Zhu et al., 2001), Bcl-2 interacts directly with the SERCA (Dremina 
et al., 2004), IP3R (Szalai et al., 1999; Pacher & Hajnoczky, 2001; Distelhorst & Roderick, 
2003; Chen et al., 2004) and cytochrome c (Boehning et al., 2003). Bcl-2 also acts by 
decreasing Ca2+ concentration in the SR (Foyouzi-Youssefi et al., 2000; Pinton et al., 2000; 
Oakes et al., 2003), even if this point is still debated (Pan et al., 2000) and other cellular 
compartments such as mitochondria or plasma membrane (Zhu et al., 1999; Williams et al., 
2000). By this way, the proteins of the Bcl-2 family modulate cytoplasmic, mitochondrial 
and/or ER/SR Ca2+ levels required for the execution of apoptosis. 
However, to date, the exact mechanism of action is not clear and still debated 
(Distelhorst & Shore, 2004). 
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1.5 Aim of the present work 
Ca2+ plays a critical role in DMD. Although its dysregulation is now well established 
and accepted, the key question of wether Ca2+ increase is the cause or the consequence of 
muscle degradation has not been answered yet. Moreover, the characterization of all the 
cellular consequences triggered by the lack of dystrophin, and the urgent need for effective 
treatments for the disease are very challenging. Many laboratories are involved in this effort 
but all the responses have not been answered yet. 
The main topic of this work was to try to have a better understanding of the Ca2+ 
regulation in mdx mice, the murine model of the disease. Numerous studies have described 
upregulation or downregulation of key proteins that are involved in Ca2+ responses. Among 
them, one group has shown that an important Ca2+ channel located on the sarcoplasmic 
reticulum membrane, the IP3R, have a significantly higher density in dystrophic cells 
compared to normal cells. As this receptor is responsible for Ca2+ release from the 
sarcoplasmic reticulum, it could have a possible role in the deficiency of intracellular Ca2+ 
regulation in DMD. Here, we have used plasma membrane and mitochondrial targeted 
aequorin to study the role of the IP3R in the dysregulation of Ca2+ homeostasis in dystrophic 
myotubes. We found that IP3R are involved in Ca2+ responses triggered by physiological 
stimulation of dystrophic myotubes only. Moreover, IP3R appears to be involved in the 
increased apoptosis occurring in dystrophic myotubes. 
As it has been shown that the anti-apoptotic protein Bcl-2 can decrease [Ca2+] in 
different subcellular compartements when it is overexpressed, we also determine the effect of 
the protein on Ca2+ dysregulation and apoptosis in dystrophic myotubes. Our results show that 
Bcl-2 overexpression can correct abnormal Ca2+ homeostasis in dystrophic cells, presumably 
by inhibiting leaky IP3R. 
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2 CHAPTER 2-MATERIALS AND METHODS  
 
 
2.1 Cell culture 
Satellite cells from extensor digitorum longus (EDL) muscles were isolated by Drs. O. 
Dorchies and S. Wagner in the laboratory of Professor P. Poindron (University of Strasbourg, 
France).  
Myogenesis can be divided in 3 different parts (see introduction, 1.1.1): 
- proliferation, which involve myoblasts (figure 2.1.A). These cells are small and 
mononucleated,   
- differentiation, where confluent myoblasts  align each other and fuse. The resulting 
cells are called myotubes (figure 2.1.B). They are multinucleated and can be 
hundreds of micrometers tall.  
- fiber formation, where myotubes become mature and functional fibers (figure 2.1.C). 
This maturation needs innervation. 
 
Cultures of purified myoblasts were prepared in Petri dishes (Falcon, Becton 
Dickinson) and maintained at 37°C in a water-saturated atmosphere of 95% air / 5% CO2. 
They were obtained as described previously (Pinset & Montarras, 1998) with minor 
modifications. Briefly, 3-week old mdx C57Bl/10 and control C57Bl/10 mice were killed by 
cervical dislocation, EDL muscle was aseptically removed bilaterally, cleaned of their 
tendinous ends and adhering connective tissue, and minced into small pieces of approximately 
1 mm3. Individual muscles from 2 mice were pooled. After the muscle tissues were rinsed in 
Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco), digestion was performed by 3 
successive rounds of incubation in 10 ml of DMEM supplemented with 10 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, pH 7.4), 10% fetal calf serum (FCS) 
(Invitrogen, Life Technologies), and 0.15% pronase (Roche), at 37°C. After the first 
incubation (5 min) the tissues were triturated with a serologic pipette and the supernatant, 
containing mainly blood cells and connective debris, was discarded. The second and third 
incubations lasted 20 min each with frequent triturations. The supernatants were collected, 
pooled, filtered through a 40 µm mesh cell strainer (Falcon, Becton Dickinson) and 
centrifuged at 300 x g for 10 min. The cell pellets were resuspended in growth medium (see 
below) and the suspensions plated onto collagen type I-coated (1 µg/cm2; Sigma) 100 mm 
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diameter Petri dishes, one dish per original muscle. Growth medium is composed of a 1:1 
(v/v) mixture of DMEM and MCDB202 (CryoBioSystem), supplemented with 20% FCS, 2% 
Ultroser® SF (Biosepra SA), antibiotics (Ciproxin, Bayer) and NaHCO3 from concentrated 
solution (Gibco) to get 2.6 g/l in complete medium. Myoblasts were plated on coated dishes 
and grown for approximately 2 days in growth medium. For the experiments cells were 
induced to fuse by changing the growth medium to differentiation medium (DMEM 
supplemented with 1.7% FCS, 3.3% horse serum (HS, Sigma), 10 µg/ml insulin (Fluka) and 
Ciproxin). 
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2.2 Aequorin 
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versions of ampicillin and tetracyclin-resistance genes. Once transformed, the presence of the 
supF suppressor tRNA gene confers to the bacteria the ampicillin and tetracyclin resistance by 
the translational suppression of the defective genes. The plasmids were amplified as follows. 
Competent bacteria MC1061/P3 were placed for 20 minutes in ice. Then bacteria were heat 
shocked at 37°C for 90 seconds in the presence of 100 ng of the plasmid. After a second 
incubation in ice for 10 minutes, transformed bacteria were grown in LB medium for 30 
minutes at 37°C. Bacteria were seeded in a LB-agar plate containing 25 µg/ml ampicilin and 
10 µg/ml tetracycline. After an overnight incubation at 37°C, resistant colonies of bacteria 
were isolated and further grown in 200 ml LB containing the same antibiotics for 16 hours. 
Then, bacterial suspension was centrifuged and the plasmids were purified using the kit 
Nucleobond® AX500 (Machery-Nagel, Oensingen, CH). The purified plasmids were checked 
by enzyme digestion. 
 
      
 
Figure 2.2: Plasmid map and aequorin targeting sequences. 
Mitochondrial aequorin (mtAEQ) is targeted with the cytochrome oxidase subunit VIII (COX), 
subsarcolemmal aequorin (pmAEQ) with the SNAP-25 sequence and sarcolpasmic reticulum aequorin 
(srAEQ) with the calsequestrin sequence (CSQ) while cytosolic aequorin (cytAEQ) is not tagged. 
 
 
2.2.2 Transient transfection 
Control and mdx myoblasts were plated at 15,000 cells per cm2 on 13 mm Thermanox 
coverslips (Nalge Nunc International) in 4-well plates. When 80 to 90 % confluent, growth 
medium was removed and replaced with a serum free medium, Optimem 1 (Gibco). Cells 
were transfected overnight using Lipofectamine 2000 (Invitrogen, Life Technologies) at a 
ratio of 1µg DNA per 2µl transfection reagent per well. The DNA-Lipofectamine 2000 
 39
complex was prepared in Optimem 1 medium. After overnight incubation this medium was 
replaced by differentiation medium. Myotubes were used after 3 or 4 days of differentiation. 
 
2.2.3 Calcium measurement 
After 3 or 4 days of differentiation, [Ca2+] was measured on a population of 
transfected myotubes as follow. The aequorins were reconstituted in a physiological salt 
solution (PSS, for composition see 2.8) containing 5 µM coelenterazine (Calbiochem) for at 
least 1 h before the experiment. Specific conditions are needed for the sarcoplasmic reticulum 
(SR) and subsarcolemmal targeted aequorin because the removal of intracellular Ca2+ is 
required for the complete aequorin reconstitution (Marsault et al., 1997). Indeed, [Ca2+] in 
these organelles is very high and removal of Ca2+ is essential in order to prevent the 
immediate reconstitution/degradation of aequorin. Thus, SR and subsarcolemmal aequorin 
was reconstituted in a Ca2+ free PSS containing 0.1 mM EGTA in order to decrease the [Ca2+] 
within the cell, while mitochondrial targeted aequorin was reconstituted in 1.2 mM Ca2+. 
Cells were superfused at a rate of 1 ml/min in a custom made 0.5 ml chamber thermostated at 
37 °C (MecaTest, Geneva, Switzerland). Emitted luminescence was detected at 466 nm with a 
photomultiplier apparatus (EMI 9789A, Electron Tubes Limited, UK) and recorded every 
second using a computer photon-counting board (EMI C660).  
 
 
 
Figure 2.3: Schematic picture of the system used for Ca2+ measurement 
 
The relationship between recorded counts and [Ca2+] is shown in Equation 1 (Alvarez 
& Montero, 2002): 
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[ ] + × −
where L are the recorded photons/s and Lmax the remaining photons which correspond to the 
total light output during the whole experiment minus the photons emitted up to the measured 
point. KTR and KR are the parameters of the aequorin and n is the number of Ca2+ binding 
sites. For example, at 37°C, KTR= 120, KR= 1.01x107 M-1 and n= 2.99 for the wild type 
aequorin. Total light output was obtained by exposing cells to 10 mM CaCl2 after 
permeabilization with 100 µM digitonin to consume all the aequorin. 
  
Ca2+ concentrations were further analyzed using a software created by R. Pitarelli 
(Swiss Federal Institute of Technology, Lausanne) under the environment Matlab 7 SP1 (The 
MathWorks Inc.). Several parameters were determined (figure 2.4).  
 
 
 
Figure 2.4: Summary of the analyzed parameters. (AUC: Area Under Curve) 
 
 
 
( ) ratio ratio K( ) 1 +2 = TRin   Ca M ,−K ratio K( )× RR
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 41
2.3 Other calcium measurements 
 
2.3.1 45Ca2+ uptake 
Influx measurement was performed using 45Ca2+ (5-50 mCi/mg, Perkin-Elmer Life 
Sciences) as described with minor modifications (Passaquin et al., 1998). Briefly, myotubes 
were washed twice and pre-incubated at 37°C for 10 min in 250 µl PSS solution and 
containing 0.12 mM CaCl2 and eventually the indicated inhibitor. 45Ca2+ influx was initiated 
by incubation with 200 µl PSS containing 1.2 mM CaCl2 alone or with 100 µM of the 
nicotinic agonist carbachol (CCh) and 0.4 mCi of 45Ca2+ for 10 min at 37°C. The exposure 
time was 15 minutes. In order to remove extracellularly bound 45Ca2+ and block the influx, the 
cells were subsequently washed four times with ice-cold free-Ca2+ PSS supplemented with 0.1 
mM EGTA. Cells were lysed with 250 µl sodium dodecyl sulfate (SDS; 1 %, w/v). The 
radioactivity of 250 µl of lysate was measured by scintillation counting (Packard 460C, 
Zurich, Switzerland) using 3 ml of Ultima Gold. Values are expressed in counts per minute 
(cpm). 
 
2.4 Other plasmids 
 
2.4.1 Bcl-2 
The Bcl-2 plasmid (Cleary et al., 1986) was a gift from Professor Karl Heinz Krause, 
Department of Physiology, Geneva, Switzerland. The plasmid is pcDNA3-based and requires 
ampicillin for selection and amplification. Bcl-2 was cloned from a human common acute 
lymphoblastic leukemia cell line. 
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       Figure 2.5: Bcl-2 plasmid map 
 
2.4.2 Inositol 1, 4, 5-trisphosphate sponge 
The inositol 1, 4, 5-trisphosphate (IP3) “sponge” plasmid was a gift from Drs H.L. 
Roderick and M.D. Bootman, Cambridge, UK. Cells were transfected with a pdc515 
expression vector (Microbix Biosystems Inc.) containing a cDNA encoding enhanced GFP, 
the high affinity IP3 sponge (Uchiyama et al., 2002). This IP3 sponge is derived from the 
ligand-binding site of the mouse type 1 IP3 receptor (IP3R1) and exhibited a 1000-fold higher 
affinity for IP3 than the parental IP3R1 (Kd=92 pM) and specifically competed with the 
endogenous IP3R for binding to IP3. This sponge will act as an IP3 chelator and trap 
messenger, thus inhibiting IP3-induced Ca2+ response.  
 
 
 
Figure 2.6: IP3 sponge construct (adapted from Uchiyama T et al.) 
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2.4.3 Plasma membrane targeted green fluorescent protein 
To study subsarcolemmal Ca2+, we used plasma membrane targeted aequorin. For this, 
aequorin was tagged with the SNAP-25 sequence (see 2.2.1). In this plasmid, the aequorin 
was removed and replaced by the Green Fluorescent Protein (GFP). Then the localization of 
the protein was determined by confocal microscopy. The localization of the SNAP-aequorin is 
supposed to be the same than the SNAP-GFP. The plasmid was a gift from Professor T. 
Pozzan and is pcDNAI-based. Plasmid was selected and amplified with ampicillin and 
tetracycline. 
    
Figure 2.7: SNAP-GFP plasmid map 
 
2.5 Immunochemistry and confocal microscopy for protein localization 
 
2.5.1 Immunochemistry 
After 3 to 4 days of differentiation, myotubes were washed with PSS. Then cells were 
fixed with methanol/acetic acid (95 % - 5 %) for 20 minutes. After saturation with PSS 
containing 3 % Bovin Serum Albumin (BSA), antibody raised against the Bcl-2 protein 
(1:500 dilution, sc-509, Santa Cruz Biotechnology, Inc) was added for 1 hour at 37°C and 
revealed by an Alexa Fluor 488 conjugated goat anti-mouse antibody (1:1000 dilution, 
Molecular Probes). Cells were washed 4 times with PSS after each incubation. Moviol was 
used for mounting agent. 
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2.5.2 Confocal microscopy 
After myotubes preparation (transfection, immunochemistry), all the confocal sections 
were done in collaboration with other laboratories. The pmAEQ localization was assessed in 
collaboration with Dr. Jean-Yves Chatton, Department of Physiology and Cellular Imaging 
Facility, University of Lausanne, Switzerland. Mdx myotubes were grown in plastic culture 
dishes and transfected with a pcDNAI expression vector containing the cDNA encoding GFP-
tagged SNAP-25 targeting sequence. Confocal imaging was performed on a living myotube 
on a LSM 510 Meta confocal scanner mounted on an upright Axioskop 2 FS microscope (Carl 
Zeiss). Fluorescence was excited at 488 nm and emission was detected at 505-530 nm using a 
40x 0.8 NA water immersion objective (Achroplan, Carl Zeiss). Simultaneous Differential 
Interference Contrast (DIC) images of cells were recorded on the transmitted light detector 
with the polarized 488 nm light used for GFP fluorescence excitation.  
The Bcl-2 protein localization was studied in collaboration with Dr. Bruno Constantin, 
University of Poitiers, France. Mdx and C57 myotubes were grown in plastic culture dishes 
and transfected with pcDNA3 expression vector containing c-DNA encoding Bcl-2. Three to 
4 days after differentiation, the immunolabelled samples were examined by confocal laser 
scanning microscopy (CLSM) using a Bio-Rad MRC 1024 ES (Bio-Rad, Hemel Hempstead, 
UK) equipped with an argon-krypton gas laser. The Alexa Fluor fluorochrome was excited 
with the 488 nm green line and the emission was collected at 520 nm. Mitotracker was excited 
with the 550 nm red line and the emission was collected at 580 nm. Data were acquired using 
an inverted microscope (Olympus IX70) and processed with the LaserSharp software (version 
3.0, Bio-Rad). 
 
2.6 Western blotting 
 
2.6.1 Protein extraction 
After cell transfection with Bcl-2 and 3 to 4 days of differentiation, cells were washed 
twice with phosphate buffered saline solution (PBS, see 2.8 for composition) and scraped into 
200 µl of 2X Laemmli sample buffer (0.18 M Tris-HCl pH = 6.8, 2 % SDS (w/v), 10 mM 
EDTA and 20 % glycerol). Cell lysates were homogenized by aspiration-reflux with a 0.6 mm 
diameter syringe needle and put in ice to avoid protein degradation. Then lysates were heated 
at 95°C for 10 minutes in order to denature proteins. Five µl of these lysates were used to 
determine protein content (see 2.6.2) and sample were diluted in Laemmli dilution buffer (2X 
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Laemmli sample buffer, 10 % β-mercaptoethanol and 0.2 % bromophenol blue) to reach a 
total protein concentration of 2.5 mg/ml. Diluted samples were finally aliquoted and stored 
(see 2.6.3). 
 
2.6.2 Protein content 
Protein content was determined by means of the bicinchoninic assay (BCA) with the 
BCA Protein Assay kit (Pierce Biotechnology) as follows.  Briefly, 1 µl of the lysate was 
diluted in 4 µl of a solution composed by 180 mM Tris-HCl, 2 % SDS, 20 % glycerol, 20 µl 
H2O and 200 µl BCA working reagent. Twenty five µl of the diluted lysate were added in a 
96 well plate and the absorbance was red at 560 nm (Labsystem Multiskan MS, Bioconcept). 
This method combines the detection of the reduction of Cu2+ to Cu1+ by protein in an alkaline 
medium (biuret reaction) and the colorimetric detection of the Cu1+ cation by chelation with 
bicinchoninic acid. The reaction results in a purple-colored complex. Measurements were 
performed in triplicate using BSA as a standard (from 0 to 2 µg/µl). 
 
2.6.3 SDS/PAGE (polyacrylamide gel electrophoresis) 
Twenty five µl of standardized protein extract were loaded on a 5 % stacking gel for 
protein concentration and 12 % running gel (for proteins from 250 to 15 kDa) for 30 minutes 
at 80 V and 60 minutes at 160 V in a running buffer (25 mM Tris, 192 mM glycine and 0.1 % 
SDS). Proteins were transferred onto 0.2 µm pure nitrocellulose membrane (BioRad) using a 
transfer buffer composed by 25 mM Tris, 192 mM glycine and 10 % methanol. Transfer was 
performed at 100 V for 60 minutes. After electrophoresis, nitrocellulose membrane was 
colored with Ponceau S red staining solution (Sigma) to verify the protein transfer. 
 
2.6.4 Immunoblots 
Nitrocellulose membranes with transferred proteins were incubated for 60 minutes at 
room temperature in a solution composed by 5 % (v/v) low fat milk dissolved in Tris-buffered 
saline (TBS: 20 mM Tris, 500 mM NaCl). This will block the unspecific antibody binding 
site. After 3 washes with TBS supplemented with 0.05 % Tween 20 (TBST), membranes were 
incubated overnight at 4°C with the primary antibody diluted in TBST and 5 % low fat milk 
(anti-Bcl-2, Santa Cruz Biotechnology, sc-509, dilution 1:2500). Actin was used as a standard 
(Sigma, A2172, dilution 1:500) 
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After 3 washes in TBST, membranes were incubated with the secondary antibody for 
45 minutes at room temperature. Alkaline-phosphatase conjugated antibody (goat anti-mouse, 
A9688, Sigma, dilution 1:1000) was used and detection was performed using the ECF kit 
(ECF Western Blotting reagent pack, Amersham Biosciences). 
 
2.7 Cell Survival assay 
 
2.7.1 Acid Phosphatase assay 
Acid phosphatase is a hydrolase that catalyze ester dephosphorylation. The optimal 
activity of the enzyme is below pH 7. The enzyme also displays a tranferase activity, thus 
allowing transfer of a phosphate ion on the hydroxyl function of an alcohol. Acid phosphatase 
is normally expressed in the cells and its concentration rises when cells die. 
The measurement of the activity is done by the reduction of the enzyme substrate: 
p-nitrophenyl phosphate substrate (pNPP) in p-nitrophenolate (PNP) which is yellow in 
alkaline medium. Absorbance is then measured at 405 nm (Labsystem Multiskan MS, 
Bioconcept). The reaction is as follow: pNPP + H2O → PNP + phosphate. 
The enzymatic colorimetric measurement of the phosphatase acid activity was used to 
determine the effect of Bcl-2 overexpression on the survival of the myotubes. To induce cell 
death, 3 to 4 days aged myotubes were exposed to different stresses. Stauroporine, a bacterial 
alkaloid that was first described as a broad spectrum inhibitor of protein kinases, many of 
which are involved in intracellular signaling cascades (Weil et al., 1996) and H2O2 which 
generates oxygen species. After 18 hours treatment with these compounds, myotubes were 
washed twice for 5 minutes with 500 µl PBS. 250 µl of substrate solution containing citrate 
buffer aqueous solution (0.1 M, pH = 5.5), 0.1 % triton X-100 and 1 mg/ml pNPP was added 
to each well for 90 minutes. Then the reaction was stopped by adding 25 µl NaOH 1M.  
 Unfortunately, this test does not allow discriminating between necrosis and 
apoptosis. 
 
2.7.2 Apoptosis measurement 
APOPercentage Apoptosis Assay (Biocolor, Newtownabbey, UK) was used to assess 
the effect of Bcl-2 overexpression on apoptosis. The APOPercentage Apoptosis Assay is a 
detection and measurement system to monitor the occurrence of apoptosis in cells during in 
vitro culture. The assay uses a dye that is selectively imported by cells that are going onto 
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apoptosis and target a late event of apoptosis, membrane alteration (phosphatidylserine flip, 
see figure 2.8). The dye is diluted in PBS and has a purple-red color, whereby the detection of 
apoptosis can be readily observed with a conventional inverted microscope. With an attached 
digital camera, images can be obtained and transferred to a computer for analysis. Cellular 
dye uptake was analyzed according to the manufacturer’s protocol modified for our myotubes. 
Briefly, after 90 minutes incubation at 37°C with APODye reagent (dilution 1:20), cells were 
washed with PBS to remove extracellular dye. Subsequently, APODye release reagent was 
applied for 10 minutes and absorbance of the released dye was measured at 550 nm with a 
plate reader (Fluostar Galaxy, BMG Labtechnologies GmbH). 
 
 
 
Figure 2.8: Mechanism of APOdye entry. 
The asymmetry of the cellular membrane is essential for normal functions of viable cells. Maintaining 
this asymmetry requires flippases which are ATP-dependent enzymes that catalyse the active transport 
of phospholipids from the outer to the inner leaflet of the membrane. During apoptosis, flippase 
activity is decreased by the activation of floppases. This could be due to the increased Ca2+ 
concentration that occurs during apoptosis. Then, loss of plasma membrane asymmetry occurs and 
triggers both transport of phosphatidylserine to the outer leaflet of the membrane and dye uptake by a 
“flip-flap” mechanism. Dye uptake is irreversible.    
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2.8 Buffers 
 
PSS was composed by 5 mM HEPES, 5 mM KCl, 1 mM MgCl2, 145 mM NaCl, 1.2 mM 
CaCl2 and 10 mM glucose. PBS was composed by 2.7 mM KCl, 1.5 mM KH2PO4, 140 mM 
NaCl, 8.4 mM NaH2PO4. All buffers were at pH=7.4 and heated at 37°C before manipulation 
except otherwise indicated. 
 
2.9 Data analysis 
 
Results are expressed as means ± standard error of the mean (SEM). Statistical 
significance between the different values was assessed with GraphPad® Prism 4 software 
(GraphPad Software Inc.) and the two-tailed unpaired Student’s t-test or one-way analysis of 
variance test (ANOVA) followed by a Dunnett test for multiple comparison with a control 
experiment. P>0.05 was considered not significant, P values ≤ 0.05 were considered 
significant. 
 
2.10 Materials 
 
Product Source Working concentration/dilution 
2-APB Alexis 75 µM 
Acrylamide BioRad 
depends of gel 
concentration 
Alexa fluor 488 conjugated 
goat anti-rabbit Molecular Probes 1/1000 
Ammonium persulfate BioRad 10 % (w/v) 
Ampicillin sodium salt Sigma 25 µg/ml 
Atropine Sigma 100 µM 
β-mercaptoethanol BioRad 10 % (v/v) 
BCA Reagent kit Pierce  
BAPTA-AM Fluka 10 µM 
Bovin serum albumin 
(BSA) Fluka 4 % (w/v) 
Bromophenol blue Sigma 0.2 % (w/v) 
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45Ca2+ Perkin Elmer 0.4 mCi 
Cadmium Sigma 1 mM 
Caffeine Sigma 20-50 mM 
Carbachol (CCh) Fluka 100 µM 
Ciproxine® Perfusion Bayer 5 ml  in 1l DMEM 
Coelenterazine Calbiochem 5.10-6 M 
Cy3 conjugated goat 
anti-mouse Jackson ImmunoResearch 1/2000 
Collagen Sigma 1 mg/ml 
d-tubocurarine Sigma 10 µM 
Digitonin Calbiochem 100 µM 
Dulbecco’s modified Eagle 
Medium (DMEM) Gibco  
ECF Western Blotting 
Reagent pack Amersham Biosciences  
EGTA Fluka 0.1 mM 
Fetal calf serum Invitrogen, Life Technologies 
10 % proliferation 
1.7% differentiation (v/v) 
Glycerol Fluka  
H2O2 Sigma 1 µM 
HEPES AppliChem 5 mM 
Horse serum Sigma 3.3 % (v/v) 
Insulin Fluka 10 µg/ml 
LB Broth base Difco 20 g/l 
Lipofectamine 2000 Invitrogen, Life Technologies 2 µl/1 µg DNA 
Matrigel Becton Dickinson 1:30 
MCDB202 CryoBioSystem  
Mitotracker Molecular Probes 100 nM 
Mouse monoclonal anti-
Bcl-2 
Santa-Cruz Biotechnology 
(sc-509) 
1:2500 WB 
1:500 IC 
Mouse monoclonal anti-
actin Sigma (A2172) 1:500 WB 
NaHCO3 Gibco 2.6 g/l 
NaOH Fluka 1N 
Nifedipine Sigma 1 µM 
N, tert-butylhydroquinone Alexis 30 µM 
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Optimem Gibco  
pNPP Sigma 1 mg/ml 
Potassium chloride Fluka 125 mM 
Pronase Roche 0.15 % (v/v) 
Rapilait Migros 5 % (w/v) in TBS buffer 
Ryanodine Sigma 20 µM 
SDS Fluka 1 / 2 % 
SK&F 96365 Sigma 10 µM 
Staurosporine Alexis 0.1 µM 
TEMED BioRad  
TBS 10X BioRad 1/10 
TGS 10X BioRad 1/10 
Tetracyclin Fluka 10 µg/ml 
Thapsigargin Alexis 1 µM 
Triton X-100 BioRad 0.1 % 
Trypsin Invitrogen 1/10 
U73122 Sigma 20 µM 
Ultima Gold Packard BioScience  
Ultroser® SF Biosepra SA  
Xestospongin D Calbiochem 0.1 µM 
Suppliers’ addresses (in Switzerland, except otherwise indicated): Alexis, Läufelfingen; Amersham 
Biosciences, Dubendorf; Applichem (Axon Lab AG), Lausanne; Bayer, Zürich; BioRad Laboratories, 
Glattbrugg; CryoBioSystem, L’Aigle, France; Fisher Scientific, Wohlen; Fluka/Sigma/Aldrich, Buchs; 
Juro Supply (Molecular Probes), Lucerne; Invitrogen, Life Technologies, Basel; Packard BioScience, 
Zürich; Roche Diagnostics, Rotkreuz; Socochim, Lausanne. 
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3 CHAPTER 3-RESULTS 
 
 
3.1 Publication 1: Involvement of the inositol 1, 4, 5-trisphosphate receptor 
in nicotinic Ca2+ response in dystrophic myotubes assessed by near-
plasma membrane measurement. 
 
3.1.1 Introduction to the publication 
Numerous studies have shown that RyR represents the main Ca2+ release channel in 
skeletal muscle (Benkusky et al., 2004; Brini, 2004). However, skeletal muscle cells also 
express IP3R but the exact role of this type of receptor has not been studied in dystrophic 
myotubes so far. Recently, it has been suggested that basal levels of IP3 and IP3R expression 
were increased in dystrophic human and murine cell lines compared to normal cell lines. 
Moreover, high potassium depolarization induced a time-dependent IP3 rise in normal human 
cells which returned rapidly to their basal levels while in the human dystrophic cell line, IP3 
levels remained high for a longer time after depolarization. The authors concluded on a 
possible role for this system in the deficiency of intracellular Ca2+ regulation in DMD. 
Surprisingly, no more work has been done concerning the involvement of IP3R in the disease.  
Here, we have made experiments indicating that IP3Rs are involved in physiological 
Ca2+ responses in dystrophic myotubes only. We show that the same physiological stimulation 
involves another pathway, i.e. Ca2+ release mainly through RyR, in control myotubes. This 
difference in pathways that trigger Ca2+ responses and muscle contraction in mdx myotubes 
could explain the Ca2+ overload that occurs in dystrophic cells and the subsequent muscle 
degradation in DMD. 
3.1.2 Publication 
The manuscript has been published in the Journal of Biological Chemistry, volume 
279(45), issue of November 5 2004, pages 47092-47100.  
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In skeletal muscle cells, plasmamembrane depolariza-
tion causes a rapid calcium release from the sarcoplas-
mic reticulum through ryanodine receptors triggering
contraction. In Duchenne muscular dystrophy (DMD), a
lethal disease that is caused by the lack of the cytoskel-
etal protein dystrophin, the cytosolic calcium concen-
tration is known to be increased, and this increase may
lead to cell necrosis. Here, we used myotubes derived
from control andmdxmice, themurinemodel of DMD, to
study the calcium responses induced by nicotinic ace-
tylcholine receptor stimulation. The photoprotein ae-
quorin was expressed in the cytosol or targeted to the
plasma membrane as a fusion protein with the synapto-
some-associated protein SNAP-25, thus allowing cal-
cium measurements in a restricted area localized just
below the plasma membrane. The carbachol-induced
calcium responses were 4.5 times bigger in dystrophic
myotubes than in control myotubes. Moreover, in dys-
trophic myotubes the carbachol-mediated calcium re-
sponses measured in the subsarcolemmal area were at
least 10 times bigger than in the bulk cytosol. The initial
calcium responses were due to calcium influx into the
cells followed by a fast refilling/release phase from the
sarcoplasmic reticulum. In addition and unexpectedly,
the inositol 1,4,5-trisphosphate receptor pathway was
involved in these calcium signals only in the dystrophic
myotubes. This surprising involvement of this calcium
release channel in the excitation-contraction coupling
could open new ways for understanding exercise-in-
duced calcium increases and downstreammuscle degen-
eration in mdx mice and, therefore, in DMD.
Duchenne muscular dystrophy (DMD)1 is an X-linked dis-
ease that affects about 1 in 3500 males. DMD results in pro-
gressive muscle degeneration (1) that ultimately leads to pre-
mature death by respiratory or cardiac failure during the third
decade. Pharmacological interventions such as glucocorticoids
improve the quality of life of patients (2). DMD is caused by the
absence of dystrophin, a 427-kDa protein localized under the
plasma membrane (3). In normal skeletal muscle fibers, dys-
trophin is associated with a glycoprotein complex and provides
a linkage between the extracellular matrix and the cytoskele-
ton. This complex tends to stabilize the plasma membrane (4).
Numerous studies have shown that the absence of dystrophin
in DMD impairs the stability of the plasma membrane, result-
ing in a greater fragility toward mechanical stress and in-
creased permeability to calcium (Ca2) (5–9). Indeed, it has
been proposed that an alteration of Ca2 homeostasis might be
responsible for the muscle degeneration that occurs in muscle
fibers from DMD patients or in those of the mouse model of
DMD, the mdx mouse (10–12). Elevations of cytosolic or near-
plasma membrane Ca2 concentrations in myotubes and skel-
etal muscle fibers from DMD patients or mdx mice have been
reported (13, 14). How this increased entry of Ca2 affects the
local concentration of Ca2 in subcellular compartments and
whether this process is involved in the development of the
disease is still unclear (15). However it has already been sug-
gested that altered Ca2 homeostasis and fiber degeneration in
mdx mice is “use-dependent” (16–18). In skeletal muscle cells
and myotubes, it has been shown that activation of nicotinic
receptors leads to plasma membrane depolarization, which
triggers a voltage-gated Ca2 channel opening. Contraction is
then triggered by the release of Ca2 from the sarcoplasmic
reticulum through the opening of ryanodine receptors, which
are activated by voltage-gated Ca2 channels (19). However,
although the role of ryanodine receptors and voltage-gated
Ca2 channels are well established in excitation-contraction
coupling, the skeletal muscle sarcoplasmic reticulum possesses
another type of Ca2 release channel, IP3 receptors (20–22). In
many cells, increases in intracellular Ca2 are mediated by the
inositol 1,4,5-trisphoshate pathway in the following manner.
The activation of numerous G-protein-coupled receptors trig-
gers hydrolysis of phosphatidylinositol 4,5-bisphosphate to
generate IP3, which triggers the opening of IP3 receptors, and
intracellular Ca2 increases (23). Furthermore, IP3 receptors
may also be involved in the control of Ca2 influx through
plasma membrane store-operated Ca2 channels (24–27).
In skeletal muscle cells, IP3 receptors are localized in the
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nuclear envelope as well as in the sarcoplasmic reticulum (20,
22). In addition, it has been suggested that the intracellular
messenger IP3 may contribute to excitation-contraction cou-
pling (28). Indeed, it has been shown that IP3 can potentiate
depolarization-induced Ca2 release or produce the contraction
of intact or skinned skeletal muscle fibers (29–31). These re-
sults suggest that IP3 may play a role in excitation-contraction
coupling in skeletal muscle cells. Furthermore, it has also been
shown that the plasma membrane depolarization that acti-
vates voltage-gated Ca2 channels can induce IP3 production
and IP3 receptor activation in myotubes with a mechanism
involving a G-protein (20, 32, 33).
The mechanisms involved in Ca2 responses during physio-
logical stimulation (using nicotinic receptor agonists) have not
been studied in dystrophic myotubes to date. Here, we have
studied the IP3 receptor pathway in dystrophic myotubes using
plasma membrane-targeted aequorin (SNAP-25 aequorin) for
measuring the near-plasma membrane Ca2 concentration. We
show here that SNAP-25 aequorin is a reliable tool to measure
Ca2 increases occurring just below the plasma membrane. We
also show that nicotinic receptor stimulation triggers near-
plasma membrane Ca2 increases that depend on IP3 receptor
activation in myotubes derived frommdxmice only, thus show-
ing a non-common pathway for excitation-contraction coupling.
EXPERIMENTAL PROCEDURES
Cell Culture—Cultures of purified myoblasts were prepared in Petri
dishes (Falcon; BD Sciences) and maintained at 37 °C in a water-
saturated atmosphere of 95% air and 5% CO2.
The cell cultures were obtained as described previously (34) with
minor modifications. Briefly, 3-week-old mdx C57Bl/10 and control
C57Bl/10 mice were killed by cervical dislocation, extensor digitorum
longus (EDL) muscle was aseptically removed bilaterally, cleaned of its
tendinous ends and adhering connective tissue, and minced into small
pieces of 1 mm3. Individual muscles from two mice were pooled. After
the muscle tissues were rinsed in DMEM (Invitrogen), digestion was
performed by three successive rounds of incubation in 10 ml of DMEM
supplemented with 10 mM HEPES (pH 7.4), 10% fetal calf serum
(Invitrogen), and 0.15% Pronase (Roche Applied Science) at 37 °C. After
the first incubation (5 min), the tissues were triturated with a serologic
pipette, and the supernatant, containing mainly blood cells and connec-
tive debris, was discarded. The second and third incubations lasted 20
min each with frequent triturations. The supernatants were collected,
pooled, filtered through a 40-m mesh cell strainer (Falcon; BD Bio-
sciences), and centrifuged at 300  g for 10 min. The cell pellets were
resuspended in growth medium (see below), and the suspensions were
plated onto collagen type I-coated (1 g/cm2; Sigma) 100-mm diameter
Petri dishes, one dish per original muscle. Growth medium was com-
posed of a 1:1 (v/v) mixture of DMEM and MCDB202 (CryoBioSystem)
supplemented with 20% fetal calf serum, 2% Ultroser® SF (Biosepra
SA), antibiotics (Ciproxin; Bayer), and NaHCO3 from concentrated so-
lution (Invitrogen) to get 2.6 g/liter in complete medium. Myoblasts
were plated on coated dishes and grown for 2 days in growth medium.
For the experiments, cells were transfected (see below) and induced to
fuse by changing the growth medium to differentiation medium
(DMEM supplemented with 1.7% fetal calf serum, 3.3% horse serum
(Sigma), 10 g/ml insulin (Fluka), and Ciproxin).
Transfection—Myoblasts were plated at 12,000 cells/cm2 on 13-mm
Thermanox coverslips (Nalge Nunc International) in four-well plates.
When 80–90% confluent, growth medium was removed and replaced
with a serum-free medium, Opti-MEM I (Invitrogen). Cells were trans-
fected overnight using LipofectAMINE 2000 (Invitrogen) at a ratio of 1
g of DNA per 2 l of transfection reagent. The DNA-LipofectAMINE
2000 complex was prepared in Opti-MEM I medium. After overnight
incubation, this medium was replaced by a differentiation medium.
Myotubes were used 3 or 4 days after differentiation.
Plasmids—The aequorin plasmids were gifts from T. Pozzan,
Padova, Italy. Cells were transfected with a pcDNAI expression vector
containing a cDNA encoding either green fluorescent protein (GFP) for
localization or wild type aequorin for Ca2 measurement, both fused
with the SNAP-25 targeting sequence to measure subsarcolemmal cal-
cium (pm[Ca2]) (35) or with cytosolic aequorin to measure cytosolic
calcium concentrations ([Ca2]c) (13). The IP3 sponge plasmid was a gift
from H. L. Roderick and M. D. Bootman, Cambridge, United Kingdom.
Cells were co-transfected with a pdc515 expression vector (Microbix
Biosystems Inc.) containing a cDNA encoding enhanced GFP, the high
affinity IP3 sponge (36), and a pcDNAI expression vector containing a
cDNA encoding the SNAP-25 aequorin.
Confocal Microscopy—Mdxmyotubes were grown in plastic culture
dishes and transfected with a pcDNAI expression vector containing
the cDNA encoding a GFP-tagged SNAP-25 targeting sequence. Con-
focal imaging was performed on a living myotube on a LSM 510 Meta
confocal scanner mounted on an upright Axioskop 2 FS microscope
(Carl Zeiss). Fluorescence was excited at 488 nm, and emission was
detected at 505–530 nm using a 40  0.8 numerical aperture water
immersion objective (Achroplan, Carl Zeiss). Simultaneous differen-
tial interference contrast images of cells were recorded on the trans-
mitted light detector with the polarized 488-nm light used for GFP
fluorescence excitation.
Intracellular Calcium Measurement—After 3 or 4 days of differenti-
ation, subsarcolemmal Ca2 concentration was determined in a popu-
lation of myotubes as described previously with minor modifications
(37). Briefly, the SNAP-25 aequorin was reconstituted in a Ca2-free
physiological salt solution (PSS) (145 mM NaCl, 5 mM KCl, 1 mM MgCl2,
5 mM HEPES, and 10 mM glucose, pH 7.6) containing 0.1 mM EGTA and
5 M coelenterazine (Calbiochem) for 1 h before the experiment to
decrease the [Ca2] within the cell. Cells were superfused at a rate of 1
ml/min in a custom-made 0.5-ml chamber thermostated at 37 °C
(MecaTest, Geneva, Switzerland). Emitted luminescence was detected
at 466 nm with a photomultiplier apparatus (EMI 9789A, Electron
Tubes Limited, United Kingdom) and recorded every second using a
computer photon-counting board (EMI C660) as described previously
(38). The relationship between recorded counts and [Ca2] is shown in
Equation 1 (39),
Ca2 (in M) 
ratio ratioKTR	 1
KR ratioKR	
with ratio  LLmax
1/n
(Eq. 1)
where L represents the recorded photons/s and Lmax represents the re-
maining photons that correspond to the total light output during the
whole experiment minus the photons emitted up to the measured point.
KTR and KR are the parameters of the aequorin and n is the number of
Ca2 binding sites. At 37 °C, KTR  120, KR  1.01E  07 M

1, and n 
2.99. Total light output was obtained by exposing cells to 10 mM CaCl2
after permeabilization with 100 M digitonin to consume all the aequorin.
45Ca2 Influx Measurement—Influx measurement was performed
using 45Ca2 (5–50 mCi/mg; PerkinElmer Life Sciences) as described
with minor modifications (40). Briefly, myotubes were washed twice
and preincubated at 37 °C for 10 min in 250 l of the PSS solution
described above also containing 0.12 mM CaCl2 and, eventually, the
indicated inhibitor. 45Ca2 influx was initiated by incubation with 200
l of PSS containing 1.2 mM CaCl2 alone or with 100 M carbachol
(CCh) and 0.4 mCi of 45Ca2 for 10 min at 37 °C. The cells were
subsequently washed four times with ice-cold PSS containing no CaCl2
but 0.1 mM EGTA (to remove extracellularly bound 45Ca2). Cells were
lysed with 250 l of 1% SDS (w/v). The radioactivity of the lysate was
measured by scintillation counting (Packard 460C, Zurich, Switzer-
land). Values are expressed in counts per minute.
Data Analysis—Data analysis was performed using the software
GraphPad Prism (GraphPad Software, San Diego, CA) and Matlab (The
MathWorks Inc, Natick, MA). Results are expressed as means  S.E.
Statistical significance between the different values was assessed with
the unpaired Student’s t test or one-way analysis of variance test
followed by a Dunnett test. p  0.05 was considered not significant; p
values  0.05 were considered significant.
RESULTS
As the removal of intracellular Ca2 is required for the
complete reconstitution of aequorin (41), SNAP-25 aequorin-
expressing cells were preincubated in Ca2-free PSS contain-
ing 0.1 mM EGTA for 1 h before performing the experiment.
For each experiment the basal level of luminescence was
recorded for 1 min before performing the experiment. The
stimulus applied was PSS containing 1.2 mM Ca2 and the
test compounds.
SNAP Aequorin Localization—To investigate the localiza-
tion of the SNAP-25 aequorin, cells were transfected with
cDNA encoding the GFP fused with the SNAP-25 targeting
sequence. Fig. 1 shows a representative confocal section of a
transfected living mdx myotube after 3 days of differentiation.
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SNAP-25-GFP-mediated fluorescence (Fig. 1A) appeared to be
mainly localized at the sarcolemma when compared with the
localization assessed with differential interference contrast im-
aging (Fig. 1, B and C). However, some SNAP-25-GFP fluores-
cence was detected in the cytosol, which could correspond to a
non-palmitoylated protein (35). Similar results were obtained
with control C57 myotubes (data not shown).
To further investigate the localization of the SNAP-25 ae-
quorin, cells were incubated for 10 min with the high affinity
Ca2 chelator BAPTA-AM to buffer cytosolic Ca2. Cytosolic
Ca2 responses assessed with cytosolic aequorin triggered by
CCh and Ca2 readdition were completely inhibited in cells
loaded with BAPTA-AM (Fig. 2A). In contrast, in cells trans-
fected with SNAP-25 aequorin the maximal Ca2 responses
and time to peak values (17.50  2.0 s and 20.17  2.7 s) were
not significantly reduced by BAPTA-AM (Fig. 2B). These re-
sults indicate that Ca2 responses measured with SNAP-25
aequorin were due to Ca2 increases in a restricted area under
the plasma membrane, presumably where BAPTA-AM had
very limited access. Moreover, as shown in Fig. 2C, the Ca2
peaks triggered by these stimuli were 10 times larger when
measured with SNAP-25 aequorin than with cytosolic aequorin
(4.97  0.66 and 0.53  0.04 M, respectively). Altogether,
these results indicate that SNAP-25 aequorin was mainly lo-
calized at the plasma membrane. Therefore the probe appears
to be a reliable tool for measuring near-plasma membrane
Ca2 concentrations.
CCh-induced Ca2 Responses in Control and Dystrophic
Cells—To test the hypothesis that the IP3 receptor pathway
could be involved in acetylcholine receptor activation, we meas-
ured the effects of the nicotinic agonist carbachol (100 M) and
the effects of the potent IP3 receptor inhibitor, 2-aminoethoxy-
diphenyl borate (2-APB) (42), on subsarcolemmal Ca2 tran-
sients in both control and dystrophic myotubes. As shown in
Fig. 3, 100 M CCh together with 1.2 mM Ca2 triggered peak
pm[Ca2] increases of 1.06  0.11 M for control cells and
4.97  0.66 M for dystrophic cells, representing a 4.5-fold
increase. When cells were incubated for 10 min with 75 M
2-APB, the CCh-induced Ca2 response was not significantly
changed in control myotubes but was significantly decreased in
dystrophic myotubes (from 4.97  0.66 to 1.63  0.21 M).
These results therefore suggest that the Ca2-release path-
ways involved in CCh responses are different between control
and dystrophic myotubes and that the IP3 pathway may be
involved in CCh-induced Ca2 responses. We then investigated
the pathway involved in dystrophic myotubes.
Ca2 Increases Triggered by CCh Are Mediated by Nicotinic
Receptors—The application of CCh together with Ca2 trig-
FIG. 1. SNAP-25 aequorin localiza-
tion in mdx myotubes. Shown is a con-
focal section of a living mdx myotube ex-
pressing the GFP protein tagged with the
SNAP-25 targeting sequence, indicating
SNAP-25 aequorin localization. A, GFP
fluorescence. B, differential interference
contrast. C, superposition of panels A
and B.
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gered pm[Ca2] increases of a maximal amplitude of 4.97 
0.66 M. As shown in Fig. 4, C and E, preincubation of cells for
10 min with atropine (100 M), a selective muscarinic receptor
antagonist, did not affect the maximal amplitude of the CCh-
induced Ca2 peak. On the other hand, 10 min of incubation
with the highly selective nicotinic receptor antagonist d-tubo-
curarine (10 M) decreased CCh-induced Ca2 responses from
4.97  0.66 M in non-treated cells to 1.47  0.03 M in the
presence of the compound (Fig. 4, D and E). Average CCh
responses in the presence of d-tubocurarine were not statisti-
cally different from the Ca2 responses triggered by Ca2 re-
addition alone. Altogether, these results indicate that CCh-
induced Ca2 increases were mediated by the activation of
nicotinic receptors.
Initial Ca2 Influx Induced by CCh—Ca2 increases trig-
gered by CCh may rely on Ca2 influx through plasma mem-
brane channels. Fig. 5A shows that CCh-induced Ca2 in-
creases were triggered by an influx through plasma membrane
Ca2 channels. Indeed, incubation for 10 min with 1 mM cad-
mium, a non-selective Ca2 channel inhibitor (43), drastically
decreased the CCh-induced Ca2 response (from 4.97  0.66
M for non-treated cells to 0.46  0.02 M for treated cells).
Moreover, CCh had no effect on the pm[Ca2] when added to a
Ca2-free solution, whereas the addition of CCh together with
Ca2 led to a Ca2 response (Fig. 5B). These results strongly
suggest that the Ca2 responses were triggered at least in part
by Ca2 influx through plasma membrane Ca2 channels.
We then tested the effect of nifedipine (1 M), a potent and
selective blocker of L-type voltage-gated Ca2 channels, on the
CCh-induced Ca2 response. Results indicated that L-type volt-
age-gated Ca2 channel activation was involved in the re-
sponse triggered by CCh (Fig. 5C). To confirm that this re-
sponse was truly due to influx, we used the 45Ca2 influx
technique. As shown in Fig. 5D, Ca2 influx was increased from
638  51 cpm/well with Ca2 alone to 910  69 cpm/well with
100 M CCh. Moreover, when cells were incubated with 1 M
nifedipine and both Ca2 and CCh, the Ca2 influx was de-
creased (591  13 cpm/well). These results confirm that CCh
triggered Ca2 influx through voltage-gated L-type Ca2
channels.
Quick Sarcoplasmic Reticulum Ca2 Refilling and Ca2
Release—Results from experiments described above have
shown that in dystrophic myotubes CCh-induced Ca2 re-
sponses were at least in part due to Ca2 influx. To go
further, we tested the effect of the sarcoplasmic-endoplasmic
reticulum Ca2 ATPase (SERCA) blocker thapsigargin (44).
As shown in Fig. 6, incubation for 10 min with 1 M thapsi-
gargin decreased the CCh-induced Ca2 response from
4.97  0.66 to 1.92  0.24 M for the thapsigargin-treated
cells, which is very similar to the response triggered by Ca2
alone (1.84  4.4 M). Altogether these results show that the
FIG. 2. BAPTA-AM effect on the Ca2 response. A and B, repre-
sentative traces of the global Ca2 concentration in a population of EDL
mdx myotubes showing the effect of a 10 M BAPTA-AM preincubation
compared with non-treated myotubes. Confluent myoblasts were trans-
fected with cytosolic aequorin (A) and SNAP-25 aequorin (B). Myotubes
were used at days 3 or 4 after differentiation. Arrows indicate the
beginning of stimulation with CCh. C, summarizing histogram; a cross
indicates myoblasts transfected with SNAP-25 aequorin. Cytosolic Ca2
response with BAPTA-AM is not shown because of complete abolition.
The bar graphs correspond to mean [Ca2] values  S.E. (n  6; ns, not
significant (p  0.05); *** corresponds to a significant inhibition (p 
0.001) using an unpaired Student’s t test).
FIG. 3. CCh-induced Ca2 response in control and dystrophic
cells. Shown is a summarizing histogram showing the effect of 1.2 mM
Ca2 readdition together with 100 M CCh and 75 M 2-APB in control
C57 and dystrophic myotubes. The bar graphs correspond to mean
pm[Ca2] values  S.E. (n  4; ns, not significant (p  0.05); ***
corresponds to a significant inhibition (p  0.001) using an unpaired
Student’s t test). Plain columns represent results from the control cells;
hatched columns represent results from the dystrophic cells.
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CCh-induced Ca2 transients are due to both Ca2 influx and
Ca2 release from the sarcoplasmic reticulum.
Involvement of the IP3 Pathway in CCh-induced Response—
Results shown in Fig. 3 suggest that IP3 pathway may be
involved in CCh-induced Ca2 response in dystrophic myo-
tubes. To test the involvement of this pathway, we investigated
the effect of U73122, a potent phospholipase C (PLC) inhibitor
(45). Indeed, PLC is required for IP3 formation through phos-
phatidylinositol 4,5-bisphosphate cleavage. As shown in Fig. 7,
incubation of the cells with 20 M U73122 decreased the CCh-
induced Ca2 peak amplitude from 4.97  0.66 M for non-
treated cells to 2.76  0.19 M for treated cells. This result
FIG. 4. Nicotinic receptors are involved in the CCh-induced response. A–D, representative traces of subsarcolemmal Ca2 increases in
a population of EDL-derived mdx myotubes showing the effect of 1.2 mM Ca2 readdition (A), 1.2 mM Ca2 readdition together with 100 M CCh
(B), 100 M atropine (C), and 10 M d-tubocurarine (D). Arrows indicate the beginning of stimulation with CCh. E, summarizing histogram; the
bar graphs correspond to mean pm[Ca2] values  S.E. (n  6; ns, not significant (p  0.05); * and ** correspond to a significant inhibition (p 
0.05 and 0.01 and p  0.001, respectively) using a one-way analysis of variance test followed by a Dunnett test to compare all of the columns with
the 1.2 mM Ca2 and 100 M CCh bar).
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suggests that the PLC/IP3 pathway may be involved in the
CCh-mediated Ca2 response. Moreover, we tested the effect of
xestospongin D, a potent blocker of IP3 receptors, at a very low
concentration (0.1 M) (46). Preincubation of the cells for 10
min with this compound decreased the CCh-induced Ca2 re-
sponses from 4.97  0.66 to 2.44  0.34 M.
Because 2-APB and xestospongin D may have nonspecific
effects (47, 48) we co-transfected cells with both a high affinity
IP3 sponge and SNAP-25 aequorin. This IP3 sponge has been
shown to behave as an IP3 chelator and to inhibit IP3-mediated
Ca2 responses (36). Again, the CCh-induced Ca2 peak was
strongly decreased in co-transfected cells (from 4.97  0.66 to
0.72 0.13 M) and was below that of the response due to Ca2
alone. Altogether, these results clearly show that the IP3 path-
way was involved in CCh-induced Ca2 response in our mdx
myotubes.
DISCUSSION
In this study we used SNAP-25, a plasma membrane protein,
to target the Ca2 sensitive photoprotein aequorin to the sub-
sarcolemmal area of both control and dystrophic myotubes.
Because of the complexity (different degrees of maturation) and
density (heavy cytoskeleton, actin, and myosin) of skeletal
muscle cells, we first checked the localization of the probe. This
was investigated by confocal microscopy using SNAP-25-GFP
on living mdx myotubes. Results suggest that this probe and,
therefore, also SNAP-25 aequorin was preferentially localized
at the sarcolemma. Confocal sections of mdx myotubes also
showed some cytosolic fluorescence that corresponds to non-
targeted protein or, most probably, non-palmitoylated SNAP-
25. Indeed, working with live cells indicates that proteins are
continuously expressed, and it has been shown previously that
the SNAP-25 protein must be palmitoylated on cysteine resi-
FIG. 5. Initial Ca2 influx induced by CCh. A, histogram showing the effect of cadmium (1 mM) on the CCh-induced Ca2 response (n  6;
*** indicates significant inhibition (p 0.001) using unpaired Student’s t test). B, representative trace of a subsarcolemmal Ca2 response induced
by 100 M CCh in a population of EDL-derived mdx myotubes showing the effects of a Ca2 omission and the readdition of 1.2 mM Ca2. C,
histogram illustrating the effect of nifedipine (1 M) on subsarcolemmal Ca2 response induced by 100 M CCh (n  6; * indicates significant
inhibition (p  0.05) using an unpaired Student’s t test). D, histogram showing the effect of 100 M CCh and 1 M nifedipine on 45Ca2 influx. The
bar graph corresponds to the means of 45Ca2 influx values  S.E. (n  8; *** corresponds to a significant difference (p  0.001) using an unpaired
Student’s t test).
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dues to be targeted correctly to the inner leaflet of the plasma
membrane (35). In our case, the cytosolic fluorescence is likely
to be due to non-mature SNAP-25-GFP protein.
Localization of SNAP-25 aequorin was also assessed with
functional experiments. Indeed, BAPTA-AM pretreatment of
the cells did not significantly decrease CCh-induced Ca2 re-
sponses measured with SNAP-25 aequorin but completely sup-
pressed those detected with cytosolic aequorin. The fact that
the time needed to reach the peak was also unaltered by
BAPTA-AM pretreatment suggests that this finding is due to
the inability of BAPTA to chelate Ca2 in the space below the
plasma membrane. These results clearly indicate that
SNAP-25 aequorin allows us to measure Ca2 in a restricted
area under the plasma membrane that may correspond to the
“fuzzy space” described in other cell types (49, 50). In this
restricted area BAPTA-AM appears to have little or no access.
These results also confirm that SNAP-25 aequorin was mainly
localized at the plasma membrane and that it is a reliable tool
for measuring near-plasma membrane Ca2 concentration in
these myotubes. Ca2 increases in response to CCh were much
bigger when measured under the plasma membrane rather
than in the cytosol. This is very likely due to the fact that
SNAP-25 aequorin is very close to Ca2 channels and also that
Ca2 increases may occur in a physically restricted area, which
prevents diffusion of Ca2 in the bulk cytosol.
CCh-induced pm[Ca2] increases were 4.5 times bigger in
dystrophic myotubes than in control myotubes. This result is in
agreement with previous results obtained in muscle fibers that
also showed a subsarcolemmal Ca2 overload due to enhanced
Ca2 influx in dystrophic fibers as compared with control (14).
Moreover, we found that 2-APB, an IP3 receptor inhibitor,
strongly decreased the CCh-induced Ca2 responses in dystro-
phic but not in control C57 myotubes. These results also sug-
gest that the mechanisms involved in CCh-induced subsar-
colemmal increases may be different between control and
dystrophic myotubes.
In mdx myotubes, CCh was able to trigger Ca2 increases
only when Ca2 was added and CCh-induced Ca2 responses
were completely blocked by cadmium ion, a non-selective Ca2
channel blocker. This result indicates that CCh-induced Ca2
increases after preincubation in a Ca2-free solution are trig-
gered by Ca2 influx through plasma membrane Ca2 chan-
nels. Moreover, CCh-induced Ca2 responses were partially
inhibited by nifedipine, showing that L-type voltage-gated Ca2
channel activation are involved in CCh-induced Ca2 re-
sponses. When cells were incubated with the sarcoplasmic-
endoplasmic reticulum Ca2 ATPase blocker thapsigargin, the
CCh-induced Ca2 responses were significantly decreased and
reached the same amplitude as the response triggered by Ca2
readdition. Altogether, these results suggest that CCh-induced
Ca2 responses are due to Ca2 influx through plasma mem-
brane Ca2 channels followed by a fast Ca2 refilling of the
sarcoplasmic reticulum and a secondary Ca2 release from the
store.
In mdx myotubes, CCh-induced pm[Ca2] increases were
significantly reduced when cells were incubated with two po-
tent IP3 receptor inhibitors (2-APB and xestospongin D) or
when cells were co-transfected with an IP3 sponge together
with SNAP-25 aequorin. These results demonstrate that IP3
receptors are involved in CCh-induced Ca2 increases in dys-
trophic myotubes. Consistently, CCh-induced Ca2 increases
were also inhibited by the phospholipase C inhibitor U73122.
Altogether, these results indicate that nicotinic receptor acti-
vation triggers PLC activation and IP3 release in our dystro-
phic myotubes, raising a question about the mechanism of PLC
activation. It has been shown recently that the activation of
voltage-gated Ca2 channels by potassium chloride depolariza-
tion can activate PLC in myotubes by a mechanism involving a
G-protein (32). This could indeed be the case in our dystrophic
myotubes, as CCh triggers activation of L-type voltage-gated
Ca2 channels. PLC may therefore be activated by near-
plasma membrane Ca2 increases due to Ca2 influx occurring
through nicotinic receptors and/or voltage-gated Ca2 channels
(51). Altogether, these results indicate that CCh-induced Ca2
increases rely on IP3 receptor activation in dystrophic myo-
tubes. On the other hand, 2-APB was without effect on CCh-
induced Ca2 responses in control myotubes, indicating that
the IP3 pathway is not involved in nicotinic responses in this
cell type.
However, recent studies have shown that 2-APB is also a
potent inhibitor of channels activated by the depletion of the
Ca2 stores (store-operated channels or SOCs) (52, 53). Indeed,
since our cells were incubated for 1 h in a Ca2-free solution for
complete aequorin reconstitution, Ca2 stores have been de-
pleted. These conditions raise the question about the involve-
ment of SOCs in the CCh-induced Ca2 responses. Our results
FIG. 6. Quick sarcoplasmic reticulum Ca2-refilling and Ca2-
release. A, representative trace of subsarcolemmal Ca2 response in a
population of EDL mdx myotubes showing the effect of 1 M thapsigar-
gin on the CCh-induced Ca2 response. Arrow indicates the beginning
of stimulation with CCh. B, summarizing histogram. The bar graphs
correspond to mean of pm[Ca2] values  S.E. (n  12; ns, not signif-
icant (p  0.05); *** corresponds to a significant difference (p  0.001)
using an unpaired Student’s t test).
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with thapsigargin and IP3 pathway inhibitors strongly suggest
that IP3 receptor-induced Ca
2 release is involved in CCh-
induced Ca2 response. However, we can not exclude the in-
volvement of SOCs in CCh responses. Indeed, IP3 receptor
activation could trigger SOCs opening, as has already been
shown in numerous types of cells including skeletal muscle
cells (24, 26, 54). Moreover it has been shown that SOCs, which
belong to the family of the transient receptor potential chan-
nels (TRPC) (55), could be involved in the increased Ca2 influx
in dystrophic fibers (56).
In conclusion, our results indicate that IP3 receptors are
involved in near-plasma membrane Ca2 increases triggered
by the activation of nicotinic receptors in dystrophic myotubes.
The involvement of IP3 receptors represents a new and unex-
pected pathway for the excitation of dystrophic skeletal muscle
cells. Indeed, our control myotubes do not display any IP3
FIG. 7. Involvement of the IP3 pathway in CCh-induced Ca
2 response. A–D, representative traces of subsarcolemmal Ca2 response in
a population of EDL mdx myotubes showing the effect of 20 M U73122 (A), 75 M 2-APB (B), 0.1 M xestospongin D (Xesto D) (C), and an IP3
sponge co-transfected with SNAP-25 aequorin (D). Arrows indicate beginning of stimulation with CCh in the presence of the compounds indicated.
E, summarizing histogram. The bar graphs correspond to mean pm[Ca2] values  S.E. (n  6; *** corresponds to a significant inhibition (p 
0.001) as assessed by a one-way analysis of variance test followed by a Dunnett test to compare all the column with the 1.2 mM Ca2 and 100 M
CCh bar).
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inhibitor sensitivity. It has been shown in muscle cells that the
main pathway for Ca2 release from the sarcoplasmic reticu-
lum and muscle contraction is the ryanodine receptor (19).
Moreover, increases in IP3 receptor number and a 2- to 3-fold
increase in IP3 levels have been reported inmdxmyotubes (21).
Altogether, these results suggest that IP3 receptors may be
involved in altered Ca2 homeostasis and the subsequent mus-
cle degeneration that occurs in dystrophic muscle cells.
Acknowledgments—We thank Philippe Lhote for technical help with
the cell culture and Drs. H.L. Roderick and M.D. Bootman (Calcium
Group, Laboratory of Molecular Signaling, The Babraham Institute,
Babraham, Cambridge, United Kingdom) and Professor T. Pozzan (Uni-
versity of Padova, Italy) for their generous gift of plasmids.
REFERENCES
1. Emery, A. E. (1991) Neuromuscul. Disord. 1, 19–29
2. Muntoni, F., Fisher, I., Morgan, J. E., and Abraham, D. (2002) Neuromuscul.
Disord. 12, Suppl. 1, S162–S165
3. Ahn, A. H., and Kunkel, L. M. (1993) Nat. Genet. 3, 283–291
4. Fabbrizio, E., Bonet-Kerrache, A., Limas, F., Hugon, G., and Mornet, D. (1995)
Biochem. Biophys. Res. Commun. 213, 295–301
5. Gillis, J. M. (1996) Acta Physiol. Scand. 156, 397–406
6. Alderton, J. M., and Steinhardt, R. A. (2000) J. Biol. Chem. 275, 9452–9460
7. McCarter, G. C., and Steinhardt, R. A. (2000) J. Membr. Biol. 176, 169–174
8. Tutdibi, O., Brinkmeier, H., Rudel, R., and Fohr, K. J. (1999) J. Physiol. 515,
859–868
9. Leijendekker, W. J., Passaquin, A. C., Metzinger, L., and Ruegg, U. T. (1996)
Br. J. Pharmacol. 118, 611–616
10. Turner, P. R., Fong, P. Y., Denetclaw, W. F., and Steinhardt, R. A. (1991)
J. Cell Biol. 115, 1701–1712
11. Gailly, P. (2002) Biochim. Biophys. Acta 1600, 38–44
12. Bulfield, G., Siller, W. G., Wight, P. A., and Moore, K. J. (1984) Proc. Natl.
Acad. Sci. U. S. A. 81, 1189–1192
13. Robert, V., Massimino, M. L., Tosello, V., Marsault, R., Cantini, M.,
Sorrentino, V., and Pozzan, T. (2001) J. Biol. Chem. 276, 4647–4651
14. Mallouk, N., Jacquemond, V., and Allard, B. (2000) Proc. Natl. Acad. Sci.
U. S. A. 97, 4950–4955
15. Ruegg, U. T., and Gillis, J.-M. (1999) Trends Pharmacol. Sci. 20, 351–352
16. Sacco, P., Jones, D. A., Dick, J. R., and Vrbova, G. (1992) Clin. Sci. (Lond.) 82,
227–236
17. Vilquin, J. T., Brussee, V., Asselin, I., Kinoshita, I., Gingras, M., and
Tremblay, J. P. (1998) Muscle Nerve 21, 567–576
18. De Luca, A., Pierno, S., Liantonio, A., Cetrone, M., Camerino, C., Fraysse, B.,
Mirabella, M., Servidei, S., Ruegg, U. T., and Conte Camerino, D. (2003)
J. Pharmacol. Exp. Ther. 304, 453–463
19. Berchtold, M. W., Brinkmeier, H., and Muntener, M. (2000) Physiol. Rev. 80,
1215–1265
20. Powell, J. A., Carrasco, M. A., Adams, D. S., Drouet, B., Rios, J., Muller, M.,
Estrada, M., and Jaimovich, E. (2001) J. Cell Sci. 114, 3673–3683
21. Liberona, J. L., Powell, J. A., Shenoi, S., Petherbridge, L., Caviedes, R., and
Jaimovich, E. (1998) Muscle Nerve 21, 902–909
22. Salanova, M., Priori, G., Barone, V., Intravaia, E., Flucher, B., Ciruela, F.,
McIlhinney, R. A. J., Parys, J. B., Mikoshiba, K., and Sorrentino, V. (2002)
Cell Calcium 32, 193–200
23. Berridge, M. J. (1993) Nature 361, 315–325
24. Ma, H. T., Patterson, R. L., van Rossum, D. B., Birnbaumer, L., Mikoshiba, K.,
and Gill, D. L. (2000) Science 287, 1647–1651
25. Kiselyov, K., Mignery, G. A., Zhu, M. X., and Muallem, S. (1999) Mol. Cell 4,
423–429
26. Kiselyov, K., Xu, X., Mozhayeva, G., Kuo, T., Pessah, I., Mignery, G., Zhu, X.,
Birnbaumer, L., and Muallem, S. (1998) Nature 396, 478–482
27. Kiselyov, K., and Muallem, S. (1999) Trends Neurosci. 22, 334–337
28. Vergara, J., Tsien, R., and Delay, M. (1985) Proc. Natl. Acad. Sci. U. S. A. 82,
6352–6356
29. Talon, S., Vallot, O., Huchet-Cadiou, C., Lompre, A.-M., and Leoty, C. (2002)
Am. J. Physiol. 282, R1164–R1173
30. Talon, S., Huchet-Cadiou, C., and Leoty, C. (1999) Pflugers Arch. 438,
804–816
31. Yamaguchi, N., and Kasai, M. (1997) Biochem. Biophys. Res. Commun. 240,
772–777
32. Araya, R., Liberona, J. L., Cardenas, J. C., Riveros, N., Estrada, M., Powell,
J. A., Carrasco, M. A., and Jaimovich, E. (2002) J. Gen. Physiol. 121, 3–16
33. Jaimovich, E., Reyes, R., Liberona, J. L., and Powell, J. A. (2000) Am. J.
Physiol. 278, C998–C1010
34. Pinset, C., and Montarras, D. (1998) in Cell Biology: A Laboratory Handbook
(Celis, J., ed) Vol. 1, 2nd Ed., pp. 226–232, Academic Press, New York
35. Brini, M., Pinton, P., Pozzan, T., and Rizzuto, R. (1999)Microsc. Res. Tech. 46,
380–389
36. Uchiyama, T., Yoshikawa, F., Hishida, A., Furuichi, T., and Mikoshiba, K.
(2002) J. Biol. Chem. 277, 8106–8113
37. Challet, C., Maechler, P., Wollheim, C. B., and Ruegg, U. T. (2001) J. Biol.
Chem. 276, 3791–3797
38. Kennedy, E. D., Rizzuto, R., Theler, J. M., Pralong, W. F., Bastianutto, C.,
Pozzan, T., and Wollheim, C. B. (1996) J. Clin. Investig. 98, 2524–2538
39. Alvarez, J., and Montero, M. (2002) Cell Calcium 32, 251–260
40. Passaquin, A. C., Lhote, P., and Ruegg, U. T. (1998) Br. J. Pharmacol. 124,
1751–1759
41. Marsault, R., Murgia, M., Pozzan, T., and Rizzuto, R. (1997) EMBO J. 16,
1575–1581
42. Maruyama, T., Kanaji, T., Nakade, S., Kanno, T., and Mikoshiba, K. (1997)
J Biochem. 122, 498–505
43. Oba, T., Yamaguchi, M., Wang, S., and Johnson, J. D. (1992) Biophys. J. 63,
1416–1420
44. Janczewski, A. M., and Lakatta, E. G. (1993) Am. J. Physiol. 265, H517–H522
45. Hou, C., Kirchner, T., Singer, M., Matheis, M., Argentieri, D., and Cavender,
D. (2004) J. Pharmacol. Exp. Ther. 309, 697–704
46. Gafni, J., Munsch, J., Lam, T., Catlin, M., Costa, L., Molinski, T., and Pessah,
I. (1997) Neuron 19, 723–733
47. Peppiatt, C. M., Collins, T. J., Mackenzie, L., Conway, S. J., Holmes, A. B.,
Bootman, M. D., Berridge, M. J., Seo, J. T., and Roderick, H. L. (2003) Cell
Calcium 34, 97–108
48. Smet, P. D., Parys, J. B., Callewaert, G., Weidema, A. F., Hill, E., Smedt, H. D.,
Erneux, C., Sorrentino, V., and Missiaen, L. (1999) Cell Calcium 26, 9–13
49. Lederer, W. J., Niggli, E., and Hadley, R. W. (1990) Science 248, 283
50. Scriven, D., Klimek, A., Lee, K., and Moore, E. (2002) Ann. N. Y. Acad. Sci.
976, 488–499
51. Berridge, M. J., Bootman, M. D., and Roderick, H. L. (2003)Nat. Rev. Mol. Cell
Biol. 4, 517–529
52. Pan, Z., Yang, D., Nagaraj, R., Nosek, T., Nishi, M., Takeshima, H., Cheng, H.,
and Ma, J. (2002) Nat. Cell Biol. 4, 379–383
53. Prakriya, M., and Lewis, R. S. (2001) J. Physiol. (Lond.) 536, 3–19
54. Launikonis, B. S., Barnes, M., and Stephenson, D. G. (2003) Proc. Natl. Acad.
Sci. U. S. A. 100, 2941–2944
55. Clapham, D. E. (2003) Nature 426
56. Vandebrouck, C., Martin, D., Colson-Van Schoor, M., Debaix, H., and Gailly, P.
(2002) J. Cell Biol. 158, 1089–1096
IP3 Control of Calcium Response in mdx Myotubes47100
3.1.3 Additional results and discussion 
As described above in the manuscript and because of the relative non specificity of 
the IP3R inhibitor 2-APB and its possible effect on store-operated Ca2+ channels (SOC, 
Peppiatt et al., 2003), we tested the effect of this inhibitor on the Ca2+ influx using the 45Ca2+ 
technique. As shown in figure 3.1, 45Ca2+ influx was increased from 638 ± 15 cpm/well with 
Ca2+ alone to 910 ± 24 cpm/well with Ca2+ together with 100 µM CCh. Moreover, when cells 
were incubated for 10 minutes with 2-APB (75 µM) and both Ca2+ and CCh, the Ca2+ influx 
was significantly decreased (387 ± 15 cpm/well). 
This result leads to 2 different suggestions. First, a direct inhibition of SOC by 2-APB 
could explain the 58 % decrease of Ca2+ influx (Peppiatt et al., 2003). Indeed, following 
nAChR stimulation with CCh and Ca2+ release from the store, the depletion of the SR is 
likely to trigger SOC activation. In the case of SOC inhibition by 2-APB, Ca2+ influx might 
be decreased. 
As it has been shown that IP3R can be coupled to SOC in different types of cells 
(Kiselyov et al., 1998; Ma et al., 2000; Launikonis et al., 2003), another explanation would 
be that the inhibition of IP3R by 2-APB results in subsequent SOC gating inhibition. 
However, as it appears very unlikely that the specific IP3 sponge (Kd= 92 pM) directly 
inhibits SOC, results obtained with the IP3 sponge are rather in favour of an inhibition of the 
IP3R-induced Ca2+ release which would result in SOC inhibition. 
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Figure 3.1: Effect of 2-APB on the 45Ca2+ influx in dystrophic myotubes. 
Summarizing histogram showing the effect of 100 µM CCh and 75 µM 2-APB on the 45Ca2+ influx. 
The bar graphs correspond to mean of 45Ca2+ influx values ± SEM (n ≥ 4, *** corresponds to a 
significant inhibition (P<0.001) using one-way ANOVA test followed by a Dunnett test to compare 
all the column with the 1.2 mM Ca2+ and 100 µM CCh bar). 
 
 
We have shown here the implication of the IP3R, but we also investigated the 
involvement of RyR in the CCh-induced subsarcolemmal Ca2+ responses. Indeed, it has long 
been hold that the RyR is the main receptor involved in Ca2+ release from the stores. It has 
been shown that in skeletal muscle cells the activation of nAChR leads to plasma membrane 
depolarization which triggers voltage-gated Ca2+ channel (DHPR) opening. Contraction is 
then triggered by the release of Ca2+ from the SR through the opening of RyR (Pessah et al., 
1985; Berchtold et al., 2000).  
Ryanodine was used at a concentration known to inhibit RyR, 20 µM (Meissner, 
1986). As shown in figure 3.2, the CCh-induced Ca2+ response was strongly decreased (from 
4.97 ± 0.66 µM to 0.58 ± 0.09 µM) in dystrophic myotubes. This result suggests that the RyR 
may also be involved in the Ca2+ response triggered by the activation of nAChR. This result 
suggests that CCh-induced Ca2+ responses could rely on both IP3R and RyR in our dystrophic 
myotubes. Therefore, these results suggest that the 2 Ca2+ release channels cooperate and are 
required for CCh responses. Indeed, functional cooperativity  or  interaction  between  both  
type  of  receptors  has  already been  described in vascular smooth muscle cells and in other 
cell types such as cardiac myocytes or PC12 cells (Boittin et al., 1999; Koizumi et al., 1999; 
Lipp et al., 2000; McGeown, 2004). 
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Figure 3.2: Effect of ryanodine on the CCh-induced subsarcolemmal Ca2+ response in 
dystrophic myotubes. 
Summarizing histogram showing the effect of 1.2 mM Ca2+ readdition together with 100 µM CCh and 
20 µM ryanodine. The bar graphs correspond to mean pm[Ca2+] values ± SEM (n ≥ 6, *** 
corresponds to a significant inhibition (P<0.001) using unpaired Student’s t-test). 
 
 
3.1.4 Conclusion 
It has been shown in this publication that IP3Rs play a key role in the subsarcolemmal 
Ca2+ response triggered by the activation of nAChR in dystrophic myotubes only. Moreover, 
it appears that IP3Rs are responsible for enhanced Ca2+ responses and subsequent near-plasma 
membrane Ca2+ overload in dystrophic myotubes. The involvement of this receptor in altered 
Ca2+ homeostasis in mdx myotubes represent a new and unexpected pathway and IP3 may 
therefore appear as a new potential target for the treatement of DMD. 
All these experiments have been done on myotubes. It would be interesting to 
determine if the IP3R have the same importance on physiological Ca2+ responses in mature 
dystrophic fibers. A hypothetic involvement of the receptor in dystrophic fibers could then be 
very promising. No study has been done yet.  
Finally, it would be interesting to characterize the exact role of the RyR in dystrophic 
myotubes. Here we hypothesize a possible interaction between IP3R and RyR but it has been 
suggested that RyR could be a target of calpaïn which triggers degradation of the receptor in 
skeletal muscle cells (Shoshan-Barmatz et al., 1994) and particularly in mdx myotubes 
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(Nicolas-Métral V., unpublished data of the laboratory). This degradation could explain the 
key role of the IP3R in these cells. 
 
3.2 Publication 2: Bcl-2 overexpression prevents Ca2+ overload and 
subsequent apoptosis in dystrophic myotubes. 
 
3.2.1 Introduction to the publication 
As shown in part 3.1, CCh induces near-plasma membrane Ca2+ response that rely on 
IP3R activation in dystrophic myotubes only. The fact that control C57 myotubes pm[Ca2+] 
increases induced by CCh are not affected by different IP3 inhibitors suggest that these 
myotubes respond with a different pathway. Moreover, near-plasma membrane Ca2+ 
responses are strongly increased in mdx myotubes when compared to control C57 ones. 
Altogether, results show that IP3Rs are likely to be responsible for the exaggerated 
subsarcolemmal Ca2+ transients occurring in dystrophic myotubes. 
 As the mechanism that leads to muscle degradation in DMD is still unclear and 
debated, we have explored the consequence(s) of the Ca2+ overload that occurred in 
dystrophic myotubes on cell survival and apoptosis. It has been shown that programmed cell 
death (apoptosis) could be Ca2+ dependent (Demaurex & Distelhorst, 2003) and that 
mitochondria are a key elements of apoptosis (Green & Reed, 1998). Moreover, apoptosis is 
a highly regulated process and one of the most important regulators of this programmed cell 
death is the Bcl-2 family. Then, taking into account that Ca2+ overload occurs in dystrophic 
myotubes, it was interesting to investigate the role of Bcl-2 in cell survival and apoptosis of 
both C57 and mdx myotubes. 
 In this manuscript, we have studied the effect of the overexpression of the anti-
apoptotic protein Bcl-2 on the Ca2+ responses triggered by physiological stimulation of the 
nAChR with CCh in subcellular compartments using targeted aequorins. We have also 
investigated the effect of Bcl-2 overexpression on cell survival and apoptosis of myotubes 
derived from control C57 and dystrophic mice. As it has been shown that Bcl-2 could 
regulate apoptosis by modifying the [Ca2+] in different types of cell (Pinton et al., 2000), we 
hypothesized that overexpression of this protein could decrease the Ca2+ overload in 
dystrophic myotubes and by this way, protect cells against early apoptosis. 
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3.2.2 Publication 
The manuscript has been submitted to the Journal of Biological Chemistry. 
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Duchenne muscular dystrophy (DMD) is a 
lethal disease caused by the lack of the 
cytoskeletal protein dystrophin. Altered 
calcium homeostasis and increased calcium 
concentrations in dystrophic fibers may be 
responsible for the degeneration of muscle 
occurring in DMD. Here we used 
subsarcolemmal and mitochondrial targeted 
aequorin to study the effect of the anti-
apoptotic Bcl-2 protein overexpression on 
carbachol-induced near-plasma membrane 
and mitochondrial calcium responses in 
myotubes derived from control C57 and 
dystrophic (mdx) mice. We show that Bcl-2 
overexpression decreases subsarcolemmal 
and mitochondrial calcium overload that 
occurs during physiological activation of 
nicotinic acetylcholine receptors in dystrophic 
myotubes. Moreover, our results suggest that 
overexpressed Bcl-2 protein may prevent 
near-plasma membrane and mitochondrial 
calcium overload by inhibiting IP3 receptors, 
which we have shown earlier to be involved in 
abnormal calcium homeostasis in dystrophic 
myotubes. Most likely as a consequence, the 
inhibition of IP3 receptor function by Bcl-2 
also inhibits calcium-dependent apoptosis in 
these cells.  
 
Duchenne muscular dystrophy (DMD) 
is an X-linked neuromuscular disease that 
affects about 1 in 3500 males and which results 
in progressive muscle degeneration (1). DMD 
ultimately leads to premature death by 
respiratory or cardiac failure during the third 
decade and is caused by the absence of 
dystrophin, a 427 kDa protein localised under 
the plasma membrane (2). Numerous studies 
have shown that the absence of dystrophin in 
DMD impairs the stability of the plasma 
membrane, results in a greater fragility toward 
mechanical stress and increased permeability to 
calcium (Ca2+) (3-8). Indeed, it has been 
proposed that an alteration of Ca2+ homeostasis 
might be responsible for the muscle 
degeneration that occurs in muscle fibres from 
DMD patients or in those of the mouse model of 
DMD, the mdx mouse (3,9,10). Moreover, 
elevations of basal Ca2+ concentration in 
myotubes and skeletal muscle fibres from DMD 
patients or mdx mice have been reported (3,11). 
Long term elevation of cytosolic Ca2+ is 
linked to apoptosis (12,13) and mitochondrial 
Ca2+ overload activates the permeability 
transition pore (PTP) leading to cell death 
(14,15). Because Ca2+ overload occurs in 
dystrophic myotubes and fibers, the involvement 
of apoptosis in these cells has been studied but is 
still a matter of debate. Indeed, it remains 
unclear if apoptosis causes or is secondary to 
muscle degradation (16,17). Thus, some groups 
have suggested that necrosis only occurs in 
dystrophin-lacking cells (18,19). Other groups 
have shown that apoptosis occurs in dystrophic 
cells (16,20,21) and finally that both apoptosis 
and necrosis occur in DMD (22,23). Then, 
apoptosis linked or not to necrosis could be 
responsible for the muscle degeneration that 
occurs in mdx cells and DMD patients (24,25). 
Apoptosis is a highly regulated process 
and numerous studies have shown that the Bcl-2 
protein, which belongs to the Bcl-2 family, 
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could regulate apoptosis by modulating the 
release of mitochondrial apoptogenic factors like 
cytochrome c or apoptosis-inducing factor that 
activate proteases such as caspases (26-28). 
Even if the exact role of the Bcl-2 protein is still 
unclear and debated (29), Bcl-2 could act by 
decreasing Ca2+ concentration in the 
sarcoplasmic reticulum (SR) (30-32) and other 
cellular compartments such as mitochondria or 
plasma membrane (33,34). Recent studies have 
postulated that Bcl-2 could interact directly with 
the inositol 1, 4, 5-trisphosphate receptor (IP3R) 
(35-37). This receptor is known to be 
overexpressed in dystrophic myotubes (38). We 
have shown recently that IP3R is involved in 
increased CCh-induced near-plasma membrane 
Ca2+ responses (39). However the effect of Bcl-2 
overexpression on both near-plasma membrane 
and mitochondrial Ca2+ transients has not been 
studied in dystrophic myotubes so far. 
Here we have studied the effect of 
overexpression of the anti-apoptotic protein Bcl-
2 on CCh-induced Ca2+ responses in subcellular 
compartments. We have also investigated the 
effect of Bcl-2 overexpression on cell survival 
and apoptosis of myotubes derived from control 
C57 and dystrophic mice. We show that Bcl-2 
overexpression prevents both near-plasma 
membrane and mitochondrial CCh-induced Ca2+ 
transients in dystrophic myotubes. We also show 
that Bcl-2 overexpression prevents Ca2+-
dependent apoptosis in dystrophic myotubes and 
that the beneficial effect of Bcl-2 overexpression 
may be mediated by a direct Bcl-2-dependent 
IP3R inhibition. 
  
EXPERIMENTAL PROCEDURES 
 
Cell culture – Cultures of purified 
myoblasts were prepared in Petri dishes (Falcon, 
Becton Dickinson) and maintained at 37°C in a 
water-saturated atmosphere of 95 % air / 
5 % CO2. 
They were obtained as described 
previously (40) with the minor modifications. 
Briefly, 3-week old mdx C57Bl/10 mice and 
control C57Bl/10 mice were killed by cervical 
dislocation, extensor digitorum longus (EDL) 
muscle was aseptically removed bilaterally, 
cleaned of their tendinous ends and adhering 
connective tissue. After the muscle tissues were 
rinsed in DMEM (Gibco), digestion was 
performed by 3 successive rounds of incubation 
in 10 ml of DMEM supplemented with 10 mM 
HEPES (pH 7.4), 10 % fetal calf serum (FCS) 
(Invitrogen, Life Technologies), and 0.15 % 
pronase (Roche), at 37°C. The supernatants 
were collected, pooled, filtered through a 40 µm 
mesh cell strainer (Falcon, Becton Dickinson) 
and centrifuged at 300 x g for 10 min. The cell 
pellets were resuspended in growth medium (see 
below) and the suspensions plated onto collagen 
type I-coated (1 µg/cm2; Sigma) 100 mm 
diameter Petri dishes. Growth medium is 
composed of a 1:1 (v/v) mixture of DMEM and 
MCDB202 (CryoBioSystem), supplemented 
with 20 % FCS, 2 % Ultroser® SF (Biosepra 
SA), antibiotics (Ciproxin, Bayer) and NaHCO3 
from concentrated solution (Gibco) to get 2.6 g/l 
in complete medium. Myoblasts were plated on 
coated dishes and grown for approximately 
2 days in growth medium. For the experiments 
cells were transfected (see below) and induced 
to fuse by changing the medium to 
differentiation medium (DMEM supplemented 
with 1.7% FCS, 3.3% horse serum (Sigma), 10 
µg/ml insulin (Fluka) and Ciproxin). 
Transfection – Control C57 and mdx 
myoblasts were plated at 15’000 cells per cm2 
on 13 mm Thermanox coverslips (Nalge Nunc 
International) in 4-well plates. When 80 to 90 % 
confluent, growth medium was removed and 
replaced with a serum free medium, Optimem 1 
(Gibco). Cells were transfected overnight using 
Lipofectamine 2000 (Invitrogen, Life 
Technologies) at a ratio of 1 µg DNA per 2 µl 
transfection reagent. The DNA-Lipofectamine 
2000 complex was prepared in Optimem 1 
medium. After overnight incubation this 
medium was replaced by differentiation 
medium. Myotubes were used after 3 or 4 days 
of differentiation. 
Plasmids – The aequorin plasmids were 
gifts from Prof. T. Pozzan, Padova, Italy. Cells 
were transfected with a pcDNAI expression 
vector containing a cDNA encoding aequorin for 
Ca2+ measurement, fused with the SNAP-25 
sequence to measure subsarcolemmal Ca2+ 
(pm[Ca2+]) (41), mitochondrial cytochrome C 
oxidase subunit VIII to measure mitochondrial 
Ca2+ (m[Ca2+]) (42). The Bcl-2 plasmid (43) was 
a gift from Prof. Karl Heinz Krause, University 
of Geneva, Geneva, Switzerland. The IP3 sponge 
plasmid was a gift from Drs. H.L. Roderick and 
M.D. Bootman, Cambridge, UK. Cells were 
transfected with a pdc515 expression vector 
(Microbix Biosystems Inc.) containing a cDNA 
encoding enhanced GFP and the high affinity 
IP3 sponge (44). 
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Immunochemistry – After 3 to 4 days of 
differentiation, myotubes were washed with a 
physiological salt solution (PSS: NaCl 145 
mM, KCl 5 mM, MgCl2 1mM, HEPES 5 
mM, glucose 10 mM, pH 7.6). Then cells were 
fixed with methanol/acetic acid (95 % - 5 %). 
After saturation with PSS containing 3 % Bovin 
Serum Albumin, antibody raised against the Bcl-
2 protein (1:500 dilution, sc-509, Santa Cruz 
Biotechnology, Inc) was added for 1 hour at 
37°C and revealed by an Alexa Fluor 488 
conjugated anti-mouse antibody (1:1000 
dilution, Molecular Probes). Cells were washed 
4 times with PSS after each incubation.  
Confocal Microscopy – mdx and control 
C57 myotubes were grown in plastic culture 
dishes and transfected with pcDNA3 expression 
vector containing c-DNA encoding Bcl-2. Three 
to 4 days after differentiation, the 
immunolabelled samples were examined by 
confocal laser scanning microscopy (CLSM) 
using a Bio-Rad MRC 1024 ES (Bio-Rad, 
Hemel Hempstead, UK) equipped with an 
argon-krypton gas laser. The Alexa Fluor 
fluorochrome was excited with the 488 nm 
green line and the emission was collected at 520 
nm. Mitotracker was excited with the 550 nm 
red line and the emission was collected at 580 
nm. Data were acquired using an inverted 
microscope (Olympus IX70) and processed with 
the LaserSharp software (version 3.0, Bio-Rad). 
Western Blot – Bcl-2 protein content of 
control C57 and mdx myotubes was determined 
using western blotting. Equal amounts of protein 
extracted were loaded on 12 % 
SDS-polyacrylamide gels. The relative content 
of muscle protein in the samples was adjusted 
according to the actin (dilution 1:500, A2172, 
Sigma) band. Proteins were transferred to 
nitrocellulose membranes (Bio Rad). The Bcl-2 
protein was detected using the Bcl-2-specific 
antibody at a dilution of 1:2500. Subsequently, 
phosphatase alkaline-conjugated goat anti-
mouse (170-6520, Bio Rad) was used at a 
dilution of 1:1000. Specific signals were 
detected with the enhanced fluorescence western 
blotting detection reagent (ECF, Amersham 
Biosciences). 
Intracellular calcium measurement – 
After 3 to 4 days of differentiation, Ca2+ 
concentration was determined in a population of 
myotubes as described previously (39). Briefly, 
aequorins were reconstituted in a PSS solution 
containing 5 µM coelenterazine (Calbiochem) 
for 1 h before the experiment. Particular 
conditions are needed for the subsarcolemmal 
targeted aequorin because the removal of 
intracellular Ca2+ is required for the complete 
aequorin reconstitution (45). Thus SNAP-25 
aequorin was reconstituted in a Ca2+ free PSS 
containing 0.1 mM EGTA in order to decrease 
the [Ca2+] within the cell. Mitochondrial targeted 
aequorin was reconstituted in 1.2 mM Ca2+. 
Cells were perfused at a rate of 1 ml/min in a 
custom made 0.5 ml chamber thermostated at 
37 °C (MecaTest, Geneva, Switzerland). 
Emitted luminescence was detected at 466 nm 
with a photomultiplier apparatus (EMI 
9789A, Electron Tubes Limited, UK) and 
recorded every second using a computer photon-
counting board (EMI C660) as described 
previously (46). The relationship between 
recorded emitted light and [Ca2+] was calculated 
using a previously described equation (47). 
Total light output was obtained by exposing 
cells to 10 mM CaCl2 after permeabilization 
with 100 µM digitonin to consume all the 
aequorin. 
 Survival assay and apoptosis – The 
enzymatic colorimetric measurement of the 
phosphatase acid activity was used to determine 
the effect of Bcl-2 overexpression on the 
survival of the myotubes. Myotubes were 
cultured in 24 well plates coated with collagen. 
Briefly, after 3 to 4 days of differentiation, cells 
were washed twice for 5 minutes with 500 µl 
phosphate-buffered saline (PBS: KCl 0.2 g/l, 
KH2PO4 0.2 g/l, NaCl 8 g/l, NaH2PO4 1.15 g/l, 
pH = 7.2). 250 µl of substrate solution 
containing citrate buffer aqueous solution (0.1 
M, pH = 5.5), 0.1 % triton X-100 and 1 mg/ml 
p-nitrophenyl phosphate substrate (pNPP) was 
added to each well for 90 minutes. Then the 
reaction was stopped by adding 25 µl NaOH 
1M. Absorbance was measured at 405 nm. 
APOPercentage Apoptosis Assay 
(Biocolor, Newtownabbey, UK) was used to 
assess the effect of Bcl-2 overexpression on 
apoptosis. Cellular dye uptake was analyzed 
according to the manufacturer’s protocol 
modified for our myotubes that were cultured in 
24 well plates coated with collagen. Briefly, 
after 90 minutes incubation at 37°C with 
APODye reagent (dilution 1:20), cells were 
washed with PSS to remove extracellular dye. 
Subsequently, APODye release reagent was 
applied for 10 minutes and absorbance of the 
released dye was measured at 550 nm with a 
plate reader (Fluostar Galaxy, BMG 
Labtechnologies GmbH). 
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Data analysis – Data analysis was 
performed using the software GraphPad Prism 4 
(GraphPad Software, San Diego, CA, USA) and 
Matlab 7 SP1 (The MathWorks Inc, Natick, 
MA, USA). Results are expressed as means ± 
SEM. Statistical significance between the 
different values was assessed with the unpaired 
Student’s t-test and one-way ANOVA followed 
by Dunnett post-test when necessary. P>0.05 
was considered not significant, P values ≤ 0.05 
were considered significant. 
 
RESULTS 
 
Bcl-2 localization and overexpression – 
In order to investigate the localization of the 
Bcl-2 protein, myoblasts were transfected with 
cDNA encoding Bcl-2. Localization of Bcl-2 
was assessed using immunochemistry and 
confocal imaging. Figure 1 shows representative 
confocal sections of dystrophic myotubes after 3 
days of differentiation. The green fluorescence 
alone corresponds to overexpressed Bcl-2 
protein (figure 1A), as no fluorescence was 
detected in non-transfected myotubes (data not 
shown). Overexpressed Bcl-2 protein appears to 
be located on membranes which could be SR 
membranes and also in the perinuclear area. 
Double staining of Bcl-2 protein and 
mitochondria (with mitotracker, red 
fluorescence) indicates that overexpressed Bcl-2 
proteins were located in part in mitochondria 
(yellow fluorescence, figure 1B). Similar results 
were obtained with control C57 myotubes (data 
not shown). Bcl-2 overexpression was 
confirmed by western blot analysis of both 
control C57 and mdx myotubes (figure 1C). 
Indeed, Bcl-2 protein was only detected in 
transfected myotubes. Moreover, results from 
figure 1C indicate that Bcl-2 was similarly 
expressed in both cell types.  
Effect of Bcl-2 overexpression on 
subsarcolemmal [Ca2+] – In order to study the 
effect of Bcl-2 overexpression on Ca2+ 
homeostasis in both control C57 and mdx 
myotubes, we investigated subsarcolemmal and 
mitochondrial Ca2+ increases triggered by 
nicotinic acetylcholine receptor (nAChR) 
stimulation using carbachol (CCh). CCh-
induced subsarcolemmal Ca2+ increases 
(pm[Ca2+]) were measured with plasma 
membrane-targeted aequorin as previously 
described (39). Due to very high [Ca2+] in this 
compartment, aequorin was reconstituted in Ca2+ 
free physiological salt solution (PSS) containing 
0.1 mM EGTA for 1 hour before the experiment 
in order to decrease the [Ca2+] within the cell. 
This allows complete reconstitution of aequorin 
(45). Stimulation of myotubes with CCh 
triggered near-plasma membrane Ca2+ increases 
with average amplitudes of 1.10 ± 0.11 µM and 
5.04 ± 0.81 µM for control C57 and dystrophic 
myotubes, respectively. Bcl-2 overexpression 
did not affect significantly the CCh-induced 
near-plasma membrane Ca2+ increases in control 
C57 myotubes but decreased this response in 
dystrophic myotubes from about 2 fold 
(2.35 ± 0.35 µM) (figure 2). Altogether these 
results indicate that the amplitude of CCh-
induced Ca2+ increases is 5 times higher in 
dystrophic myotubes when compared to control 
C57 cells. These results also indicate that Bcl-2 
overexpression decreases CCh-induced near-
plasma membrane Ca2+ increases only in 
dystrophic myotubes. Bcl-2 overexpression 
appears to correct exaggerated near-plasma 
membrane Ca2+ transients that occurred during 
physiological stimulation of nAChRs in 
dystrophic myotubes. We have previously 
shown that the increased CCh-induced Ca2+ 
response in dystrophic myotubes involves Ca2+ 
release through IP3R (39) that have been 
reported to be overexpressed in these myotubes 
(38). 
Effect of IP3R inhibitors on the near-
plasma membrane Ca2+ response in dystrophic 
myotubes that overexpress Bcl-2 – As Bcl-2 
protein has been shown to interact directly with 
the IP3R and to inhibit its opening (35), we next 
investigated the effect of potent IP3R inhibitors 
on CCh-induced near-plasma membrane Ca2+ 
increases in dystrophic myotubes. As shown in 
figure 3, incubation of dystrophic myotubes that 
overexpress Bcl-2 with either 
2-aminoethoxydiphenyl borate (2-APB, 75 µM) 
(48) or xestospongin D (0.1 µM) (49) for 10 
minutes did not affect the CCh-induced Ca2+ 
response when compared to non-treated cells 
(2.32 ± 0.30 µM and 1.63 ± 0.21 µM 
respectively for 2-APB, 2.32 ± 0.30 µM and 
2.20 ± 0.15 µM respectively for xestospongin D) 
(figure 3C). On the opposite, in dystrophic 
myotubes that do not overexpress Bcl-2, the two 
IP3R inhibitors have been shown to strongly 
reduce CCh-induced Ca2+ responses (39). 
Altogether, these results suggest that Bcl-2, 
when overexpressed in dystrophic myotubes, 
may reduce CCh-induced Ca2+ responses by 
inhibiting the IP3R, as shown in other cell types 
(35). However, Bcl-2 overexpression has also 
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been shown to affect SR Ca2+ content in some 
cases (30,32,50). To test the hypothesis that Bcl-
2 overexpression could also correct near-plasma 
membrane Ca2+ overload in dystrophic 
myotubes by reducing the SR Ca2+ content, we 
investigated the effect of caffeine (20 mM), a 
potent activator of the ryanodine receptor (51), 
on the pm[Ca2+]. Caffeine-induced near-plasma 
membrane Ca2+ increases were not significantly 
affected in dystrophic myotubes overexpressing 
Bcl-2 when compared to the myotubes that do 
not overexpress the anti-apoptotic protein (data 
not shown). This result suggests that Bcl-2 
overexpression does not correct CCh-induced 
Ca2+ response by reducing the Ca2+ content of 
caffeine-sensitive pools. Altogether, these 
results therefore indicate that Bcl-2 
overexpression is likely to result in inhibition of 
IP3R-dependent Ca2+ release in dystrophic 
myotubes. Since the high increase in near-
plasma membrane Ca2+ is dependent on IP3R 
activation in dystrophic cells, this could 
explained the protective effects of Bcl-2 during 
CCh activation of dystrophic myotubes. This 
inhibition could correct elevated near-plasma 
membrane Ca2+ transients occurring during 
physiological activation of dystrophic myotubes. 
Effect of Bcl-2 overexpression on 
mitochondrial [Ca2+] – It has been shown that a 
tight coupling between SR Ca2+ release channels 
(IP3Rs and ryanodine receptors) and 
mitochondrial Ca2+ uptake sites operates in 
various types of cells (52-55). CCh-induced 
mitochondrial Ca2+ increases (m[Ca2+]) were 
measured with mitochondrial-targeted aequorin. 
As shown in figure 4, the amplitudes of CCh-
induced Ca2+ response were 3.05 ± 0.34 µM and 
5.15 ± 0.92 µM in control C57 and dystrophic 
myotubes respectively. In myotubes 
overexpressing Bcl-2, CCh-induced 
mitochondrial Ca2+ increases were significantly 
decreased in both control C57 and mdx 
myotubes (1.56 ± 0.18 µM and 2.47 ± 0.4 µM, 
respectively). These results indicate that CCh-
induced mitochondrial Ca2+ transients are about 
1.5 fold higher in dystrophic myotubes than in 
control C57 cells. This shows that elevated 
mitochondrial Ca2+ responses occur in 
dystrophic myotubes during physiological 
activation and also that Bcl-2 overexpression 
decreases these transients to a value close to 
control C57 levels. Altogether these results 
indicate that Bcl-2 overexpression decreases 
exaggerated subsarcolemmal and mitochondrial 
Ca2+ responses during physiological activation 
of dystrophic myotubes. 
Effect of Bcl-2 overexpression on near-
plasma membrane staurosporine-dependent 
Ca2+ response – As Bcl-2 is known to have anti-
apoptotic effects mediated by modifications of 
Ca2+ homeostasis in various cell types (56,57), 
we investigated the effect of Bcl-2 
overexpression on Ca2+ responses triggered by 
the proapoptotic agent staurosporine (STS), in 
both control C57 and mdx myotubes. STS is 
known to trigger Ca2+-dependent apoptosis (58). 
To investigate the effect of STS on the Ca2+ 
homeostasis in our dystrophic myotubes we 
measured pm[Ca2+] during 75 minutes in basal 
conditions (1.2 mM Ca2+) and in the presence of 
0.1 µM of the apoptotic compound. This limited 
recording time was chosen to prevent elevated 
aequorin consumption that may disturb 
calibration at the end of the experiment. 
Dystrophic myotubes were transfected with the 
plasma membrane targeted aequorin for control 
experiments and with both Bcl-2 and plasma 
membrane targeted aequorin to study the effect 
of the anti-apoptotic protein. When perfused 
with a PSS solution containing 1.2 mM Ca2+, 
STS induced a 3.5 fold increase in near-plasma 
membrane Ca2+ spike frequency as compare 
with the frequency of spontaneous Ca2+ spikes 
occurring in these myotubes when perfused with 
1.2 mM Ca2+ alone. Moreover, when the IP3R 
inhibitor 2-APB (75 µM) was perfused together 
with STS the Ca2+ spike frequency decreased 
approximately 1.5 fold (figure 5A and 5C). This 
suggests that the increased Ca2+ spike frequency 
may be due to Ca2+ release through IP3R. In Bcl-
2 overexpressing myotubes, near-plasma 
membrane Ca2+ spike frequency was only 
increased 2.5 fold in the presence of STS (figure 
5B and 5C), which indicates that Bcl-2 
overexpression inhibits Ca2+ spikes triggered by 
STS. The addition of the IP3R inhibitor 
xestospongin D did not further increase the 
inhibition already triggered by Bcl-2 
overexpression. Moreover, Ca2+ spike frequency 
in Bcl-2 overexpressing dystrophic myotubes 
was similar to that recorded in dystrophic 
myotubes perfused with 2-APB but that do not 
overexpress Bcl-2. Altogether, these results 
show that STS increases near-plasma membrane 
Ca2+ spike frequency in dystrophic myotubes 
and that overexpression of Bcl-2 counteracts the 
effect of STS. Moreover, near-plasma 
membrane Ca2+ spike frequencies are reduced in 
myotubes by Bcl-2 or by 2-APB suggesting that 
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the decrease of Ca2+ spike frequency may be 
dependent on reduction of IP3R-dependent Ca2+ 
release. 
Effect of Bcl-2 overexpression on cell 
survival and apoptosis – We next investigated 
the effect of Bcl-2 overexpression on the cell 
survival. In addition to STS, we used H2O2 
which induces reactive oxygen species 
formation in similar cultures (59). Control C57 
and dystrophic myotubes were exposed to H2O2 
(1 µM) or STS (0.1 µM) followed by cell 
survival assay using acid phosphatase activity. 
As shown in figure 6, both compounds 
decreased cell survival of control C57 and mdx 
myotubes. Indeed, in the presence of STS, cell 
survival was 74.64 ± 3.07 % for control C57 
cells and 40.26 ± 4.12 % for mdx myotubes. In 
the presence of H2O2, cell survival was 57.85 ± 
7.20 % for control C57 cells and 13.73 ± 4.80 % 
for mdx myotubes. Altogether these results show 
that dystrophic myotubes are more sensitive to 
H2O2 and STS compared to control C57 
myotubes. However, when myotubes were 
treated for 18 hours with STS, cell survival of 
Bcl-2 overexpressing myotubes was 
significantly increased (from 40.26 ± 4.12 % to 
57.50 ± 6.17 %) only in dystrophic myotubes 
(figure 6B). On the opposite, cell survival of 
control C57 myotubes was not affected by Bcl-2 
overexpression (figure 6A). When myotubes 
were treated with H2O2, Bcl-2 overexpression 
had no effect on cell survival on both cell types 
(figure 6A and 6B). These results therefore 
indicate that Bcl-2 overexpression protects only 
dystrophic myotubes against cell death triggered 
by STS. 
As acid phosphatase measurement does 
not discriminate between necrosis and apoptosis, 
we used a specific apoptosis assay. When 
myotubes were treated with STS, 
28.35 ± 3.30 % of the control C57 cells and 
59.91 ± 2.56 % of dystrophic cells were 
apoptotic (figure 7A), confirming the fact that 
dystrophic myotubes are more sensitive to STS 
than control C57 cells. When Bcl-2 was 
overexpressed in these myotubes, the number of 
apoptotic cells decreased only in dystrophic cells 
(from 59.91 ± 2.56 % to 45.55 ± 3.35 %) 
showing that Bcl-2 overexpression does not 
protect control C57 myotubes. When cells were 
treated with H2O2, Bcl-2 overexpression did not 
change significantly the apoptotic rate in both 
control C57 and dystrophic myotubes (figure 
7B). Altogether these results show that Bcl-2 
overexpression counteracts the STS-induced 
apoptosis in dystrophic myotubes only and that 
H2O2-induced apoptosis remains unchanged in 
Bcl-2 overexpressing myotubes. 
IP3 sponge protects dystrophic myotubes 
from STS-induced apoptosis – Dystrophic 
myotubes were transfected with either Bcl-2 or 
the IP3 sponge. IP3 sponge has been shown to 
behave as a very specific IP3 chelator and to 
inhibit IP3 mediated Ca2+ responses (44). After 3 
to 4 days of differentiation, cells were treated 
with STS (0.1 µM) for 18 hours. As already 
shown before (figure 7A), Bcl-2 decreases 
STS-induced apoptosis in dystrophic myotubes. 
More interestingly, apoptosis rate was also 
decreased from 59.91 ± 2.56 % to 39.09 ± 1.32 
% in myotubes transfected with the IP3 sponge 
(figure 8). The decrease observed in Bcl-2 
overexpressing myotubes is not statistically 
different than the decrease in IP3 sponge 
transfected cells. This result strongly suggests 
that the IP3 pathway is involved in STS-induced 
apoptosis in dystrophic myotubes. Moreover, by 
inhibiting IP3R, Bcl-2 could protect cells against 
apoptosis. 
 
DISCUSSION 
 
In this study we have investigated the 
effect of Bcl-2 overexpression on Ca2+ 
homeostasis and apoptosis in both control C57 
and dystrophic myotubes. Plasma membrane and 
mitochondrial targeted aequorin have been used 
to study the effect of Bcl-2 overexpression on 
near-plasma membrane and mitochondrial Ca2+ 
concentrations during nAChR stimulation of 
both types of myotubes.  
We found that CCh-induced near-
plasma membrane Ca2+ responses are 4.5 times 
increased in dystrophic myotubes compared to 
control C57 cells, which indicate that 
exaggerated near-plasma membrane Ca2+ 
responses occurred in dystrophic myotubes 
during physiological activation. These results 
are in agreement with previous reports on 
dystrophic myotubes showing that a 
subsarcolemmal Ca2+ overload occurs in these 
cells (42,60). We show here for the first time 
that Bcl-2 overexpression counteracts this 
elevated Ca2+ transients upon physiological 
activation. On the other hand, Bcl-2 
overexpression had no effect in control C57 
myotubes, indicating that overexpressed Bcl-2 
protein reduce CCh-induced near-plasma 
membrane Ca2+ responses in dystrophic 
myotubes by a mechanism that is present or 
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visible only in these cells. We have previously 
shown that Ca2+ release mechanisms are 
different between control C57 and dystrophic 
myotubes (39). Increased CCh-induced near-
plasma membrane Ca2+ responses in dystrophic 
myotubes are indeed involving Ca2+ release 
from stores dependent on IP3R which is 
overexpressed in these cells (38). In dystrophic 
myotubes that do not overexpress Bcl-2, CCh-
induced near-plasma membrane Ca2+ responses 
were strongly affected by two potent IP3R 
inhibitors (2-APB and xestospongin D), as 
previously shown on other cellular systems 
(48,49). On the other hand, in dystrophic 
myotubes overexpressing Bcl-2, the two IP3R 
inhibitors did not affect CCh-induced near-
plasma membrane Ca2+ responses. This suggests 
that overexpressed Bcl-2 protein may reduce 
CCh-induced near-plasma membrane Ca2+ 
transients by inhibiting IP3R, as proposed in 
other cell types (35-37,61). As 2-APB can also 
inhibits store-operated Ca2+ channels (SOC) (62) 
that are increased in dystrophic fibres (63) it is 
possible that part of the decrease in near-plasma 
membrane Ca2+ transients through these 
channels during CCh activation could be due to 
inhibition of Ca2+ influx within the cell. 
Moreover, IP3R may be linked to SOC in some 
cases (64,65). IP3R inhibitor like 2-APB may 
therefore act by decreasing Ca2+ release but also 
by reducing store-dependent Ca2+ influx that 
depend on IP3R stimulation. 
Bcl-2 overexpression has also been 
shown to reduce SR Ca2+ content in some cell 
types (30-32). In our experiments, such an effect 
of Bcl-2 overexpression on SR Ca2+ content can 
be discarded, as the amount of Ca2+ from 
ryanodine receptors-dependent pools (estimated 
using caffeine-induced near-plasma membrane 
Ca2+ responses) was not significantly different 
between dystrophic myotubes overexpressing or 
not Bcl-2. Our results therefore indicate that 
Bcl-2 proteins, when overexpressed in 
dystrophic myotubes, are likely to inhibit IP3R-
dependent Ca2+ release after CCh stimulation.  
We also found that CCh induced 
mitochondrial Ca2+ increases in both control 
C57 and dystrophic myotubes, which suggests 
that mitochondrial Ca2+ uptake sites are closely 
linked to SR in our myotubes, as demonstrated 
in other cell types (53,66). Moreover, we show 
that CCh-induced mitochondrial Ca2+ responses 
are significantly increased in dystrophic 
myotubes compared to control C57 ones (1.5 
times), which indicates that transient 
mitochondrial Ca2+ overload occurred during 
physiological activation of dystrophic myotubes 
(similar to what was observed by Robert et al. 
during hyperpotassic stimulations). In both 
control C57 and dystrophic myotubes, Bcl-2 
overexpression decreases CCh-induced 
mitochondrial Ca2+ responses. In dystrophic 
myotubes overexpressing Bcl-2, reduced 
mitochondrial Ca2+ responses may be linked to 
reduced SR Ca2+ release, as we show that near-
plasma membrane CCh-induced Ca2+ responses 
are decreased. However, in control C57 
myotubes overexpressing Bcl-2, reduced 
mitochondrial Ca2+ responses can not be 
explained by reduced SR Ca2+ release, as CCh-
induced near-plasma membrane Ca2+ increases 
were not affected by Bcl-2 overexpression. Bcl-
2 proteins, when overexpressed in these control 
C57 myotubes, are likely to act on mitochondria 
by a direct mechanism such as the inhibition of 
cytochrome c release (27) or the decreased Ca2+ 
influx within the mitochondria through its Ca2+ 
uniporter (67), which is consistent with the 
colocalization of Bcl-2 and mitochondria in our 
myotubes. 
Ca2+ overload is known to play a key 
role in apoptosis by activating various 
proteolytic enzymes (12,68). In particular, 
mitochondrial Ca2+ overload can induce PTP 
opening, which results in the release of pro-
apoptotic factors such as cytochrome c (69-71). 
Moreover, cytochrome c has been shown to bind 
to the IP3R and to induce Ca2+ release from the 
endoplasmic reticulum, amplifying Ca2+-
dependent apoptosis (72). As Bcl-2 
overexpression counteracts transient near-
plasma membrane and mitochondrial Ca2+ 
overload, we have investigated the effect of Bcl-
2 overexpression on cell survival and apoptosis 
in our myotubes. When myotubes were exposed 
to 2 types of stress both control C57 and 
dystrophic myotubes displayed an increased 
apoptotic rate and decreased cell survival. 
However, dystrophic myotubes were more 
sensitive to H2O2- and STS-induced stresses. 
These results are in agreement with previous 
studies, which indicate that dystrophin-deficient 
cells were more susceptible to free radicals (59). 
Bcl-2 overexpression was unable to protect both 
control C57 and dystrophic myotubes against 
reactive oxygen species produced by H2O2. On 
the opposite, Bcl-2 overexpression decreases 
STS-induced apoptosis in dystrophic myotubes 
only. As this compound increases the frequency 
of near-plasma membrane Ca2+ spikes in 
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dystrophic myotubes, our results indicate that 
STS is likely to trigger Ca2+-dependent 
apoptosis, as it has been shown previously (58). 
Moreover, once apoptosis is induced by STS in 
HeLa cells, caspase 3 can remove the IP3 
binding site and the most part of the regulatory 
domain of the IP3R1 then triggering formation 
of a “channel only” domain that remains 
constitutively open and which leads to Ca2+ leak 
in the cytosol (73,74). Our results show that both 
an IP3R inhibitor (2-APB) and Bcl-2 
overexpression reduced the STS effect on Ca2+ 
spike frequency. These results suggest that leaky 
IP3R may be involved in Ca2+ spikes and 
subsequent Ca2+ overload triggered by STS.  
Altogether, results also suggest that the 
anti-apoptotic effect of Bcl-2 may be explained 
by its inhibitory effect on Ca2+ overload 
(increased Ca2+ spike frequency) triggered by 
STS, possibly by a direct inhibition of IP3R (35). 
Moreover, the fact that the transiently 
transfected IP3 sponge inhibits STS-dependent 
apoptosis indicate that the IP3 pathway is 
involved in this cell death. Overexpressed Bcl-2 
proteins may therefore exert their anti-apoptotic 
effect by inhibiting IP3R, whose overexpression 
in dystrophic myotubes (38) could trigger 
abnormal Ca2+ homeostasis (Ca2+ leak) near the 
plasma membrane and subsequent proteolytic 
enzymes activation (75). 
To conclude, our results indicate that 
Bcl-2 overexpression reduces both near-plasma 
membrane and mitochondrial Ca2+ responses 
occurring during physiological activation of 
dystrophic myotubes most likely by inhibiting 
IP3R. Our results also indicate that Bcl-2 
overexpression can prevent STS-induced 
apoptosis selectively in dystrophic myotubes, 
presumably by reducing near-plasma membrane 
Ca2+ overload. As the IP3 pathway is involved in 
CCh-induced Ca2+ transients and in STS-
induced apoptosis, beneficial effect of Bcl-2 
overexpression in dystrophic myotubes may 
then be explained by a direct inhibition of IP3R, 
which are indeed involved in abnormal Ca2+ 
homeostasis in these cells. Thus, overexpression 
of Bcl-2 or other anti-apoptotic proteins could 
represent an interesting pathway to prevent 
muscle damage occurring in DMD. 
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Figure 2. 
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Effect of Bcl-2 overexpression on the pm[Ca2+]. Representative traces of subsarcolemmal Ca2+ 
increases in a population of (A) control C57 and (B) mdx myotubes showing the effect of nAChR 
stimulation and Bcl-2 overexpression on the pm[Ca2+]. (C) Summarizing histogram of CCh-induced 
subsarcolemmal Ca2+ responses measured in control C57 (n ≥ 4) and mdx myotubes (n ≥ 14). The bar 
graphs correspond to mean pm[Ca2+] values ± SEM (ns not significant (P>0.05),** corresponds to a 
significant inhibition (0.01<P<0.001 respectively) using unpaired Student’s t-test). 
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Effect of IP3R inhibitors on dystrophic Bcl-2-transfected myotubes. (A) Representative traces of 
subsarcolemmal Ca2+ increases in a population of mdx myotubes showing the effect of Bcl-2 
overexpression alone and Bcl-2 overexpression together with 75 µM 2-APB or xestopongin D (xesto 
D, 0.1 µM) on the CCh-induced Ca2+ response. (B) Summarizing histogram. The bar graphs 
correspond to mean pm[Ca2+] values ± SEM (n ≥ 8, *** corresponds to a significant inhibition 
(P<0.001) using one-way ANOVA followed by a Dunnett post-test when compared to the control bar, 
e.g. 1.2 mM Ca2+, 100 µM CCh, no Bcl-2 overexpression). 
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Figure 4. 
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Effect of the Bcl-2 overexpression on the m[Ca2+]. Representative traces of mitochondrial Ca2+ 
increases in a population of (A) control C57 and (B) mdx myotubes showing the effect of nAChR 
stimulation and Bcl-2 overexpression on the m[Ca2+]. (C) Summarizing histogram of CCh-induced 
mitochondrial Ca2+ responses measured in control C57 (n = 5) and mdx myotubes (n = 14). The bar 
graphs correspond to mean m[Ca2+] values ± SEM (ns not significant (P>0.05), * and ** correspond 
to a significant inhibition (P<0.05 and 0.01<P<0.001 respectively) using unpaired Student’s t-test). 
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STS effect on the pm[Ca2+] in dystrophic myotubes. Representative trace of the effect of STS (0.1 
µM) in the presence or not of IP3R inhibitors on the pm[Ca2+] in (A) control dystrophic myotubes and 
(B) in dystrophic myotubes that overexpress Bcl-2. (C) Summarizing histogram of the mean plasma 
membrane Ca2+ spike frequency (n ≥ 3). Frequency is manually calculated and represents spikes that 
point out from the basal pm[Ca2+]. Plain columns represent dystrophic myotubes that are not 
transfected with Bcl-2. Hatched columns represent Bcl-2 overexpressing dystrophic myotubes.  *, **, 
*** correspond to a significant decrease (P<0.05, 0.01<P<0.001, P<0.001 respectively) using 
Student’s t-test. 
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Figure 6. 
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STS and H2O2 effect on cell survival of control C57 and mdx myotubes. Summarizing histogram of 
the sensitivity of control C57 (A) and mdx myotubes (B) to STS (0.1 µM, plain bar) and H2O2 (1 µM, 
hatched bar) combined with the effect of Bcl-2 overexpression. The bar graphs correspond to mean 
cell survival ± SEM (n ≥ 6; ns, not significant (P>0.05) and * corresponds to a significant increase 
(P<0.05) using unpaired Student’s t-test). 
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Figure 7. 
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Apoptosis rate of control C57 and mdx myotubes that overexpress Bcl-2. (A) Summarizing histogram 
of the sensitivity of control C57 (n ≥ 6) and mdx myotubes (n ≥ 15) to STS (0.1 µM). (B) 
Summarizing histogram of the sensitivity of control C57 (n ≥ 3) and mdx (n ≥ 5) myotubes to H2O2 
(1 µM). The bar graphs correspond to mean apoptosis rate ± SEM (ns, not significant (P>0.05) and ** 
corresponds to a significant decrease (0.01<P<0.001) using Student’s t-test). 
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Figure 8. 
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IP3 sponge protects cells against STS-induced apoptosis. Histogram showing the effect of Bcl-2 
overexpression and IP3 sponge on the apoptosis induced by STS in dystrophic myotubes. The bar 
graphs correspond to mean apoptosis rate ± SEM (n ≥ 15, *** corresponds to a significant decrease 
(P<0.001) using one-way ANOVA followed by a Dunnett post-test when compared to the control 
bar). The Bcl-2 bar and IP3 sponge bar were not significantly different (using Student’s t-test). 
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3.2.3 Additional results and discussion 
We were unable to measure directly the sr[Ca2+] because of the very fast aequorin 
consumption. Following previous experiments (Robert et al., 2001), mutated aequorin was 
reconstituted in a Ca2+ free PSS solution containing 3 mM EGTA, 30µM N, tert- 
butylhydroquinone (tBHQ, a reversible SERCA inhibitor) and 5 µM n-coelenterazine in 
order to decrease the [Ca2+] within the cell. Even with this pretreatment and once Ca2+ was 
readded in the solution, a huge Ca2+ refilling occurred (up to 1.5 mM in some experiments) 
and the aequorin was quickly consumed, preventing any application and steady sate in the 
emitted luminescence as observed by other groups (Brini et al., 2000; Robert et al., 2001). 
Moreover, the high rate consumption did not allow us to calibrate the aequorin in the end of 
the experiments with digitonin (figure 3.3A).  
We then decided to use caffeine (20mM) to estimate the sr[Ca2+]. Indeed, caffeine 
activates RyR and triggers Ca2+ release from the SR. As shown in figure 3.3B, no statistical 
difference was observed between dystrophic myotubes that overexpress or not Bcl-2 (2.00 ± 
0.25 µM and 1.57 ± 0.20 µM, respectively), suggesting that the sr[Ca2+] is similar in both 
cases. Similar results were found with 50 mM caffeine. 
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Figure 3.3: Estimation of the sr[Ca2+] content in dystrophic myotubes with caffeine. 
(A) Representative trace of SR Ca2+ increases in a population of mdx myotubes showing the effect of 
Ca2+ readdition. Data are given in count per second (cps). (B) Summarizing histogram of caffeine (20 
mM)-induced subsarcolemmal Ca2+ responses measured in mdx myotubes that overexpress or not Bcl-
2 (n ≥ 7). The bar graphs correspond to mean pm[Ca2+] values ± SEM (ns not significant (P>0.05) 
using unpaired Student’s t-test). 
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3.2.4 Conclusion 
Here we show that the overexpression of the anti-apoptotic protein Bcl-2 decreases 
Ca2+ responses induced by CCh in mitochondria in both dystrophic and control C57 
myotubes while decreases in subsarcolemmal Ca2+ responses are observed only in dystrophic 
myotubes. Furthermore, the effect of Bcl-2 on dystrophic myotubes is more pronounced. We 
show that Bcl-2 prevents staurosporine-induced apoptosis only in dystrophic myotubes. 
These effects could be mediated by a direct inhibition of Bcl-2 on IP3Rs that have been 
shown to be overexpressed (Liberona et al., 1998) and involved in nAChR-dependent Ca2+ 
responses (see 3.1) in dystrophic cells. Moreover, we show that the IP3 pathway is involved 
in the staurosporine-induced apoptosis. The protective and selective effect of Bcl-2 could 
represent a new perspective in DMD treatment. 
In order to strengthen the manuscript, some experiments could be carried out. First, it 
would be important to determine the effect of staurosporine on mitochondrial Ca2+. Indeed, in 
the case of Ca2+-dependent apoptosis triggered by the proapoptotic compound, mitochondria 
could be a specific target and m[Ca2+] might be affected by the treatment. Second, we should 
demonstrate that Bcl-2 interacts with and inhibits the IP3R. One of the possible experiments 
would be Fluorescence Resonance Energy Transfer (FRET), which can be used to establish 
close proximity (typically 10–100 Å) between proteins. Finally, it would be of interest to 
determine the kind of inhibition triggered by Bcl-2: decreased binding affinity for IP3, 
decreased open probability of the receptor, etc. 
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4 CHAPTER 4-GENERAL CONCLUSIONS AND PERSPECTIVES 
 
 
As Duchenne Muscular Dystrophy is one of the most severe and frequent muscular 
disease, intensive work has been done to understand processes implicated in muscle 
degradation. Even though no treatment is available yet, the cause of the myopathy is fully 
known. The absence of the plasma membrane protein dystrophin leads to greater membrane 
fragility toward mechanical stress that triggers muscle degradation. It has been proposed that 
cytosolic Ca2+ could be involved in the muscle loss, as the ion is indirectly responsible for the 
activation of numerous “death” proteins such as caspases. This hypothesis based on Ca2+ 
toxicity in DMD is still debated. 
 
The present work was defined to improve our understanding of Ca2+ homeostasis in 
myotubes derived from dystrophic mice, and to submit possibilities or clues for effective 
treatment for the disease. Using the Ca2+-sensitive photoprotein aequorin, which can be 
targeted in almost all subcellular compartments, we were able to study the effect of the 
physiological activation of the nAChR on the subsarcolemmal and mitochondrial Ca2+ 
responses. We investigated the role of an important Ca2+ release channel located on the 
sarcoplasmic reticulum membrane, IP3R. Earlier experiments showed that the IP3R and its 
messenger IP3 are increased in dystrophic myotubes derived from both human and mice 
(Liberona et al., 1998). Surprisingly, no more work concerning the receptor has been done in 
DMD although the IP3R pathway could represent a potential target for drug treatment. As a 
potential effector of Ca2+ deregulation, the IP3R study was very challenging.  
Moreover, as numerous data concerning Ca2+ overload in the disease have been 
accumulated in our laboratory, we have overexpressed the anti-apoptotic protein Bcl-2 in our 
dystrophic myotubes. Indeed, this protein has been shown the modulate Ca2+ homeostasis 
once it has been overexpressed in the cell. Thus, our working hypothesis was that Bcl-2 could 
prevent muscle degradation in dystrophic myotubes by its effect on Ca2+ homeostasis. 
Here, we have shown that dystrophic myotubes display exaggerated mitochondrial 
and subsarcolemmal Ca2+ transients when Ca2+ responses are triggered by activation of the 
nAChR with CCh. We also show that IP3R is involved in Ca2+ release from the store in 
dystrophic myotubes only. Potent IP3 inhibitors greatly reduced the CCh-induced Ca2+ 
responses in these cells while Ca2+ responses in control C57 myotubes remained unaffected 
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by these inhibitors. We demonstrate that Bcl-2 prevents staurosporine-induced apoptosis in 
dystrophic myotubes only, presumably by a direct inhibition of the IP3R. We provide 
evidence of the involvement of IP3R in the Ca2+ leak and apoptosis triggered by 
staurosporine. Indeed, IP3R inhibitors decrease staurosporine-induced apoptosis which shows 
that IP3R are implicated in increased apoptosis observed in mdx myotubes. 
Briefly, our conclusions are that in dystrophic myotubes, the IP3 pathway triggers 
exaggerated nAChR-induced Ca2+ responses. Refilling capability of the cell could handle this 
overload for a certain amount of time. After that, the cell may not able to pump back Ca2+ 
into the stores (SERCA) and the elevated cytosolic Ca2+ may push it towards apoptosis. Bcl-
2, by decreasing the Ca2+ release function of the IP3R could prevent Ca2+ overload and the 
subsequent muscle degradation that occurs in DMD (see figure 4.1 for a recapitulative 
scheme). It would be interesting to clearly characterize the interaction(s) between both 
proteins in our cellular model. Although it is known that Bcl-2 directly interacts with IP3R in 
other cell types (Chen et al., 2004), the exact mechanism of inhibition remains to be 
determined. Moreover, it would be of interest to study the phosphorylation state of the IP3R 
in Bcl-2 overexpressing myotubes. Indeed, the activity of the receptor is closely linked to its 
phosphorylation degree (Krizanova & Ondrias, 2003). Bcl-2 could also act by modifying 
these properties. 
The potential key role of the IP3R might lead to new treatments for DMD. The vast 
amount of knowledge on the receptor could indeed allow the design of specific drugs. 
However, due to the wide expression of this receptor in all cell types, precautions will have to 
be taken in order to avoid side effects, principally in the central nervous system.  
 
The overexpression of Bcl-2 in our myotubes decreased the staurosporine-induced 
apoptosis and the amplitude of the carbachol-induced Ca2+ responses in the subsarcolemmal 
area and in mitochondria. The overexpression of such anti-apoptotic protein could be 
criticized as toxicity of transient Bcl-2 overexpression has been reported (Uhlmann et al., 
1998) and as Bcl-2 overexpression could trigger alteration in the expression of proteins 
involved in Ca2+ homeostasis (Distelhorst & Shore, 2004). However, no visual and 
physiological modifications were observed in our transfected myotubes. As Bcl-2 was not 
detected in non-transfected cells, the only way to study its effect was overexpression. Thus, it 
would be of interest to find a way to increase the endogenous expression of this anti-
apoptotic protein. 
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Figure 4.1: Summary scheme of CCh-induced Ca2+ responses in skeletal myotubes.  
(A) Control C57 myotubes, (B) dystrophic myotubes. Plain arrows represent known 
pathways. Hatched arrows mean hypothetical pathway. 
1- The activation of the nAChR with CCh triggers Na+ entry through the receptor. 2- Na+ entry 
depolarizes the plasma membrane and activates VOCs (DHPR). 3- Ca2+ influx occurs through these 
voltage-gated channels. 4- In control C57 myotubes, this influx activates RyRs that release Ca2+ from 
the SR while in dystrophic myotubes PLC is activated by Ca2+ increases, membrane depolarization or 
G protein. Activation of PLC leads to IP3 formation which activates IP3R. IP3Rs release Ca2+ from the 
store. Bcl-2 could inhibit this receptor and the subsequent Ca2+ release. 5- Ca2+ release from the store 
increases pm[Ca2+] that can be pumped back by SERCA for store refilling. 6- In case of long term 
Ca2+ elevation, apoptosis is triggered by mitochondria. Bcl-2 inhibits apoptosis. 
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Finally, the use of anti-apoptotic proteins as a potential treatment for DMD should be 
considered carefully as the possible cell immortalization brought by the protein could result 
in tumor formation. This transient overexpression has shown that it is possible to enhance 
survival of skeletal muscle cell derived from dystrophic mice by decreasing Ca2+ 
concentration. Further work should take into account this possibility, together with the 
implication of the IP3R. 
 
The use of myotubes obtained from purified satellite cell lines allows performing 
numerous experiments under controlled conditions. However, myotubes are non mature cells 
and are quite far in term of physiology and genetic properties from mature fibers. Indeed, 
hundreds of proteins are expressed in their fetal form in myotubes, while they have adult 
form in fibers. Although the use of fibers should represent another model for studying 
skeletal muscle biology, the difficulties to obtain intact fibers in a sufficient number after 
muscle extraction limits the use of these cells. Moreover, in our particular case, the use of 
fibers is limited as these cells are difficult to transfect so that the aequorin technique could 
not be optimal. Altogether, these remarks indicate that even if the use of fibers is another 
solution to fit better with “reality”, myotubes are more attractive for basic experiments such 
as intracellular Ca2+ measurement, immunochemistry or western blots. Nevertheless, IP3R 
study in dystrophic fibers would be interesting. 
 
In conclusion, even if the etiology of DMD appears relatively simple because it is a 
monogenic disease, the mechanisms linking of the lack of dystrophin to disease remain 
unclear. More work need to be done in order to clarify all the consequences of the absence of 
the protein, and to find an effective treatment. This work brought to the light the possible key 
role of the IP3R and its possible regulation by Bcl-2 of the mdx dystrophy. Even if genetic 
research has opened new doors with the era of DNA delivery, and if most of the hope for a 
cure is concentrated on this approach, basic research is still central for a better understanding 
of the disease. Pharmacology is still promising for DMD patients, for the improvement of the 
way of life and for a better treatment. 
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RÉSUMÉ DESTINÉ À UN LARGE PUBLIC 
 
La Dystrophie Musculaire de Duchenne (DMD) est une des maladies génétiques des 
plus graves et des plus fréquentes : elle frappe un garçon sur 3500. Elle se déclare dès 
l’enfance et conduit à une dégénérescence progressive de la musculature, obligeant les jeunes 
patients à se déplacer très tôt en chaise roulante. Actuellement, il n’existe pas de traitement et 
la mort survient aux alentours de la 30ème année, lorsque les muscles cardiaque et 
respiratoires sont touchés. La maladie est due à l’absence d’une énorme protéine (le gène qui 
la code est le plus grand gène existant chez l’Homme) qui normalement maintien l’intégrité 
de la cellule musculaire lors d’un exercice. Bien que la cause de la maladie soit parfaitement 
connue, la pathologie exacte de la DMD est encore mal connue. Il semblerait cependant que 
l’augmentation de la concentration de calcium dans la cellule soit responsable de la 
dégradation du muscle. 
Le but de ce travail a été l’étude d’un des récepteur libérant le calcium à partir des 
stocks intracellulaires, le récepteur de l’inositol 1, 4, 5-trisphosphate (IP3). Ce récepteur est 
situé sur la membrane du plus important stock de calcium intracellulaire et est surexprimé 
dans les cellules musculaires, appelées aussi myotubes, dérivées de patients et de souris 
malades. Nous avons montré que, dans les myotubes dystrophiques uniquement, la réponse 
calcique mesurée sous la membrane plasmique et provoquée par la stimulation d’un récepteur 
spécifique est dépendante de l’IP3. Cette réponse est 4.5 fois plus grande dans les myotubes 
dystrophiques que dans les myotubes sains. Cette surcharge calcique est aussi retrouvée 
lorsque l’on mesure, dans les mêmes conditions, la concentration de Ca2+ dans les 
mitochondries, un autre compartiment cellulaire connu pour stocker transitoirement le 
calcium. A l’opposé, la réponse calcique observée dans les myotubes contrôles est 
indépendante de l’IP3. De plus, nous avons montré qu’en surexprimant dans nos cellules une 
protéine impliquée dans le contrôle de la mort programmée des cellules (bcl-2), la surcharge 
calcique était diminuée, provoquant ainsi une amélioration de la survie de myotubes 
dystrophiques uniquement. Cette amélioration pourrait être due à l’inhibition du récepteur à 
l’IP3 par cette protéine. 
Ce travail a donc montré une nouvelle fois l’importance du calcium ainsi que 
l’implication du récepteur à l’IP3 dans la réponse calcique chez les souris dystrophiques. Ces 
résultats ouvrent la voie à de nouvelles possibilités thérapeutiques. 
